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Abstract 
The 20S proteasome is a large protein complex, primarily responsible for the breakdown of 
ubiquitinated proteins. It is therefore a vital component in the ubiquitin proteasome pathway, 
disruptions of which can induce cell death. Such an effect could be targeted for cancer 
therapeutics. Some β-lactone γ-lactam scaffolds, such as the natural product omuralide (the 
biologically active form of lactacystin) have been found to inhibit the 20S proteasome. 
The discovery of several new natural 20S proteasome inhibitors such as the salinosporamides 
and cinnabaramides, have shown potential for the development of new inhibitors with 
increased potency and specificity. Development of synthetic routes to produce these targets 
and their analogues is key to developing new proteasome inhibitors with greater potency and 
reduced side effects. 
 
Figure 1. Several natural products with 20S proteasome inhibitory activity 
Our methodology involves the incorporation of amino acids into the γ-lactam core. Leucine 
and serine have been used to produce a new formal synthesis of 9-deoxy omuralide and 
omuralide respectively. Key steps include a diastereoselective acylation with Mander’s 
reagent and desulfurization. This methodology offers a flexible route allowing rapid 
generation of omuralide analogues in order to produce known and novel 20S proteasome 
inhibitors for biological testing. 
 
Figure 2. An overview of our methodology 
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In addition to our work incorporating amino acids into γ-lactam cores, we have also developed 
a new route to synthesize either diastereomer of hydroxy leucine. We hope that this valuable 
intermediate could be incorporated into the γ-lactam using our devised methodology quickly 
forming an advanced intermediate of omuralide.  
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1.0 Introduction 
1.1 Natural products and medicines 
The search for new drugs and biologically active molecules has sought inspiration from natural 
products or analogues thereof1 since the start of the study of medicine.2 Perhaps the most 
famous example is the discovery of penicillin by Alexander Fleming. As research into 
molecules derived from natural sources increased, the common and easily accessible drug 
compounds were soon discovered. This increased the difficulty of discovering new drugs and 
druglike molecules against an ever-increasing demand for new medicines. 
1.2 The discovery and early work on lactacystin 
1.2.1 The discovery of lactacystin 
In response to this problem, one method for the discovery of new bioactive compounds was 
to screen the cultured broths of numerous microbes against an assay. In 1991 Ōmura et al. 
used this method to find new compounds with neurotrophic factors (NTFs) by testing the 
broths of soil isolates.3,4 NTFs are essential for the growth and survival of neurones. A broth 
from the strain of Streptomyces sp OM-6519 was found to induce differentiation of a mouse 
neuroblastoma cell line 2A. Isolated from this broth, the active compound was characterized 
and designated lactacystin 1. Ōmura later was jointly awarded the 2015 Nobel prize for 
medicine. 
 
Figure 1: Lactacystin, discovered by Ōmura in 1991 
Lactacystin was the first microbial metabolite with neurotrophic activity; the hope of 
developing drugs to treat neurodegenerative disorders prompted several early synthetic 
efforts. The first was completed by Corey et al. in 1992,5 which was followed shortly after by 
an alternative route from Ōmura et al.6 The first insights into a mode of action for lactacystin 
were proposed by Schreiber et al.7 in an early structure activity relationship (SAR) study, it 
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was found that the most potent analogues of lactacystin had the potential to form β-lactones 
from the cysteine-derived thioester and the C6 hydroxyl group, forming compound 2, later 
named omuralide. Further modification to the cysteine had little effect on activity. Analogues 
that were unable to form the β-lactone such as the acid 3 or 6-deoxy lactacystin 4 had no 
biological activity.  
 
Figure 2: Omuralide and inactive derivatives 
In addition, the epimers at C9, C6, and an analogue with the hydroxylated iso-butyl moiety 
removed, resulted in little or no activity. Furthermore, this initial SAR study led to the 
discovery that lactacystin 1 and active analogues were able to inhibit cell cycle progression 
beyond the G1 phase in MG-63 human osteosarcoma cells. Like neurite outgrowth, the most 
active analogues of lactacystin had the structural requirements for formation of β-lactones. 
The observations of the necessity of β-lactone formation in the active compounds led 
Schreiber to hypothesize that acylation of the cellular target may occur, that is, a nucleophilic 
group on the target attacks the carbonyl of the β-lactone during the mechanism of action. 
1.3 The target and mode of action of lactacystin 
1.3.1 Discovery of the target 
The cellular target of lactacystin 1 was discovered in later work by Schreiber et al. in 1995, 
using tritium labelled forms of lactacystin and analogues.8 The target was found to be the 20S 
proteasome, for which lactacystin could inhibit specific sites at different rates. This work also 
confirmed the previous structure observations, through the testing of several analogues 
including omuralide. Omuralide associated with the 20S proteasome far faster than 
lactacystin. Several other analogues were tested, such as 6-deoxy lactacystin 4, which showed 
no inhibition. 
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1.3.2 Mode of action of lactacystin 
In 1996 Dick et al. reported the central role omuralide 2 plays in the inhibition of the 20S 
proteasome.9 These studies showed that lactacystin 1 was not the proteasome inhibitor per 
se, but only a precursor to the sole inhibitory complex omuralide 2 in a pro-drug-like form. 
Lactacystin 1, at pH 8 in an aqueous solution, undergoes reversible cyclization to omuralide 
2, then hydrolysis to the inactive compound 3. Under these basic conditions, 20S proteasome 
inhibition occurred. At a pH of 6.3, however, where cyclization of lactacystin 1 to omuralide 
does not occur, no inhibition was observed, whereas omuralide retained inhibitory activity 
under the same conditions. Dick expanded these results in a further paper10 with in vitro 
studies on mammalian cells. Lactacystin 1 is unable to enter cells until lactonization to 
omuralide 2 has occurred. In the cell omuralide can either inhibit the proteasome or form 
lactathione 5, a compound analogous to lactacystin 1, through a reversible reaction with 
glutathione (GSH). Lactathione 5 was presumed to act as a reservoir of omuralide 2, 
concentrating the inhibitor in the cell and allowing prolonged release (Scheme 1). 
 
Scheme 1: The mode of action and relationship between 1 and 2 
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1.3.3 The 20S proteasome 
The 20S proteasome is a large (around 700 KD) cylindrical multisubunit enzyme complex. The 
crystal structure of the yeast proteasome was obtained by Groll et al. in 1997.11 The shape of 
the proteasome is comparable to a barrel with a hollow core (Figure 3). 
 
 
 
Figure 3: The crystal structure of the 20S proteasome of yeast 
The 20S proteasome is a vital component of the ubiquitin proteasome pathway, the process 
by which proteins are labelled for degradation by ubiquitination and then destroyed. The 
proteasome is key in the second part of this process. Ubiquitinated proteins are fed into the 
proteasome and digested into short peptide chains ranging from 2-25 amino acids in length.12  
The structure is comprised of 4 rings, two outer α-rings and two inner β-rings, each comprised 
of 7 subunits. The quaternary structure therefore can be described as α7β7β7α7.13 The 20S 
proteasome can be further “capped” to with one or two 19S proteasomes, thus forming the 
26S proteasome. The 19S proteasomes function is to control access to the proteasome core 
by recognising ubiquitinated proteins and denaturing their structure. The denatured proteins 
are fed into the narrow core created by the α-ring subunits to be degraded by the catalytic β-
rings. Of the 7 subunits in each of the 2 β-rings, 3 of these subunits contain active sites to 
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degrade proteins (Figure 4). These 3 subunits, called post-glutamyl peptidyl hydrolytic-like, 
trypsin-like and chymotrypsin-like are known to be selective to hydrolysing the peptide bond 
following from specific amino acids. 
 
Figure 4. A diagram showing a cross section of a 20S proteasome β ring 
Post-glutamyl: Acidic, a preference for peptide bonds following amino acids such as aspartic 
acid and glutamic acid 
Tryptic: Basic, a preference for peptide bonds following amino acids such as arginine or lysine 
Chymotryptic: Hydrophobic, a preference for peptide bonds following amino acids such as 
tyrosine and phenylalanine 
Tabe 1 describes the rates of association between lactacystin or omuralide and the 3 catalytic 
sites of the 20S proteasome. Schreiber identified lactacystin and omuralide as inhibiting all 
active sites of the proteasome – albeit at different concentrations.8 Both active compounds, 
however, were found to be far more specific for the chymotrypsin like active site. 
Chymotrypsin (CT) and trypsin active sites were thought to bind irreversibly, whereas the 
post-glutamyl peptidyl hydrolytic site (the slowest inhibited site) was bound reversibly.  
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Table 1: Association rates of 1 and 2 on the 20S proteasome catalytic sites 
1.3.4 Mechanism of the inhibition of the 20S proteasome by omuralide 
The mechanism for inhibition of the proteasome shown in scheme 2 was proposed by Groll 
et al., supported by crystal structures of omuralide associated with the chymotrypsin-like 
active site.14,15 
 
Scheme 2: Mechanism of inhibition of the chymotrypsin site by omuralide 
As predicted by Schreiber,7 inhibition of the proteasome occurs due to nucleophilic attack to 
the β-lactone by a threonine residue, ordinarily the amino acid responsible for the catalytic 
Kassoc = Kobs/[I] (M-1 S-1) 
Compound 
and 
concentration 
Chymotrypsin 
like 
Trypsin like Post-glutamyl 
peptidyl 
hydrolytic like 
1 (10 µM) 194 ± 15 10.1 ± 1.8  
1 (100 µM)   4.2 ± 0.6 
2 (1 µM) 3059 ± 478   
2 (5 µM)  208 ± 21  
2 (50 µM)   59 ± 17 
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hydrolysis of peptide bonds. Various interactions then stabilize the ligand, increasing binding 
affinity, primarily the C5 moiety, which fits into the hydrophobic S1 pocket of the β5 subunit, 
prolonging retention time and allowing nucleophilic attack from the threonine Thr1Oγ 
residue. 
 
Figure 5: Omuralide and spiro cyclic analogues synthesized by Jacobsen 
A more precise nature of the critical role of the C6 hydroxyl group was reported by Groll et 
al.14 through the testing of a spiro-lactone derivative of omuralide and its C6 epimer 
synthesized by Jacobsen and Balskus.16 The spiro-lactone form of omuralide 6 had 
comparable inhibition potency to omuralide, but the spiro-lactone C6 epimer 7 potency was 
greatly decreased. This result indicated that the function of the C6 hydroxyl group was not 
solely to allow formation of the β-lactone. Comparing the crystal structures of each of these 
compounds revealed that in addition to the stabilizing hydrophobic interactions between the 
C5 isobutyl group and the S1 pocket of the CT site, the C6 hydroxyl group interacts with the 
active threonine terminal amine group, further increasing stability. Another crucial role of the 
hydroxyl group was also reported; the hydroxyl group in omuralide and 6 points out along the 
path that would be required for hydrolysis of the ester linkage, blocking attack and 
subsequent dissociation of the omuralide-enzyme complex. It is therefore clear that 
omuralide is well designed for purpose. 
1.4 The ubiquitin proteasome pathway in cancer therapy 
The ubiquitin proteasome pathway (UPP) is critical for the survival and development of both 
healthy and cancerous cells, disruption of which can induce cell death. A number of studies 
have been undertaken to disrupt this pathway at any of the key stages.17,18 One of the most 
studied methods to disrupt the UPP is 20S proteasome inhibition.19,15,20,21,22 Tumour cells are 
thought to be more susceptible to cell death through this mechanism. It has been found that 
some healthy cells can survive with up to 80% inhibition of the CT site, whereas tumour cells 
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can only withstand 25% inhibition.23 The first drug to target the UPP was a 20S proteasome 
inhibitor developed by Takeda called bortezomib 8,24 and was approved for clinical use in 
2003 for treatment of multiple myeloma. 
 
Figure 6: The structure of bortezomib 
The mechanism for inhibition of the 20S proteasome occurs through binding of the active 
threonine to the boronic acid, blocking the active site in a similar manner to omuralide.15 One 
of the mechanisms for apoptosis after inhibition of the proteasome is thought to be based on 
the proteins usually responsible for inducing cell death being retained by the cell instead of 
being destroyed by the proteasome.19 Bortezomib may also cause disruption to proteasome-
dependent pathways, which increase a cell’s resistance to radiation and other drugs.19 This 
makes bortezomib particularly potent when combined with radiotherapy or other 
chemotherapy drugs. For this reason, the discovery of new proteasome inhibitors and the 
modification of known inhibitors to increase selectivity and reduce toxic side effects plays a 
vital role in research for cancer therapies. An important role of this research is the synthesis 
of various inhibitors and their derivatives for further understanding of the SAR and mode of 
action in the hope of producing inhibitors with a greater potential to become future drug 
candidates.  
1.5 Omuralide and lactacystin as targets for total synthesis 
1.5.1 Corey’s strategy for lactacystin 
1.5.1.1 The first synthesis of lactacystin 
The first total synthesis of lactacystin 1 was completed by Corey and Reichard in 1992.5 The 
total yield was 4.6%. The total number of steps was 15 (Scheme 3).  
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Reagents and conditions: (i) (CH3)3CCHO, p-TsOH, PhMe; (ii) LDA, LiBr, isobutyraldehyde, THF, 
-78 °C 8 h 51%; (iii) MeOH, TfOH, 80 °C, 6.5 h, 91%; (iv) TBSCl, imidazole, DMF, 23 °C, 3.5 h, 
97%; (v) TsOH, CH2O, C6H6, 30 m, 96%; (vi) 1. LiBH4/THF, MeOH, 23 °C, 24 h, 2. DMSO, (COCl)2, 
Et3N, CH2Cl2, -78 °C, 85%; (vii) LDA, THF, -78 °C, 2,6-dimethylphenylpropionate, 48%; (viii) H2, 
Pd/C, EtOH, 23 °C, 1 d, 87%; (ix) 1. 5% HF/CH3CN, 23 °C, 9 h, 90%; 2. DMSO, (COCl)2, Et3N, 
CH2Cl2, -78 °C, 2 h, 73%; 3. NaClO2, NaH2PO4, t-BuOH, 2-methyl-2-butene, 23 °C, 15 m, >95%; 
(x) 1,3-propanedithiol, 2% HCl in CF3CH2OH, 50 °C, 6 h, >95%; (xi) N-acetylcystine allyl ester, 
BOPCl, Et3N, CH2Cl2, 1 h, 23 °C, 79%; (xii) Pd(Ph3P)4 HCO2H, Et3N, THF, 23 °C, 1 h, 84%. 
Scheme 3: The first synthesis of lactacystin, by Corey 
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The route is remarkable by being the first synthesis of lactacystin but also by providing much 
of the material used in the early biological testing of lactacystin 1. The route also contained 
only a few instances of column chromatography. The N-benzyl serine methyl ester 9 was 
cyclized to oxazolidine 10 with pivaldehyde in acidic conditions. An aldol reaction with iso-
butyraldehyde afforded 11 in excellent diastereoisomeric purity (>98%); after a 
recrystallization from pentane, 11 was diastereoisomerically and enantiomerically pure. Acid 
cleavage of the oxazolidine ring produced 12; following a silyl-based hydroxyl protection to 
13, a second oxazolidine 14 was formed through a formaldehyde bridge in an excellent yield 
of 96%. Reduction of the methyl ester and subsequent Swern oxidation afforded aldehyde 15, 
a key intermediate. An anti-aldol reaction using 2,6 dimethylphenyl propionate under 
Pirrung-Heathcock conditions25 gave the desired isomer 16, but the yield was low at 48%. 
Hydrogenolysis of the ester produced the γ-lactam ring found in lactacystin in a bicyclic 
system with an oxazolidine (17). A deprotection of the silyl group and an oxidation of the 
resulting alcohol to a carboxylic acid yielded 18, which, on opening of the oxazolidine ring, 
afforded the dihydroxy acid 3. Addition of an allyl protected cysteine 19 and its subsequent 
deprotection yielded lactacystin 1. 
1.5.1.2 Corey’s improvement to the aldol reaction 
Corey later revisited this synthesis (Scheme 4),26 primarily improving the anti-aldol reaction 
of 15 using a chiral zirconium enolate 21.27 
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Reagents and conditions: (i) 21, THF, -20 °C, 24 h, 80%; (ii) 1) H2, Pd/C, 2) CH2N2; 3) MeOH; 
(iii) BOPCl, Et3N, CD2Cl2, Et3N, 20 min, 23 °C, >95%. 
Scheme 4: Corey’s first improvement to the anti-aldol step 
The overall yield of the desired diastereoisomer was 80% after column chromatography. 
Conversion of 22 to the bicyclic γ-lactam intermediate 17, however, was less efficient, 
proceeding in 64% yield over 3 steps. The overall yield was, however, increased. In addition 
to the improvement of the aldol reaction, Corey reported a procedure allowing the acid 3 to 
be converted to omuralide in one step using the peptide coupling reagent bis(2-oxo-3-
oxazolidinyl)phosphinic chloride (BOPCl). 
 
Figure 7: The peptide coupling reagent BOPCl 
1.5.1.3 Further improvement to the aldol reaction 
In a final improvement to the aldol reaction (Scheme 5), Corey used addition of a simple 
achiral silyl enol ether 23 catalysed by magnesium iodide to provide the desired intermediate 
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24 in 77% yield.28 This simple intermediate could be converted to the deprotected bicyclic 
lactam 25 in 76% yield over 3 steps.  
 
Reagents and conditions: (i) MgI2, CH2Cl2, 0 °C, 20 min, -10 °C, 23, 0 °C 2 h, 77%; (ii) 1) H2, 
Pd/C, EtOH, (i-pr)2NEt, 23 °C, 30 h, 2) MeOH 55 °C, 20 h, 3) 5%, HF-MeCN, 23 °C, 24 h 76%; (iii) 
1) Et3N, DMSO-(COCl)2, CH2Cl2, -78 °C, 2) NaClO2, NaH2PO4, t-BuOH, 23 °C, 3) HS(CH2)3SH, HCl, 
CF3CH2OH, 55 °C, 8 h, 77%; (iv) BOPCl, Et3N, CD2Cl2, Et3N, 1 h, 23 °C, 93%. 
Scheme 5: Corey’s second improvement to the anti-aldol step 
1.5.1.4 Corey’s second strategy to omuralide 
In 1998 Corey et al. reported a radically different approach to omuralide and lactacystin 
(Scheme 6).29 The methylsulfanyl derivative 26 was converted to the chiral monoester 27 in 
97% yield and a 95% enantiomeric excess (ee) through hydrolysis with porcine liver esterase 
(PLE). Formation of the quinine salt and recrystallization from aqueous ethanol provided 27 
in 95% ee. Treatment with oxalyl chloride provided the acid chloride, which was coupled to a 
para-methoxy benzyl (PMB)-protected glycine methyl ester. A lithium diisopropylamide 
(LDA)-induced Dieckmann cyclization formed lactam 28 in a 1:1 mix of diastereoisomers. 
Hydroxymethylation occurred using formaldehyde in a highly stereoselective (9:1) reaction, 
formaldehyde addition favouring the face opposite the SMe group to yield 29. 
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Reagents and conditions: (i) PLE, H2O, pH 7.3, 23 °C, 24 h, 97%; (ii) 1) (COCl)2, DMF (cat), 23 
°C, 1 h, 2) PMB-NHCHCO2Me, Et3N, CH2Cl2, 23 °C, 1 h, 3) LDA, THF, -78 °C, 2 h, 93%; (iii) DBU, 
THF, -78 °C, then aq. CH2O, -78 °C, 30 m, 90%; (iv) NaBH(OAc)3, HOAc, 23 °C, 1 h, 95%; (v) 1) 
PivCl, pyridine, 23 °C, 10 h, 85%, 2) TBSOTf, 2,6-lutidine, 23 °C, 12 h, 98%, 3) NaOMe, MeOH, 
23 °C, 92%; (vi) 1) Raney Ni, EtOH, 0 °C, 1 h, 82%, 2) Dess-Martin reagent, CH2Cl2 23 °C, 1 h, 
95%; (vii) H2C=C(Me)MgBr, TMSCl, THF, -40 °C, 0.5 h, 97%; (viii) 1) H2, Pd/C, EtOH, 23 °C, 12 h, 
99%, 2) TFA/H2O 4:1, 50 °C, 4 h, 87%; (ix) 1) LiOH, THF/H2O 1:1, 23 °C, 0.5 h, 2) BOPCl, Et3N, 
CH2Cl2, Et3N, 0.5 h, 23 °C, 90%; (x) CAN, CH3CN/H2O 3:1, rt, 1 h, 62%. 
Scheme 6: Corey’s alternative route to omuralide 
A stereoselective reduction with NaH(OAc)3 formed the C6 hydroxyl group in the desired 
chirality for omuralide; again, attack occurred opposite to the SMe moiety to form 30. The 
primary hydroxyl group was protected with a pivaloyl protecting group allowing a tert-
Butyldimethylsilyl (TBS) protection of the C6 hydroxyl position. Hydrolysis of the pivaloyl (Piv) 
protecting group provided 31. An unusually stereoselective (10:1) desulphurization with 
Raney® Nickel provided the C7 methyl group with the desired stereochemistry (cis to the 
hydroxyl group). Subsequent oxidation of the primary alcohol to the aldehyde with Dess-
Martin periodinane30 yielded the advanced intermediate 32. Treatment of the aldehyde with 
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a prop-2-enyl Grignard reagent incorporated the isobutyl moiety found in omuralide. 
Reduction of the alkene, formation of the β-lactone, and final protecting group removals 
furnished omuralide in a total of 18 steps from 26. 
1.5.2 The Ōmura synthesis of lactacystin 
Shortly after Corey’s seminal synthesis, Ōmura et al. published their route to lactacystin 
(Scheme 7).6 (2R,3S) Hydroxy leucine methyl ester 36 was cyclized to oxazoline 37 by 
treatment with methyl benzimidate. Hydroformylation through a lithium enolate formed 38 
in excellent diastereoselectivity (>98%). A Moffatt oxidation formed the aldehyde 39, which 
was subjected to an allylboration with 40, a method reported by Brown utilizing camphor 
derived borane 43 (Figure 7).31  
 
Reagents: (i) Ph(MeO)C=NH, 72%; (ii) LiHMDS, HCHO, 85%; (iii) DMSO, DCC, Pyridine, TFA, 
Benzene, rt, overnight; (iv) (E)-crotyl(diisopinocampheyl)borane 40, 70% (over 2 steps); (v) 1) 
O3, DMS; 2) NaClO2, NaH2PO4, 56%; (vi) 1) Pd, HCO2NH4 2) 0.1 N NaOH, 82%; (vii) 1) N-
acetylcystine allyl ester 19, BOPCl, Et3N, 79%; 2) Pd(Ph3P)4, 81%. 
Scheme 7: Ōmura’s strategy for lactacystin 
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Figure 8: The camphor derived borane 43 
The alkene was converted to the aldehyde after treatment with ozone. The resulting aldehyde 
was oxidized to provide 42. Hydrogenation formed the γ-lactam ring, which, after ester 
hydrolysis, gave 3, which was converted to lactacystin by methods identical to Corey’s 
synthesis. From 36 the overall number of steps was 10 and lactacystin was obtained in 13% 
overall yield. 
1.5.3 The Panek synthesis of lactacystin 
 
Reagents and conditions: (i) 44, TiCl4, -78 °C - -35 °C, 60% (ii) 1) O3, DMS 2) NaClO2, NaH2PO4 
90% (over the 2 steps). 
Scheme 8: Panek’s improvement to the Ōmura synthesis 
In 1999 Panek et al.32 made several improvements to the Ōmura synthesis, firstly to the 
synthesis of the starting material (R,S) hydroxy leucine 36 in a reduced number of steps (See 
chapter 2.5.1.4.4.3). In addition, improvements were made to the incorporation of the C7 
methyl and C6 hydroxyl groups to produce 42 (Scheme 8). Panek’s strategy involved a 
crotylation with TiCl4 providing the anti diasteroisomer 45 in >30:1 ratio to the syn. Ozonolysis 
of the alkene and oxidation of the resulting aldehyde formed the common intermediate 42. 
The synthesis was then completed in an analogous fashion to Ōmura. 
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1.5.4 The Adams synthesis of omuralide  
The shortest and most high yielding route to omuralide to date was completed by Adams et 
al. in 1999,33 starting in a similar manner to Ōmura using a (R,S) hydroxy leucine derivative. 
Enone 47 was synthesized using a Wittig reaction from ylide 46. Sharpless dihydroxylation of 
the enone produced 48 in good yield and >99% ee after recrystallization. Methodology 
Developed by Sharpless34 was used to brominate the alpha position of the ester; displacement 
by sodium azide gave 50. Reduction of the azide produced a mixture of the benzyl ester 51 
and benzyl amide 52, but, on treatment with p-TsOH only the Ōmura intermediate 37 was 
formed from the mixture (Scheme 9). 
 
Reagents and conditions: (i) iso-butyraldehyde, DCM, 93%; (ii) DHQ2(PHAL), K2OsO2(OH)4, 
NMO, t-BuOH:H2O 1:1, 60%; (iii) PhC(OMe)3, BF3.OEt2, DCM, then CH3COBr, NEt3, 0 °C, 93%; 
(iv) NaN3, DMSO, 85%; (v) H2, Pd(OH)2/C, 85%; (vi) p-TsOH, 89%. 
Scheme 9: The Adams synthesis of omuralide 
A chiral aldehyde, 57, was formed from 53. Saponification of 53 and subsequent construction 
of the amide with diethyl amine formed 55. Deprotection of the alcohol, followed by 
oxidation, formed 57 (Scheme 10). Treating the Ōmura intermediate 37 to an aldol reaction 
with a chiral aldehyde 57, with the correct stereochemistry of the methyl unit already 
incorporated, furnished intermediate 58. Hydrogenation and subsequent cyclization provided 
the ester 59. Saponification and formation of the β-lactone ring formed omuralide (Scheme 
10). 
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Reagents: (i) LiOH (ii) Et2NH, DIEA, TBTU, 85% (over the 2 steps); (iii) H2, Pd(OH)2/C, 100%; (iv) 
Dess-Martin oxidation, 88%; (v) LiHMDS, Me2AlCl, 57; (vi) H2, Pd(OH)2/C, 67% (over the 2 
steps); (vii) NaOH/H2O, 93%; (viii) isopropenyl chloroformate, NEt3, 79%. 
Scheme 10: Synthesis of the chiral aldehyde 57 and its use to synthesize omuralide 
1.5.5 The Poisson synthesis of omuralide 
To date, the most recent total synthesis of omuralide was completed by Poisson et al., leading 
on from their work on highly diastereoselective [2+2] cycloadditions. Using stericol as a chiral 
auxiliary, the methodology35 was applied to the synthesis of omuralide.36 Treatment of 61 
with triethylamine formed ketene 62 in situ, which underwent a [2+2] cycloaddition with 
alkene 63 to give 64. The chiral auxiliary stericol 60 was able to produce diastereoselectivities 
of >98:2 in 64. Reduction of the carbonyl group occurred in again excellent 
diastereoselectivities (>98:2) to produce a hydroxyl group which was protected as a TBS ether. 
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Removal of the stericol chiral auxiliary 60 allowed the hydroxyl group to be oxidized to 66 
(Scheme 11). 
 
Reagents: (i) Et3N, 62, Toluene 70 °C, 97%; (ii) 1) DIBAL-H 2) TBSOTf, lutidine, 95%; (iii) 1) TFA 
2) DMP, 75%. 
Scheme 11: Part 1 of the Poisson synthesis of omuralide 
An O-mesitylenesulfonylhydroxylamine (MSH) mediated Beckmann transposition formed the 
γ-lactam found in omuralide, and protection of the amide was carried out with benzyl 
bromide and sodium hydride to form 68 (Scheme 12). Removal of the TBS ether allowed 
selective opening of the oxidisilinane to a silanol and a dimethylphenylsilane. The silanol was 
oxidized using Tamao oxidation conditions, allowing addition of the iso-propyl group through 
the corresponding organolithium species. Subsequent protection of the free hydroxyl groups 
produced 72. Deprotection of the amide and oxidation of the silane produced the alcohol 73, 
which could be further oxidized to the acid 3, in turn cyclized to 2 using Corey’s 
methodology.26  
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Reagents: (i) MSH, 58%; (ii) NaH, BnBr, 92% (iii) 1) TBAF, 2) PhLi (iv) KF, H2O2, 54% (over the 3 
steps); (v) TEMPO, NCS, 64%; (vi) 1) iso-propylLi 2) Ac2O, Py, 51%; (vii) 1) H2 Pd/C 2) KBr, 
AcOOH, 80%; (viii) 1) Jones oxidation; 2) NaOH; (ix) BOPCl, Et3N, 90%. 
Scheme 12: Part 2 of the Poisson synthesis of omuralide 
1.6 SAR studies of omuralide 
1.6.1 Introduction to the SAR of omuralide  
Total synthesis of natural products is always a worthwhile pursuit for the exploration and 
understanding of molecules and reactivity, but when a bioactive natural product is the target, 
the most prized routes are those where the final compound can be easily modified to produce 
analogues of the natural product. This can often provide critical information about the 
mechanism of action in these compounds and occasionally improve the bioactivity, or create 
more stable versions, allowing a greater chance of using the molecule as a drug candidate. 
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The largest contribution to date on the SAR studies of omuralide was made by Corey.37 Simple, 
mid to late stage modifications of two of his total syntheses was able to produce a range of 
C5, C9 and C7 analogues. 
1.6.2 Modifications of the C5 and C9 position 
The overwhelming majority of C5 and C9 analogues Corey was able to produce were from 
simply exchanging the vinyl Gringard reagent or using organochromium reagents. Taking the 
product through methodology analogous (reduction of the alkene step was removed for 
74d,f,h) to the original route discussed in Chapter 1.4.1.4  was sufficient to produce a wide 
variety of C9 analogues. Each were tested in their inhibition rates of the chymotrypsin-like 
activity of the 20S proteasome (Table 2). 
 
Analogue  R’ = Kassoc (M-1 S-1) 
Omuralide 2 CH(CH3)2 3059 ± 478 
75a H 9.7 ± 6.2 
75b C6H5 No inhibition 
75c C2H5 290 ± 12 
75d CH=CH2 188 ± 11 
75e CH2CH2CH3 192 ± 35 
75f CH2CH=CH2 255 ± 40 
75g CH2CH(CH3)2 17.4 ± 2.4 
75h CH2CH(CH3)=CH2 64.7 ± 2.2 
Table 2: Association rates of C9 analogues on the 20S proteasome CT site 
Corey was unable to improve on activity with any of the C9 analogues. Further modification 
of 32 allowed a library of C5 analogues to be produced primarily involving modifications to 
the C5 hydroxyl group (Table 3). 
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Analogue R =  Kassoc (M-1 S-1) 
Omuralide 2 (S) CHOHCH(CH3)2 3059 ± 478 
76a (R) CHOHCH(CH3)2 No inhibition 
76b COCH(CH3)2 65 ± 9.6 
76c CH2CH(CH3)2 235 ± 16 
76d CH=C(CH3)2 98 ± 5 
Table 3: Association rates of C5 analogues on the 20S proteasome CT site 
Again, activity was not improved past that of omuralide. All modifications made to either the 
C9 or C5 position drastically reduced activity. It seemed the hydroxylated iso-butyl moiety 
was optimal for proteasome inhibition. 
1.6.3 Modifications to the C7 position 
To analyse the position at C7, Corey modified his improved original route to omuralide. Not 
only did Corey’s improved anti-aldol reaction discussed in chapter 1.5.1.3 improve yields of 
the omuralide synthesis, but the reaction was also able to tolerate various other alkyl groups 
into the C7 position to produce intermediates 77a-e. The remainder of the synthesis was 
completed in an analogous way to the original route. The C7 epimer 78f (derived from the by-
product of the anti-aldol reaction) was also tested. Also included in table 4 is an analogue 
synthesized by Adams et al.33 Like Corey’s synthesis, modification during the aldol reaction 
(in this case through the use of a different chiral aldehyde) was able to provide an n-propyl 
analogue. Analogue 78g was then elaborated to the omuralide derivative in an analogous way 
to the original Adams route discussed in chapter 1.5.4.  
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Analouge R = Kassoc (M-1 S-1) 
Omuralide 2 CH3 3059 ± 478 
78a H 450 ± 77 
78b CH2CH3 6679 ± 553 
78c (CH2)3CH3 7275 ± 466 
78d CH(CH3)2 8465 ± 1572 
78e CH2C5H6 2227 ± 180 
78f CH3 (epimer) 1250 ± 180 
PS – 519 78g  CH2CH2CH3 7127 
Table 4: Association rates of C7 analogues on the 20S proteasome CT site 
Modifications to the C7 site were not only well tolerated but in many cases also vastly 
increased rates of association. In general, larger groups improved rates of inhibition. The most 
improved analogue tested was an iso-propyl group derivative. However, if the group size was 
increased vastly, such as the benzyl group in 78e, inhibition would decrease compared to 
omuralide. 
 
Figure 9: The potent dimethylated Corey analogue  
Another important C7 analogue is the gem-dimethyl omuralide analogue 79. Despite slightly 
lower activities than omuralide, the loss of one chiral centre has made the analogue a more 
attractive target for practical purposes. Corey has undertaken several syntheses of this target 
by increasingly efficient methods.38,39,40 
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It was thought by Corey that at this point omuralide and related β-lactone, γ-lactam 
proteasome inhibitors could be improved no further, concluding these investigations. 
1.7 The salinosporamides and cinnabaramides 
1.7.1 A new generation of β-lactone, γ-lactam proteasome inhibitors 
 
Figure 10: New β-lactone, γ-lactam proteasome inhibitors 
Contrary to the belief that the β-lactone, γ-lactam core could be improved no further, in 2003 
Fenical et al. reported the discovery of a new β-lactone, γ-lactam proteasome inhibitor.41 
Salinosporamide A; isolated from the newly discovered marine actinomycete salinispora 
tropica. Salinosporamide contained the same β-lactone, γ-lactam core as omuralide, but this 
scaffold contained increasingly advanced substructures. Most unusual was the modification 
to the C7 position, which now contained a chloroethyl chain. Further modifications to the 
structure included a cyclohexene moiety at C5, and a methyl at C6.  When tested against 
omuralide for proteasome inhibition activity at the chymotrypsin-like site, salinosporamide 
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showed remarkable activity; approximately 35x more potent. Later work42,43 looking at 
salinispora tropica uncovered several more members of the salinosporamide family of 
compounds, including salinosporamide B - a dechlorinated derivative of salinosporamide A. 
The majority of these salinosporamide derivatives were found to be considerably more active 
than omuralide. 
Furthermore, in 2007 the discovery of the cinnabaramides A-G was reported.44 Containing 
the same β-lactone, γ-lactam core as omuralide, and an identical cyclohexene moiety as found 
in the salinosporamides. The cinnabaramides also displayed activities far greater than 
lactacystin. Interestingly the thioester derivatives 85 and 86, unlike lactacystin, show similar, 
even increased activities compared to their β-lactone counterpart (Table 5).  
Compound IC50 [nm] inhibition of human 
proteasome 
Lactacystin 1 259 
Cinnabaramide A 82 1 
Cinnabaramide B 83 245 
Cinnabaramide C 84 12 
Cinnabaramide F 85 6 
Cinnabaramide G 86 0.6 
Table 5: Inhibition activities of the cinnabaramides 
1.7.2 Salinosporamide A’s mechanism of action 
In 2006 Groll et al. reported a crystal structure of salinosporamide A in the 20S proteasome.45 
A key difference to omuralide was the formation of a cyclic ether between the chloroethyl 
and C6 hydroxyl group. Groll suggested this blocked hydrolysis of the ester, increasing stability 
of the salinosporamide A-proteasome complex. The cyclization was also entropically and 
enthalpically favourable. The observations led Groll to propose the mechanism of 20S 
proteasome inhibition by salinosporamide A, shown below (Scheme 13). 
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Scheme 13: The mechanism of salinosporamide A inhibiting the CT site of the 20S proteasome 
Unlike the cinnabaramides, lactacystin-like thioester derivatives of salinosporamide have not 
been discovered in nature. It is likely that this is because this could induce premature 
cyclization of the cyclic ether due to the free hydroxyl group, reducing the inhibitory potential 
of salinosporamide A.46  
1.7.3 SAR of the salinosporamides 
Extensive work has been reported on the SAR studies of salinosporamide, and reviewed.46,47 
Unlike omuralide, these studies have been unable to produce dramatic changes in the 
potency of salinosporamide, however, analogues have been produced with complementary 
inhibitory potential as salinosporamide A, and have shown the importance of several  
salinosporamide functionalities (Table 6). This provides potentially useful structural 
information for future development of β-lactone, γ-lactam 20S proteasome inhibitors. 
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Name Structure IC50 Value CT site nM 
Omuralide 2 57 ± 6 
Salinosporamide A 80 80 2.6 ± 0.2 
Salinosporamide B 81 81 27 ± 4 
Salinosporamide D 88 
 
7.7 ± 3 
Salinosporamide E 89 
 
24 ± 5 
Antiprotealide 87 
 
31 ± 5 
Iodosalinosporamide 90 
 
2.8 ± 0.5 
Table 6: SAR activity of salinosporamide analogues 
Although changes to the structure of salinosporamide A generally provide less potent 
analogues. Many of these derivatives still possess activity greater than omuralide. These 
results seem to suggest the greatest modification from omuralide to salinosporamide A for 
proteasome inhibition, is the addition of the cyclohexene unit. This can be seen clearly in the 
comparison of omuralide with salinosporamide D 88, where addition of the C6 methyl and C5 
cyclohexene ring have increased potency from omuralide by about 7x. Furthermore, 
replacement of the cyclohexene ring in salinosporamide A with an omuralide like iso-propyl 
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group (antiprotealide 87) decreases potency by 12x. Antiprotealide was first synthesized by 
Corey48 as a hybrid of omuralide and salinosporamide A then, later, found also to be a natural 
product.49 Interestingly, unlike omuralide analogues, salinosporamide B appears not to 
benefit from extension of the C7 alkyl group (salinosporamide E 89), potency even increased 
on shortening the ethyl chain to a methyl, as in salinosporamide D 88. 
Where the most promising results have been found however, is modification of the chlorine 
on the C7 alkyl chain with better leaving groups. Although IC50 values have remained relatively 
unchanged, cytotoxicity has been found to increase slightly.47  
Like omuralide, key to understanding the full activity of salinosporamide A has been aided by 
a number of syntheses, first of which was completed by Corey et al.50  
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1.7.4 Total synthesis of salinosporamide A 
1.7.4.1 The first total synthesis of salinosporamide A 
 
Reagents and conditions: (i) p-TsOH, toluene, reflux, 12 h, 80%; (ii) LDA, THF, HMPA, -78 °C, 
ClCH2OBn, 4 h, 69%; (iii) NaCNBH3, AcOH, 40 °C, 12 h, 90%; (iv) 1) TMSCl, Et2O, 23 °C, 12 h, 2) 
Acrylyl chloride, i-Pr2NEt, CH2Cl2, 1 h, 0 °C, then H+ Et2O, 23 °C, 1 h, 96%; (v) Dess-Martin 
periodinane, 96%; (vi) Quinuclidine, DME, 0 °C, 7 d, 90%, 2) BrCH2Si(CH3)2Cl, DMAP, CH2Cl2, 0 
°C, 30 m, 95%; (vii) Bu3SnH, AIBN, benzene, reflux, 8 h, 89%; (viii) 1) Pd/C, EtOH, H2, 18 h, 95%, 
2) Dess-Martin periodinane, 23 °C, 1 h, 95%; (ix) 100, -78 °C, 5 h, 88%; (x) KF, KHCO3, H2O2, 
THF-MeOH (1:1), 23 °C, 18 h, 92%; (xi) 1) CAN, MeCN-H2O (3:1), 0 °C, 1 h, 83%, 2) 3 M, LiOH-
THF (3:1), 5 °C, 4 d, 3) BOPCl, Pyridine, CH2Cl2, 23 °C, 1 h, 4) Ph3PCl2, Pyridine, MeCN, 23 °C, 1 
h, (65% over the 3 steps). 
Scheme 14: Corey’s synthesis of salinosporamide A 
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The threonine amide derivative 91 was cyclized to 92 with p-TsOH allowing a completely 
diastereoselective alkylation with a chloro methyl benzyl ether (Scheme 14). Reduction with 
NaBH3CN provided the quaternary amino acid derivative 94. Protection of the threonine 
alcohol with a trimethyl silyl (TMS) protecting group allowed clean acylation of the amine, 
subsequent deprotection of the alcohol provided 95 in 96% yield over the whole sequence. 
The threonine alcohol was then oxidized with Dess-Martin periodinane. Cyclization to the γ-
lactam proceeded through a Baylis-Hillman aldol with quinuclidine in a highly 
diastereoselective manner (9:1). Protection of the hydroxyl group with a 
bromomethyldimethylsilyl chloride to 97 allowed a radical cyclization to 98. Cleavage of the 
benzyl ether and oxidation of the resulting alcohol proceeded in excellent yield to 99. The 
resulting aldehyde was used to incorporate the cyclohexene unit found in salinosporamide 
using 2-cyclohexene zinc chloride 100 in excellent diasteroselectivity (20:1). Tamo-Fleming 
oxidation provided 102 in excellent yield (92%). Removal of the PMB protecting group and 
saponification of the methyl ester was followed by formation of the β-lactone. Finally, 
chlorination of the alcohol provided salinosporamide A. 
1.7.4.2 The Romo synthesis of salinosporamide A and (±)-cinnabaramide A 
1.7.4.2.1 Introduction 
Romo et al. utilized methodology previously devised in the group51 which allowed a 1-pot 
production of β-lactone, γ-lactam scaffolds to great effect, applying this to both the synthesis 
of salinosporamide A and cinnabaramide A.52  
1.7.4.2.2 Romo’s synthesis of (±)-salinosporamide A 
Benzyl protected serine 103 was protected with PMB on the amine and an allyl protecting 
group for the carboxylic acid to product 104. The β-Lactone 105 was coupled to the protected 
serine derivative 104 in good yield (80%) using 115. The pyridine derivative 114 opens the 
lactone 105 through attack of the carbonyl, forming an activated ester which is attacked by 
amine 104. Amide 106 was deprotected to produce the cyclization precursor 107. The bis-
cyclization (Scheme 16) proceeded in low yields (up to 35%) and produced 2 diasteroisomers 
in up to a 3:1 ratio. Removal of the benzyl ether protecting group and oxidation of the 
resulting aldehyde provided 110. Using Corey’s methodology to install the cyclohexene ring 
(Scheme 14), which was surprisingly tolerant to the β-lactone, produced a 3.5:1 ratio of 
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diastereoisomers which, after PMB removal by ceric ammonium nitrate (CAN), produced 
salinosporamide A (Scheme 15). 
 
Reagents and conditions: (i) 1) p-methoxy benzaldehyde, MeOH, NaBH4, 2) p-TsOH, allyl 
alcohol, (2 steps, 74%); (ii) 105, 112, THF, 60 °C, 36 h, 80%; (iii) (Pd(PPh3)4, morpholine, 75%; 
(iv) 114, i-Pr2NEt, 113, CH2Cl2, -10 °C, 6 h, up to 35%; (v) 1) H2 Pd/C, THF, 25 °C, 98%; 2) 
EDAC.HCl, DMSO, Cl2CHCO2H; (vi) 100, THF, -78 °C, 33% over the 2 steps; (vii) CAN, 
MeCN/H2O, 49%. 
Scheme 15: Romo’s synthesis of salinosporamide A 
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1.7.4.2.3 The key bis-cyclization in Romo’s synthesis of salinosporamide A 
The bis-cyclization reported by Romo first requires activation of the acid 107 by 112. 
Substitution of this by the 4-dimethylaminopyridine (DMAP)-like derivative 113 further 
activated the acid, providing the intermediate 117 with an excellent leaving group. 
Deprotonation to the pyridinium enolate allows an aldol reaction, to form the γ-lactam (119). 
Attack from the newly formed alkoxylate on the pyridinium-activated-carbonyl forms the β-
lactone (Scheme 16). 
 
Scheme 16: The mechanism for the bis-cyclization reported by Romo 
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Despite several steps with decreased yields, Romo synthesized salinosporamide A in a 
remarkably short number of steps. In addition, modification of the lactone 105 allowed the 
methodology to be expanded further. 
1.7.4.2.4 The first synthesis of (±)-cinnabaramide A by Romo 
The methodology designed by Romo was then applied to cinnabaramide A (Scheme 17). Like 
the route to salinosporamide A, benzyl protected serine 103 was used, and protected with a 
PMB group and a methyl ester. Coupling of this to 120 produced the bis-cyclization precursor 
after deprotection of the ester to the acid with trimethyltin hydroxide. The cyclization 
proceeded in slightly better yield than the route to salinosporamide A, and better 
diastereoselectivity - (4.7:1) 123:124. The final steps occurred in an analogous fashion to 
Romo’s synthesis of salinosporamide A. 
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Reagents and conditions: (i) 1) p-methoxy benzaldehyde, MeOH, NaBH4, 2) TMSCHN2, 
MeOH/Et2O, (2 steps, 58%); (ii) 120, 114, THF, 50 °C, 48 h, 85%; (iii) Me3SnOH, 69%; (iv) 112, 
i-Pr2NEt, 113, CH2Cl2, 0 °C, up to 45%; (v) 1) H2 Pd/C, THF, 25 °C, 79%; 2) SO3.pyridine, DMSO; 
vi) 100, THF, -78 °C, 57% over the 2 steps; (vii) CAN, MeCN/H2O, 48%. 
Scheme 17: Romo’s synthesis of cinnabaramide A 
Later variants of this synthesis, primarily the separation of the 107 diastereoisomers, allowed 
an enantioselective route to salinosporamide A, including the production of new analogues 
of this valuable compound.53  
1.8 Similar γ-lactam cores in other natural products 
Similar γ-lactam cores are found in other natural products which are currently not known to 
have proteasome inhibiting potential. Although our primary focus is omuralide and related 
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derivatives, such compounds further highlight the importance of developing methodology to 
access these biologically relevant cores. 
 
Figure 11: A selection of γ-lactam natural products 
Monascutin 127 was discovered in 2016 after being isolated from red yeast rice.54 
Streptopyrrolidine 128 was discovered in 2008 after isolation from deep sea sediment.55 
Interest in this molecule stems from its ability to inhibit angiogenesis, which could provide 
promising anti-tumour drugs. Oxazolomycin 129 is particularly interesting, not only due to its 
γ-lactam core but also the spiro β-lactone ring.56 Oxazolomycin 129 exhibits antibacterial 
activity and is under investigation by several groups.57,58 The lajollamycins are another related 
family of compounds which share similar structural features to oxazolomycin.59  
Hoshinolactam 130 was recently discovered as an isolate from a marine cyanobacterium 
which displays potent anti-parasitic properties.60 (-)-L-755,807 131 was originally discovered 
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by Merk,61 interestingly, under investigation for its ability to induce neurite outgrowth, which 
studies into omuralide have shown can be a consequence of proteasome inhibition. The 
absolute configuration was later reported using total synthesis by Kogen et al.62 Dysidamide 
C 132 belongs to a family of compounds isolated from marine sponges.63 Finally, L-tenuazonic 
acid64 133 was one of the first tetramic acid natural product to be isolated, since discovery, 
numerous additions to this class of natural products have been isolated, characterized and 
synthesized.65,66 Such compounds have been found to exhibit a wide range of biological 
activities, such as anti-microbial, anti-viral, and anti-tumour properties.  
1.9 Previous work in the Page group 
1.9.1 Previous work using glycine as the starting material 
1.9.1.1 Synthesis of an advanced intermediate from glycine 
Initial work in the Page group focussed of the synthesis of functionalized lactam cores related 
to omuralide.67 The lactam core was derived from glycine, with no original chirality, the cores 
were racemic.  
The key step was the Dieckmann cyclization (Scheme 18), allowing formation of the lactam 
core 136, then the alkylation of the tetramic acid like position with tetra-N-butylammonium 
fluoride (TBAF) and MeI. Further optimization of this step allowed a 1 pot procedure to be 
developed, where TBAF induced cyclization of 135, then, after MeI addition, facilitated 
alkylation (Scheme 19). 
 
Reagents and conditions: (i) BnOCOCH2COCl, py, DMAP, CH2Cl2, rt, 24 h, 83%; (ii) NaH, PhH, 
6 h, 63%. 
Scheme 18: Cyclization of glycine to a functionalized γ-lactam core 
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Reagents and conditions: (i) TBAF, MeI, THF, 24 h, 70%; (ii) TBAF, Et2O, rt, MeI, THF, 24 h, 
53%. 
Scheme 19: Alkylation of the γ-lactam core and the 1-pot cyclization/alkylation 
A further key step in the synthesis of the functionalized lactam core, was the addition of a 
methyl ester using Mander’s reagent.68 This allowed acetylation at the carbon, with no 
competing O-acetylation, in a diastereoselective manner (5:1). Finally, removal of the benzyl 
ester produced the advanced intermediate of omuralide (Scheme 20). 
 
Reagents and conditions: (i) LiHMDS, NCCO2Me, DMPU, THF, -78 °C, 2 h, 75%; (ii) H2, Pd(OH)2, 
THF, rt, 20 min, 95%. 
Scheme 20: Acylation of 137 leading to the advanced intermediate of omuralide 139 
1.9.1.2 Synthesis of the full carbon skeleton of omuralide from glycine 
Later work by the Page group built on this, allowing elaboration of intermediate 138 to the 
full carbon skeleton of omuralide.69 Initial work to install the C9 hydroxyl group with the iso-
butyl moiety through an acylation, was thwarted by formation of the O- acetylated product 
140. However, alkylation at this position was successful, forming the full carbon skeleton. 
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Reduction of the alkene and hydrogenolysis of the benzyl ester was achieved in one step, 
providing the advanced intermediate of C9-deoxy omuralide 142 (Scheme 21). 
 
Reagents and conditions: (i) (CH3)2CHCOCl, py, CH2Cl2 24 h, 68%; (ii) NaH, DMF, 
CH2=CCH3CH2Br, rt, 24 h, 75%; (iii) H2, Pd/C (cat), 90% (1:1 mix of diastereoisomers by NMR). 
Scheme 21: Elaboration of 138 to the full carbon skeleton of omuralide 
1.9.2 Studies towards the synthesis of C9-deoxy omuralide from L-leucine 
1.9.2.1 Synthesis of the γ-lactam core  
Later work in the Page group has concentrated on the use of chiral amino acids as starting 
materials.70 Not only does this allow the carbon skeleton of omuralide to be synthesized in a 
much more efficient manner (the iso-butyl does not need to be incorporated later), but the 
initial chirality should also be able to direct the synthesis, providing a route to enantiopure 
compounds. Varying the amino acid starting material should also be able to produce new 
analogues of omuralide. Currently, the majority of this work has focused on leucine, which, 
once fully elaborated, could produce C9-deoxy omuralide (Scheme 22). 
 
Scheme 22: Using leucine to form an omuralide analogue 
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Reagents and conditions (i) 1) para-Methoxy benzaldehyde, acetic acid, toluene, reflux 2) 
NaBH3CN, acetic acid, MeOH, 93%. (ii) 146, EDAC.HCl, DMAP, N-methyl morpholine, CH2Cl2, 
72%. 
Scheme 23: Synthesis of a leucine derived Dieckmann cyclization precursor 147 
 
Figure 12: EDAC.HCl in straight chain and cyclized form 
Leucine methyl ester 144 was protected with PMB using an acid catalysed reductive 
amination procedure. Coupling to 146 with peptide coupling reagent 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide HCl  (EDAC.HCl) provided a Dieckmann cyclization 
precursor 147 similar to 135 (Scheme 23). 
 
Reagents and conditions: (i) TBAF (1M in THF), THF, MeI, rt, overnight, 59%. 
Scheme 24: The Dieckmann cyclization incorporation leucine into the γ-lactam core 
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Dieckmann cyclization precursor 147 was treated to a comparable reaction developed for the 
glycine route, producing a 1:2 mixture of diastereoisomers. Unfortunately, however, the 
material was found to be racemic (Scheme 24). This was assumed to have occurred during 
the Dieckmann cyclization by fluoride mediated deprotonation of the α-ketone position. 
1.9.2.2 The acylation using Mander’s reagent 
Each of the diastereoisomers were found to undergo acetylation diastereoselectivly using 
Mander’s reagent (Scheme 25).  
 
Reagents and conditions: (i) LiHMDS, DMPU, methyl cyanoformate, THF, -78 °C, using (±)-
148a: 73%, using (±)-148b 79%, using (±)-148a and (±)-148b 86%. 
Scheme 25: The acylation using Mander’s reagent of the diasteroisomers (±)-148a and (±)-
148b 
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Addition of the methyl ester occurred opposite the bulky benzyl ester. Because both 
diastereoisomers were racemic, and the reaction was diastereoselective, separation of the 
diasteroisomers (±)-148a and (±)-148b was not necessary, as both would go through the same 
racemic intermediate (±)-150. 
1.9.2.3 Elaboration of the γ-lactam core to C9-deoxyomuralide 
1.9.2.3.1 Strategy and reduction of the C6 ketone 
Following from the success of the construction of the γ-lactam core, work focused on the 
functional group manipulations required for the synthesis of C9-deoxy omuralide. The 
strategy developed involved reduction of the C6 ketone, followed by removal of the benzyl 
ester (Scheme 26). 
 
Scheme 26: Strategy consisting of reduction and removal of the benzyl ester to produce 
advanced intermediate (±)-152 
This should produce the advanced intermediate (±)-152. Reduction of (±)-149 using sodium 
borohydride occurred in surprisingly high diastereoselectivity with the hydride adding on the 
same face as both the iso-butyl and the benzyl ester (Scheme 27). 
 
Reagents and conditions: (i) NaBH4, EtOH, 0 °C to rt, 30 min, up to 57%. 
Scheme 27: Reduction of (±)-152 with NaBH4 producing (±)-151 
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1.9.2.3.2 Attempts at removal of the benzyl ester 
1.9.2.3.2.1 Removal using an acyl selenium decarboxylation 
The first decarboxylation strategy attempted was via the acyl selenium (±)-154 through a 
radical mediated pathway (Scheme 28). 
 
Scheme 28: Strategy for the formation of an acyl selenium derivative (±)-154 for 
decarboxylation 
An example by Allin et al.71 shows decarboxylation can occur in similar functionalities. 
Removal of the benzyl ester proceeded in good yield, providing the acid (±)-153 (Scheme 29). 
Formation of the acyl selenide however failed, instead producing the β-lactone (±)-155 
(scheme 30). Various methods to protect the C6 hydroxyl group were then attempted, 
however, this was surprisingly difficult. The most effective group was found to be a 
trifluoroacetate. 
 
Reagents and conditions: (i) H2, Pd(OH)2, THF, quant. 
Scheme 29: Removal of the benzyl providing acid (±)-153 
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Reagents and conditions: (i) Bu3P, (PhSe)2, CH2Cl2, 24 h, 66%. 
Scheme 30: Attempt at forming the acyl selenide (±)-154 
Trifluoroacetate protection proceeded in good yield allowing the acyl selenide (±)-154 to be 
formed, unfortunately however, subjecting this to the conditions required for 
decarboxylation resulted in a complicated mixture of products (Scheme 31). 
 
Reagents and conditions: (i) (CF3CO)2O, pyridine, Et2O, 81%; (ii) Bu3P, (PhSe)2, CH2Cl2, 24 h, 
31%; (iii) n-Bu3SnH, AIBN, toluene, 80 °C, 2 h. 
Scheme 31: Formation of acyl selenide (±)-154 and attempts at decarboxylation 
1.9.2.3.2.2 Removal using Barton decarboxylation 
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Following on from the failed decarboxylation attempts with the acyl selenide. Formation of a 
Barton ester was pursued. In the correct conditions, this should undergo Barton 
decarboxylation.  
 
Scheme 32: Decarboxylation strategy via Barton ester (±)-160 
Unfortunately, attempts to form the Barton ester (±)-157 all resulted in the β-lactone by-
product (±)-155 (Scheme 33). Both (±)-153 and the trifluoroacetic acid (TFA) ester protected 
derivative (±)-156 were treated with coupling conditions, using peptide coupling EDAC.HCl 
and 2-mercaptopyridine N-oxide sodium salt. (±)-157 was also attempted to be synthesized 
through an acyl chloride (Scheme 33) but again this resulted in β-lactone (±)-155. 
 
Reagents and conditions: (i) (±)-153, oxalyl chloride, and 2-mercaptopyridine N-oxide sodium 
salt, DMF, CHCl3; (ii) (±)-153 or (±)-156, EDAC.HCl, N-MM, DMAP, 2-mercaptopyridine N-oxide 
sodium salt, THF. 
Scheme 33: Attempts to form the Barton ester 
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1.9.2.3.2.3 Removal using a Krapcho decarboxylation 
A final attempt at decarboxylation was attempted using Krapcho72 conditions, unfortunately 
this resulted in removal of both the methyl ester and the benzyl ester (Scheme 34).  
A potential approach to future work on decarboxylation strategies of (±)-153 may find success 
using the reagent by Garner73 S-(1-Oxido-2-pyridinyl)-1,1,3,3-tetramethyl-thiouronium 
Hexafluorophosphate (HOTT). Which has been found to decarboxylate particularly hindered 
esters. 
 
Reagents and conditions: LiCl, DMF, 135 °C, 4 h, (±)-158 49% and (±)-159 38%. 
Scheme 34: Treatment of (±)-151 with Krapcho decarboxylation conditions 
With all strategies for decarboxylation failing, a new approach was undertaken. 
1.9.2.3.3 New strategy to reach intermediate (±)-152 
The new strategy involved first removing the benzyl ester, then reducing the C6 carbonyl 
(Scheme 35). 
 
Scheme 35: New strategy to (±)-152 involving removal of the benzyl ester followed by 
reduction  
Removal of the benzyl ester was achieved using hydrogenolysis conditions (Scheme 36). 
Despite a number of methods attempted however (Table 7), (±)-152 was unable to be 
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synthesized (Scheme 36). This is perhaps due to the readily enolizable nature of the ketone, 
a new strategy was devised based on a procedure used by Pattenden74,74 where a thiomethyl 
group would be installed, the ketone reduced, then the thiomethylated compound 
desulfurized. This strategy is explained in more detail in chapter 2.2.3.1. 
 
Reagents and conditions: (i) H2, Pd(OH)2/C, THF, 30 °C, > 90%; (ii) See table 7. 
Scheme 36: Hydrogenolysis followed by reduction strategy 
 
 
 
 
 
 
Table 7: Reduction conditions attempted for formation of (±)-152 
  
Reducing 
reagent 
Conditions Result 
NaBH4 EtOH 0 °C, 30 m Complex mixture 
NaBH3CN MeOH 0 °C - rt, 2 h SM 
NaBH(OAc)3 Acetic acid, rt, 1 h Unidentified compound 
LAH THF, 0 °C, 2 h Decomposition 
LAH THF, -78 °C, 1-2 h Complex mixture 
DIBAL THF, 0 °C, 2 h Complex mixture 
DIBAL THF, -78 °C, 1-2 h Complex mixture 
Red-Al® DCM, -78 °C, 1-2 h Complex mixture 
Noyori catalyst IPA/THF 5:1, 3-6 days Unidentified compound 
 46 
 
1.9.3 Studies towards the synthesis of omuralide from L-serine 
1.9.3.1 Overview of route using serine 
Previous work in the group has also focussed on incorporating serine into the γ-lactam core. 
Using the previously developed Dieckmann cyclization/alkylation methodology. Once 
incorporated, with the C5 hydroxyl group in place, elaboration to omuralide should be 
achievable (Scheme 37). 
 
Scheme 37: Incorporation of 161 into the lactam core and elaboration to omuralide 
1.9.3.2 Studies toward the synthesis of omuralide from serine 
Protection of serine proved more difficult compared to the leucine route. Methods previously 
developed failed (Scheme 23), however formation of the imine, and its subsequent reduction 
under an atmosphere of hydrogen, afforded 163 in fair yield. Unfortunately, however, 
coupling to 146 under the standard conditions produced only a small quantity of desired 
product 165. This is primarily down to the disubstituted by-product 164 being formed 
(Scheme 38). 
  
 47 
 
 
Reagents and conditions: (i) para-methoxybenzaldehyde, triethylamine, H2, Pd/C, MeOH, 
64%; (ii) 146, EDAC.HCl, DMAP, N-methyl morpholine, CH2Cl2, 165: 14%, 164: 31 %. 
Scheme 38: PMB protection of serine and coupling of the product to 168 
Due to these problems, a protection strategy was devised, protecting the hydroxyl group with 
protecting group triisopropyl silyl (TIPS). The Dieckmann cyclization precursor 167 was then 
obtained in excellent yields (Scheme 39). 
 
Reagents and conditions: TIPSCl, imidazole, DMF, reflux, 90%; (ii) 146, EDAC.HCl, DMAP, N-
methyl morpholine, CH2Cl2, 91%. 
Scheme 39: The formation of the TIPS protected cyclization precursor 167 
Unfortunately, however, when treated to the cyclization/alkylation conditions the γ-lactam 
162ab was not isolated. It was thought there could be too many competing reactions between 
cyclization and TBAF induced deprotection of the TIPS group (Scheme 40). 
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Reagents and conditions: TBAF, MeI, THF, overnight. 
Scheme 40: Treatment of 167 with the Dieckmann cyclization/alkylation conditions 
1.9.3.3 Starting from a benzyl ether serine derivative 
To avoid these problems, a benzyl ether protected version of serine was acquired (168). 
Protection of the amine again proved difficult and so 168 was coupled to 146 forming the 
Dieckmann cyclization precursor 169 as a secondary amide. Treating this to the Dieckmann 
cyclization conditions, however, failed to cyclize 169 to the lactam 170, instead, alkylating the 
malonic position twice forming 171 (Scheme 41). 
 
Reagents and conditions: 146, EDAC.HCl, DMAP, N-methyl morpholine, CH2Cl2, 69%; (ii) TBAF, 
MeI, THF, overnight, 30%. 
Scheme 41: Attempted cyclization of 170 with the Dieckmann cyclization/alkylation 
conditions 
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2.0 Results and discussion 
2.1 Retrosynthetic analysis of omuralide and related γ-lactam materials 
We aim to develop a flexible route to a highly functionalized γ-lactam core. This route, 
modified appropriately, should be able to produce known natural products such as omuralide 
and the salinosporamides, and known and novel analogues of these compounds. Scheme 1 
shows the general retrosynthetic analysis used to produce the β-lactone, γ-lactam 
proteasome inhibitors and analogues. The β-lactone γ-lactam core could be formed through 
saponification of the corresponding methyl ester to the acid, followed by lactonization to the 
C6 reduced, acylated β-lactam core. The C6 alcohol, which would also become the β-lactone, 
could be formed either through hydride reduction or alkylation of the ketone, depending on 
the analogue required. Previous work in the group had shown that the methyl ester could be 
inserted diastereo- and chemoselectivly using Mander’s reagent directed by a benzyl ester 
leading to the acylated γ lactam core. The lactam core would be produced through a tandem 
Dieckmann cyclization/alkylation leading to the Dieckmann cyclization precursor. 
Modification of the alkylating agent should produce lactam cores with various C7 alkyl groups, 
allowing further modification of the route. The Dieckmann precursor could be coupled to a 
half malonic benzyl ester through a peptide coupling, leading to the N-protected amino acid 
methyl ester. Modification of the amino acid starting material provides a final degree of 
flexibility allowing various different moieties at the C9 position. Amino acids were used as the 
starting material due to their inherent chirality, allowing the synthesis to be stereochemically 
directed. 
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Scheme 1. Retrosynthetic analysis of the β-lactone, γ-lactam core 
The work presented here describes our synthetic route from L-leucine. Fully elaborated, L-
leucine would form C9-deoxy-omuralide, which possesses the full carbon skeleton of 
omuralide. Also discussed is our work using L-serine as starting material, with the C9 hydroxyl 
group in place from the beginning. Fully elaborated, this could form omuralide. Modification 
of the L-serine route could also be used to produce other related natural products such as the 
cinnabaramides, salinosporamides and antiprotealide. 
 
Figure 1. Various β-lactone, γ-lactam natural products 
2.2 Elaboration of L-Leucine methyl ester HCl to (+)-C9-deoxy-omuralide 
2.2.1 Outline of the general procedure 
The proposed route to C9-deoxy-omuralide (Scheme 2) followed the outline of the route in 
Scheme 1. Building on previous work in the Page group,67,69,75 leading to 149, following 
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removal of the benzyl ester, the thiomethyl blocking group strategy first used by Corey29 and 
later by Pattenden76,74 would be followed to allow reduction of the C6 ketone (173). 
Desulphurization followed by protecting group removal should provide the substituted 
pyroglutamate 174, which has been cyclized to C9-deoxy-omuralide by Mereddy et al.77 
 
Scheme 2: Plan for the synthesis of 9-deoxy-Omuralide from L-Leucine 
2.2.2 Formation of the full carbon skeleton of omuralide 
2.2.2.1 N-Protection of leucine 
Corey had shown in previous syntheses that the PMB protecting group could be removed 
from late stage intermediates and analogues of omuralide and lactacystin. This result has led 
PMB to be a common protecting group in lactacystin synthesize and hence PMB was utilized 
in our route.  
Para-methoxy benzaldehyde and L-leucine were heated under reflux in acidic conditions 
using a Dean-Stark apparatus to form the corresponding imine 175. The resulting imine could 
be reduced with sodium cyanoborohydride to afford the amine 145 in excellent yield (Scheme 
3). 
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Reagents and conditions: i) 4-methoxybenzaldehyde (1.1 equiv), acetic acid (0.6 equiv), 
toluene, reflux, quant; ii) NaBH3CN (2 equiv), acetic acid (0.9 equiv), MeOH, 96%. 
Scheme 3: Two step, one pot reductive amination 
However, during further characterization, discrepancies were found between the optical 
rotation value of the amine and the literature value.78 To our surprise, it was found that the 
leucine chirality had been completely lost under the reaction conditions. Although previous 
work in the Page group had observed racemization in the synthetic route, this was assumed 
to have been much later in the synthesis. Very similar findings have been observed in the 
comprehensive study by Yamada et al.,79 where various amino acids were racemized at high 
temperatures in the presence of aldehydes and acetic acid due to the formation of a Schiff 
base, lowering the pKa of the alpha ester proton (Scheme 4). A similar racemization involving 
piridoxal phosphate (PLP) (the active form of vitamin B6) is a common occurrence in metabolic 
pathways,80 one key use being the formation of D-serine from L-serine in conjunction with 
serine racemase.81 
 
Scheme 4: Racemization of leucine and the structure of PLP 
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Due to the racemization occurring in the acidic conditions during imine formation the 
procedure was modified to a 1-pot reaction in basic conditions. A similar racemization has 
also been observed under basic conditions,82 therefore, DL-Leucine (176) was also acquired, 
esterified and subject to the same conditions. The reductive amination proceeded with good 
yield in both cases, but, more importantly, comparison of the known racemate and the N-
protected amino acid from L-leucine using high performance liquid chromatography (HPLC) 
with a chiral stationary phase, showed there had been no observable racemization using the 
new procedure (Scheme 5). 
 
Reagents and conditions: i) p-methoxybenzaldehyde (1.1 equiv), Et3N (1 equiv), MeOH, 
NaBH4 (1.9 equiv), 0 °C to rt, 76% from L-leucine, 68% from DL-leucine; ii) acetyl chloride (3 
equiv), MeOH, 0 °C – reflux, 16 h, quant. 
Scheme 5: Esterification and one step reductive amination 
2.2.2.2 Synthesis of 146 and coupling to the N-protected leucine ester 
The Dieckmann cyclization precursor 147 was synthesized from the corresponding acid 146 
and the PMB protected leucine ester 145 (Scheme 6) 
 
Scheme 6: Formation of the Dieckmann cyclization precursor 
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Synthesis of the half malonic ester was achieved by forming the dibenzyl malonic ester 
through acidic (para-toluene sulphonic acid monohydrate) (p-TSOH) esterification of malonic 
acid 146 with benzyl alcohol (BnOH) in a Dean-Stark apparatus (Scheme 7). Mono-
saponification of the di-ester 177 induced precipitation of the potassium salt in excellent 
yield. EDAC.HCl, a common peptide coupling reagent, was used to form the peptide bond 
along with catalytic quantities of DMAP and N-methyl morpholine (N-MM). After purification 
by column chromatography, the Dieckmann cyclization precursor 147 was observed as a pair 
of rotamers in 13C and 1H nuclear magnetic resonance (NMR) experiments in an 
approximately 4:1 ratio. Variable temperature experiments in dimethyl sulphoxide (DMSO) 
found that peak coalescence occurred at 100 °C. Analysis of 147 by chiral stationary phase 
HPLC in comparison to a synthesized racemate showed that no observable racemization had 
occurred at this point. 
 
Reagents and conditions: i) Benzyl alcohol (2.1 equiv), p-TsOH (0.01 equiv), toluene, reflux 
(Dean-Stark), 16 h; ii) KOH in BnOH, 74%; iii) EDAC.HCl (2.6 equiv), DMAP (0.25 equiv), N-MM 
(2.3 equiv), DCM, 93%. 
Scheme 7: Formation of 146 and its coupling to 145 
2.2.2.3.1 The Dieckmann cyclization/alkylation 
The previously developed cyclization/alkylation occurs through deprotonation of the malonic 
position in the Dieckmann precursor 147 using TBAF as the base. Nucleophilic attack of the 
malonate at the leucine ester group forms the gamma lactam as a tetramic acid. A second 
deprotonation at the C7 position forms a highly stabilized enolate; addition of iodomethane 
in situ then provides the alkylated gamma lactam with the methyl group required for 
omuralide. The tetramic acid intermediate was assumed to be planar and therefore we hoped 
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to see diastereoselective control with the methyl iodide adding opposite the leucine’s bulky 
iso-butyl group (Scheme 8). 
 
Scheme 8: The first and second steps of the cyclization/alkylation 
Compound 147 was dissolved in tetrahydrofuran (THF) and treated with TBAF. After 30 m, 
iodomethane was added at 0 °C. After work-up and purification by column chromatography, 
separable diastereoisomers 148a and 148b were isolated in a 1:2 ratio (Scheme 9).  
 
Reagents and conditions: TBAF in THF (3.6 equiv), THF, rt, 0.5 h, then MeI (4 equiv), 0 °C to 
rt, 16 h, 57 %, Ratio 2:1 by crude NMR analysis 
Scheme 9: The tandem Dieckmann cyclization/alkylation 
Unfortunately, analysis of each diastereoisomer and a synthesized racemate by HPLC using a 
chiral stationary phase showed that a loss of enantiopurity had occurred in both 
diastereoisomers, providing the first eluting diastereoisomer in 9% ee and the second in 79% 
ee. 
2.2.2.3.2 Confirmation of the relative stereochemistry 
Each diastereoisomer was subject to analysis by nuclear Overhauser effect spectroscopy 
(NOESY) NMR experiments. It was hoped that interactions would be seen between the iso-
butyl and the C7 methyl group in one of the diastereoisomers and interactions between the 
methyl and C5 proton in the other. Perhaps similar to the interactions seen on page 66 in 
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compounds 172ab. Unfortunately however, no clear interactions could be seen that could 
suggest which diastereoisomer was isolated in excess.  
 
Reagents and conditions: (i) CAN (5 equiv), 3:1 MeCN/Water, 63% for 148b, 84% for 148a. 
Scheme 10: Removal of the PMB group in compounds 148a and 148b 
Both diastereoisomers 148a and 148b were isolated as oils, and we were therefore unable to 
obtain a single crystal X-ray structure. Removal of the PMB protecting group in the major 
second eluting fraction 148b with CAN provided the deprotected lactam as an oil, but PMB 
removal from the minor, first eluting, diastereoisomer 148a provided 179 as a colourless 
crystalline solid of which a crystal of racemic material was obtained (Scheme 10). 
The crystal structure (Figure 2) shows the methyl group cis to the bulky iso-butyl group, 
meaning that our major diastereoisomer 148b has the methyl group trans. Although the 
diastereoselectivity was not as high as hoped, we expected this to be the major 
diastereoisomer due to the steric hindrance of the iso-butyl moiety. 
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Figure 2: The x-ray crystal structure of (±)-179 (hydrogen atoms and the two other structure 
conformations removed for clarity) 
2.2.2.3.3 Loss of enantiopurity 
Loss of enantiopurity has been observed before in similar cyclizations. In 1990 Poncet et al.83 
studied C5 epimerization rates in various tetramic acid derivatives in sodium methoxide and 
methanol under reflux (Scheme 11). 
 
Reagents and conditions: MeONa, MeOH, reflux, 2 h, 97%. 
Scheme 11: Poncet’s Dieckmann cyclization epimerization 
A mechanism where epimerization occurs before alkylation seems likely as double 
deprotonation of the tetramic acid core could produce a stabilized, aromatic, pyrrole-like 
intermediate (Scheme 12). 
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Scheme 12: Potential driving force for epimerization before alkylation 
However, in-depth analysis of the reaction mixture shows this cannot be the case, or at least 
not the sole reason. The intermediate necessary for racemization to occur before alkylation 
would be achiral. This intermediate would, therefore, once protonated for alkylation to occur, 
be a 50/50 mix of enantiomers. The enolate would now undergo the diastereoselective 
alkylation. Our reaction has shown that the alkylation is diastereoselective, the methyl 
preferentially adding opposite the isobutyl group in a 1:2 ratio. Scheme 13 shows the 
outcome of this mode of racemization assuming the diastereoselectivity is 1:2, favouring the 
methyl group adding opposite the iso-butyl group. This model should produce 34% of the 
racemic material in diastereoisomer 148a and 66% of the racemic material in diastereoisomer 
148b, but we find 81% of the racemic material in diastereoisomer 148a and 19% in 
diastereoisomer 148b. For a mechanism where epimerization occurs before alkylation, the 
ratio between the diastereoisomers in the racemic material should match the total 
diastereoselectivity of the reaction. However, not only did the diastereoisomer ratio not 
match, more racemic material was found in the unfavoured diastereoisomer 148a. We can 
therefore assume the material must be racemizing predominantly after alkylation. 
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Scheme 13: Diastereoisomeric outcome assuming an epimerization before alkylation 
Because of this discrepancy we believe the primary cause of loss in enantiopurity is an 
epimerization of the diastereoisomers 148a and 148b, scrambling the stereochemistry. This 
could also explain why the first eluting diastereoisomer has a lower ee. The second eluting 
diastereoisomer has the iso-butyl and the benzyl ester on the same side. Both are quite bulky 
groups, and would presumably produce considerable steric interaction. The release of this 
steric strain by enolate formation could mean 148b is more susceptible to epimerization than 
the more thermodynamically stable 148a (Scheme 14). 
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Scheme 14: Possible explanation for the partial racemization of 148a and 148b 
To provide some evidence for this hypothesis, each diastereoisomer was stirred in TBAF in an 
attempt to induce epimerization, potentially showing 148b epimerized to 148a faster than 
148a to 148b. Unfortunately, however, both decomposed to a complex mixture of products 
on addition of TBAF (Scheme 15). Nevertheless the major and more enantiopure (79% ee) 
diastereoisomer 148b was used in the next step. 
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Reagents and conditions: (i) TBAF (1 M in THF) (3.4 equiv), rt, THF. 
Scheme 15: Epimerization studies on 148a and 148b 
2.2.2.4 Acylation of C5 using Mander’s reagent 
To provide the methyl ester which would later form the β-lactone found in omuralide, an 
acylation was required at the C5 α-keto position. Mander’s reagent was chosen due to its high 
chemo-selectivity for C-acylation of enolates over addition at the O nucleophile.68  
 
Reagents and conditions: LiHMDS (2.1 equiv), DMPU (2.2 equiv), THF, −78 °C, 0.5 h, then 
NCCO2Me (3.2 equiv), −78 °C, 4 h, 70%. 
Scheme 16: Acylation using Mander’s reagent 
Enolate formation followed by addition of Mander’s reagent proceeded with good yield 
(Scheme 16). No competing O-acylation was seen and furthermore the reaction was highly 
diastereoselective, with no minor diastereoisomer observed in NMR. The acylation had 
occurred opposite the benzyl ester as expected due to the bulky nature of the group forming 
149. 
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Figure 3: The acylated lactam core 149 and omuralide 
Although at this stage we have the correct relative stereochemistry for omuralide analogues, 
the absolute stereochemistry is that of the opposite enantiomer to natural omuralide (Figure 
3). Completing the synthetic scheme with the unnatural enantiomer of leucine (D) should 
therefore produce the correct enantiomer for omuralide analogues. Although commercially 
available, the unnatural enantiomer is far more expensive, and therefore we decided not to 
complete the synthesis with this starting material unless biological testing was required. 
Comparison with a synthesized racemate of 149 by chiral phase HPLC showed no further 
racemization had taken place. With the full carbon skeleton of omuralide completed we 
started the functional group manipulations required to produce C9-deoxy-omuralide. 
2.2.3 Manipulation of the C7 and C6 stereogenic centres 
2.2.3.1 Strategy for the construction of the C7 and C6 stereogenic centres 
Our strategy for the construction of the cis C6 hydroxyl and C7 methyl was based on a blocking 
group tactic originally used by Corey29 and later by Pattenden76,74 in their respective syntheses 
of omuralide. Corey’s approach incorporated a thiomethyl group from the beginning of the 
route. The C6 ketone could be reduced with complete diastereoselectivity using NaBH(OAc)3. 
Removal of the thiomethyl group with Raney® nickel occurred with high diastereoselectivity 
(10:1), leaving the methyl group in the position cis to the alcohol as required for omuralide 
(180). Pattenden installed the thiomethyl later using a thiosulphonate reagent with good 
diastereoselectivity (182), where addition favoured the face opposite the TBS group, and then 
reduced the C6 ketone in a similar fashion, also using NaBH(OAc)3 or Zn(BH4)2 to provide the 
sulphated Corey intermediates 30 and 183 (Scheme 17). 
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Reagents and conditions: (i) NaBH(OAc)3, AcOH, 23 °C, 1 h, recrystallization, 95%; (ii) 1) PivCl, 
Pyridine, 23 °C, 10 h 85%; 2) TBSOTf, 2,6-lutidine, 23 °C, 12 h, 98%; 3) NaOMe, MeOH, 23 °C, 
5 h, 92%; (iii) Raney-Nickel, EtOH, 0 °C, 1 h, 82%; (iv) MePhSO2SMe, Et3N, DCM, rt, 78%; (v) 
PMBBr, NaH, DMF, THF, 0 °C to rt; 2) HF, pyridine, THF, rt, 40% (two steps); (vi) NaBH(OAc)3, 
AcOH, rt, 90%; (vii) Zn(BH4)2 (4.4 M in THF), THF, 0 °C, 79%; viii) 1) TBSOTf, 2,6-lutidine, DCM, 
0 °C to rt, 80%; 2) PMBBr, NaH, DMF, 0 °C to rt, 73%; viii) HF–pyridine, pyridine, THF, rt - 40 
°C, 89%. 
Scheme 17: The Corey and Pattenden approach to C6 reduction 
We decided to follow a similar strategy to Pattenden; removal of the benzyl ester would 
provide 160ab, a similar intermediate to 181, allowing addition of the thiomethyl group 
(Scheme 18). We hoped that the bulky nature of the iso-butyl group could direct the addition 
opposite the lactam ring. With the thiomethyl blocking group in place we envisaged a similarly 
diastereoselective reduction of the C6 ketone analogous to both Corey and Pattenden. 
Diastereoselective desulphurization of the thiomethyl group would then provide all the 
stereogenic centres required to produce the C9-deoxy-omuralide analogue. 
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Scheme 18: Planned approach to the functional group manipulations to provide 7 
2.2.3.2 Removal of the benzyl ester and addition of the thiomethyl group 
2.2.3.2.1 Hydrogenolysis of the benzyl ester 
Removal of the benzyl ester was achieved through a hydrogenolysis using Pearlman’s 
catalyst84 (Pd(OH)2/C) and hydrogen in THF at 35 °C (Scheme 19). Unfortunately, proper 
characterization of this compound could not be achieved due to decomposition on silica gel, 
presumably due to the readily enolizable centre. Although the no starting material could be 
seen on thin layer chromatography (TLC), a mixture of compounds was seen in 1H NMR 
spectrum. In the most abundant compounds, however, a doublet was seen in place of the 
singlet that corresponded to the methyl group, indicating that the benzyl ester had been 
removed. As it could be possible for 160ab to be in equilibrium with each of the C7 
diastereoisomers and the ketone and lactam enolates, we decided to use the compound the 
next step without further purification. 
 
Reagents and conditions: (i) Pd(OH)2/C (cat), THF, 35 °C, overnight, quant. 
Scheme 19: Removal of the benzyl ester 
2.2.3.2.2 Synthesis of the thiosulphonate reagent and use with lactam 160ab 
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Like Pattenden, we decided to synthesize 186 as an electrophilic source of thiomethyl through 
the use of p-toluene sulphinate leaving group ability. The method used for synthesizing the 
reagent was developed by Fujiki,85 who produced thiosulphonates with differing R groups in 
good yield with a wide substrate scope through oxidation of the sulphinate with iodine. 
(Scheme 20). 
 
Reagents and conditions: (i) (MeS)2 (1 equiv), I2 (2 equiv), CH2Cl2, rt, 76%, (ii) Pd(OH)2/C (cat), 
THF, 35 °C, overnight, (iii) MePhSO2SMe (1.7 equiv), Et3N (1.2 equiv), CH2Cl2, rt, 6 h mixture 
of 172ab, 68% over the 2 steps. 
Scheme 20: Synthesis of the thiomethylating reagent 186 and its use with lactam 160ab 
The conditions used by Pattenden (Table 1 entry 3) gave a disappointing yield of 48%, a short 
optimization was carried out, changing reaction time and temperature, increasing the yield 
to 68%. The isomers were obtained after column chromatography as a 1:2 mixture of 
inseparable diastereoisomers (ratio obtained by 1H NMR spectroscopy). 
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 Time Temp °C Yield %* 
1 36 h 16-18 33 
2 Overnight 0 34 
3 Overnight 25 48 
4 Overnight 35 38 
5 Overnight 20 54 
6 6 h 25 52 
7 6 h 20 68 
Table 1: Optimization of the thiomethyl addition (step (iii) scheme 20). 
*Yields shown over the 2 steps (ii) and (iii) of scheme 20. 
Unfortunately, NOESY NMR experiments on the inseparable mixture showed that the isomer 
in excess was the undesired 172b, showing that the thiomethyl group preferentially adds 
opposite the methyl ester. Although we hoped the iso-butyl would be the predominant 
directing group, it is possible that the bulky head sits too far from the lactam ring to effectively 
direct attack of the thiomethyl unit, whereas the methyl ester is in closer proximity to the ring 
(Figure 4). 
 
Figure 4: NOESY correlations of 172ab 
2.2.3.3 Reduction of the C6 ketone 
Following Corey’s strategy and Pattenden’s experimental conditions, reduction of the C6 
ketone on was attempted with NaBH(OAc)3 using the mixture of diastereoisomers 172ab. 
Unfortunately, no reaction was seen and only starting material could be isolated. It is possible 
that the increased size of the boron complex decreases accessibility to the ketone in our 
system. Fortunately, however, the stronger reducing agent sodium borohydride was able to 
reduce the ketone, and, like Corey’s reaction, was found to be stereoselective. Hydride attack 
occurred opposite the thiomethyl group. Due to the poor diastereoselectivity of the 
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thiomethyl addition, our desired isomer 173a could only be isolated in 17% yield. Recovered 
starting material indicated that the ratio of diastereoisomers had changed from 2:1 to 6:1, 
showing that the desired diastereoisomer reacted much faster than the major one. This 
potentially shows again that the ester is effectively the bulkier group, slowing down hydride 
attack more than the iso-butyl group. Both isomers were analysed by NOESY experiments, 
showing that hydride attack had occurred opposite the thioether, and again indicating that 
the major product was our undesired diastereoisomer (Scheme 21). 
 
Reagents and conditions: (i) NaBH(OAc)3 (2 equiv), AcOH, 40 °C, 16 h; (ii) NaBH4 (0.6 equiv), 
EtOH, 30 m, -10 °C, 173a 17 %, 173b 46%. 
Scheme 21: Reduction of 173ab 
2.2.3.4 Desulphurization of C7 
2.2.3.4.1 Raney® Nickel and uses 
Raney® nickel was developed by Murry Raney in 1926 as a method of hydrogenation of 
vegetable oils. The catalyst is formed by sodium hydroxide dissolution of aluminium from a 
nickel/aluminium amalgam, providing nickel with a large surface area.86 Raney® nickel’s use 
in desulphurization was observed in 1939,87 and a more comprehensive analysis was carried 
out in 194388 with a wide variety of aliphatic and aromatic compounds. Perhaps the most 
famous use of Raney® nickel’s desulphurizing ability is the Mozingo reduction, whereby a 
thioketal is formed from a carbonyl and then hydrogenolysed to an alkane through treatment 
with Raney® nickel. Despite its wide use, however, the mechanism of action of Raney® nickel 
desulphurization is under debate. The prevailing theory involves a free radical mechanism, 
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where sulphur is chemisorbed on the surface of the nickel inducing homolytic bond fission. 
Hydrogen associated with the catalyst surface can then add to the radical species. Evidence 
for this theory includes the observation of dimers89 and the racemization of chiral sulphides.90 
Although beyond the scope of this chapter, more evidence pointing to a radical mechanism 
and the counter-theories can be found in the literature.91 
2.2.3.4.2 Diastereoselective uses of Raney® nickel 
Despite the unpredictability of Raney® nickel desulphurizations, diastereoselective 
desulphurizations have been used efficiently in the synthesis of several natural products. One 
example is the synthesis of 7α-eremophilane, where reduction/desulphurization of the 
thiophene yields the alpha anomer with greater than 95% diastereoselectivity (scheme 22). 
 
Reagents and conditions: (i) W-7 Raney Nickel, hexanes, 85%. 
Scheme 22: Synthesis of 7α-eremophilane using a diastereoselective desulphurization 
Not only has Raney® nickel been used for diastereoselective reactions, but modification of 
the catalyst surface originally by glucose92 and later tartaric acid93 has provided 
enantioselective reductions. 
2.2.3.4.3 Desulphurization of the thiomethyl group with Raney® nickel 
Treatment of compound 173a with Raney® nickel under Corey’s conditions (0 °C) only 
provided starting material, as did a room temperature reaction. Heating to reflux, however, 
did produce the desulphurized compound as a 3:1 mixture of diastereoisomers, but, in a very 
disappointing yield of 7% (Scheme 23). These decreased yields meant we were unable at this 
stage to properly analyse the product to conclude whether the desired diastereoisomer was 
in excess. This result combined with the low yields and poor stereoselectivity of the previous 
two steps led us to abandon our work with the thiomethyl derivative. 
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Reagents and conditions: (i) Raney® nickel, ethanol, reflux, 4 h, 152ab (3:1), 7%. 
Scheme 23: Raney® nickel desulphurization of 173a 
2.2.3.4.4 Replacement of the thiomethyl with a thiophenyl group 
2.2.3.4.4.1 Strategy 
We decided to exchange the thiomethyl group for a thiophenyl in the hope the thiophenyl 
would be more labile (Scheme 24). Although we were unable to find examples in the literature 
of the use Raney® nickel to remove thiophenyl more efficiently than thiomethyl, examples 
showing this with azobisisobutyronitrile (AIBN)-initiated radical-based removals have been 
well studied.94,95 Because the mechanism for Raney® nickel desulphurization was potentially 
also radical based, we thought this approach worth attempting. The bulkier phenyl group 
would also mean that desulphurization could be favoured by the release of strain in the 
system. 
 
Scheme 24: Strategy for the incorporation of thiophenyl and its removal 
2.2.3.4.4.2 Hydrogenolysis and insertion of the thiophenyl 
The thiophenylating reagent was synthesized in an analogous way to the thiomethylating 
reagent, and could be used without purification.96,85 
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Reagents and conditions: (i) (PhS)2 (0.5 equiv), I2 (0.5 equiv), CH2Cl2, rt, overnight, 67%, (ii) 
Pd(OH)2/C, THF, 35 °C, overnight, (iii) MePhSO2SPh 189 (2.9 equiv), Et3N (1.6 equiv), CH2Cl2, 
rt, mixture of 187ab, 67% over the 2 steps. 
Scheme 25: Synthesis of the thiophenylating reagent 189 and its incorporation into the 
lactam core 
After hydrogenolysis, the lactam 160ab was treated with reagent 189 (Scheme 25). Using 
Pattenden’s conditions gave only moderate yields, but a slight improvement was seen using 
our optimized conditions (Table 2, entry 2) and reducing the time further provided a good 
yield of 67%. Furthermore, the diastereoselectivity was now found to be 1:0.9 and although 
this was still disappointingly low, as the thiomethyl analogue had provided the unwanted 
diastereoisomer in 2:1 excess, this was a vast improvement. Although the diastereoisomers 
were inseparable, NOESY analysis gave evidence suggesting the unwanted diastereoisomer 
was still in excess, albeit only moderately. 
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Table 2: Optimization of the thiophenylation of 160ab 
2.2.3.4.4.3 C6 reduction of compound 187ab 
The thiophenyl analogue was reduced using the same conditions as the thiomethyl and the 
reaction occurred with comparable yields and selectivity (Scheme 26). The diastereoisomers 
were easily separable by column chromatography. Led by NOESY analysis, we concluded, as 
before, that the first eluting diastereoisomer was the required stereochemistry, with the C6 
hydroxyl cis to the methyl ester. Analysis of 188a by chiral stationary phase HPLC indicated 
that the ee had decreased slightly from 79% to 77%. We believe this to be due to trace 
amounts of the unwanted diastereoisomer being produced in the acylation with Mander’s 
reagent. This would form trace amounts of the opposite enantiomer and therefore lower the 
ee. 
 
Reagents and conditions: (i) NaBH4 (0.7 equiv), EtOH, −10 °C, 0.5 h, 30% 188a and 35% 188b. 
Scheme 26: Reduction of the C6 position of 187ab 
  
Experiment Time Temp °C Yield 
1 overnight 25 49% 
2 6 h 20 56% 
3 6 h 17-18 57% 
4 5 h 20 67% 
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2.2.3.4.5 Raney nickel desulphurization with thiophenyl analogue 188a 
Compound 188a was treated with Corey’s conditions using Raney® nickel in ethanol at 0 °C, 
however once again an NMR of the crude material showed no product was formed. Increasing 
the temperature gave a trace of desired product but not enough to isolate. When increasing 
the temperature to 50 °C we were pleased to see that the same mixture of diastereoisomers 
could be isolated in 37% yield. The same diastereoisomer was in excess, however the ratio 
was now 2:1. Finally, heating to reflux as previously used for the thiomethyl analogue 173a 
provided the mixture of diastereoisomers in a 3:1 ratio and a 42% yield allowing us to separate 
and properly analyse each diastereoisomer. Separation allowed each of the diastereoisomers 
to be more accurately assigned. The first and major eluting diastereoisomer was found to 
have a J value of 9.7 Hz between the C7 and C6 protons (Scheme 27). Our minor second 
eluting diastereoisomer, however, had a value of 7.5 Hz between the same positions. The 
higher J value of our first eluting diastereoisomer suggests that the protons are trans to each 
other, and therefore the undesired diastereoisomer was in excess. Although our yield was still 
low, we had succeeded in dramatically increasing the yield by replacement of the thiomethyl 
group by the thiophenyl group. However, due to the incorrect diastereoisomer being formed 
in excess, we decided to abandon our work using Raney® nickel for the desulphurization. 
 
Reagents and conditions: (i) Raney nickel, ethanol, reflux, 4 h, 152ab (3:1), 42%. 
Scheme 27: Treatment of 188a with Raney® nickel and assignment of the diastereoisomers 
through J values 
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2.2.3.4.6 AIBN initiated radical desulphurizations 
2.2.3.4.6.1 Introduction to radical mediated desulphurizations 
Along with Raney® nickel, one of the more common methods of desulfurization is through 
use of an organotin hydride radical propagator and AIBN as a radical initiator. Such reactions 
have been comprehensively reviewed97 and have found use in natural product synthesis, 
most notably in Nicolaou’s synthesis of brevitoxin B (scheme 28).98 
 
Reagents and conditions: (i) Ph3SnH, AIBN, toluene, 100 °C, 2 h, 100% 
Scheme 28: Use of an organotin hydride desulphurization in the synthesis of brevitoxn B 
 74 
 
Study of the literature revealed examples where desulphurizations using Raney® nickel had 
been compared to AIBN initiated, organotin hydride/organosilane propagated 
desulphurizations. These examples ranged from Raney® nickel providing: 
1) The same stereochemical outcome as an organo-tin hydride: 
During the preparation of functionalized β-lactams (Scheme 29), both Raney® nickel and 
tributyltin hydride were used to desulphurize thiophenyl groups. β-Lactam 189 provided the 
propyl/propenyl cis to the phenyl in both experiments (albeit with the propyl reduced in the 
Raney® nickel experiment to provide 191.)99  
 
Reagents and conditions: (i) n-Butyl tin hydride, AIBN, toluene, reflux, 50%; (ii) Raney® nickel, 
acetone, reflux, 45%. 
Scheme 29: A comparison of the stereochemical outcome between Raney® nickel and n-
butyltin-hydride mediated desulphurization 
2) No stereochemical preference: 
During the preparation of a library of functionalized γ-lactams (Scheme 30), Raney® nickel 
desulphurization of 192 was found to be completely unselective, providing a 50:50 mix of 
diastereoisomers 193a and 193b. An AIBN, tris(trimethylsilyl)silane (TTMS) radical-
propagated desulphurization, however, was highly selective (>95:5). As before, the AIBN-
initiated desulphurized position was left cis to the bulky phenyl group.100  
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Reagents and conditions: (i) TTMS, AIBN, toluene, 90 °C, 93% (>95:5); (ii) Raney® nickel, 
THF/Ethanol (1:2), rt, 96%, (1:1 ratio of diastereoisomers). 
Scheme 30: A comparison of the stereochemical outcome between Raney® nickel and TTMS 
mediated desulphurization 
3) The opposite stereochemical outcome: 
Most importantly for our scenario, the opposite selectivity has also been observed (Scheme 
31). During the preparation of carbapenem antibiotic analogues, switching the method of 
desulphurization completely changed the observed diastereoselectivity between 195 and 
196. Previous examples have shown that the AIBN-mediated method gave the more 
thermodynamically stable product, while Raney® nickel favoured the opposite 
diastereoisomer (scheme 31).95 
 
Reagents and conditions: (i) n-butyl tin hydride, AIBN, acetone, reflux, 16 h, 195-22% 196-
72%; (ii) Raney® nickel, acetone, reflux, 2 m, 195-47%, 196-21%. 
Scheme 31: A comparison of the stereochemical outcome between Raney® nickel and n-
butyltin-hydride mediated desulphurization. 
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2.2.3.4.6.2 Tributyltin hydride desulphurization of 188a 
Due to this final positive finding, 188a was heated to reflux with AIBN and tributyltin hydride 
overnight. Crude NMR spectroscopic analysis proved very difficult due to the tin residues left 
in the reaction mixture. Following the work by Harrowven, we decided to purify this complex 
mixture using a mixed silica stationary phase. Harrowven found that 10% finely ground 
potassium fluoride mixed with silica could remove tin residues to below 30 ppm.101 Later work 
found that 10% ground potassium carbonate in silica could reduce levels to as low as 15 
ppm.102 We decided to use the potassium carbonate method due to the increased 
effectiveness. To our delight, after purification by column chromatography, we found that the 
organotin method vastly increased yields to 93% providing 152ab in a 1:2 ratio of 
diastereoisomers. Most importantly however, the desired diastereoisomer was now the 
major product (Scheme 32). 
 
Reagents and conditions: Tributyltin hydride (3.4 equiv), AIBN (0.2 equiv), acetone, reflux, 16 
h, 152a/152b (1:2), 93%. 
Scheme 32: Desulphurization of 188a with tributyltin hydride 
2.2.3.4.6.3 Exchange of the organotin radical propagator to TTMS 
Although the desulphurization had been greatly improved from our initial reactions, we 
decided to modify the reaction to see if the diastereoselectivity could be further improved. 
We theorized that a bulkier radical propagator could increase the selectivity of our desired 
diastereoisomer. The bulkiest radical propagator we could find commonly available was 
TTMS. Si-H bonds are not common radical propagators due to the relatively high bond 
dissociation energy, however, due to the steric repulsion of the TMS groups, bond 
dissociation enthalpy falls about 17 kJ/Mol per TMS bond replacement from (Me)3SiH. The 
use and scope of TTMS have been recently reviewed.103 
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When applied to our system we were delighted to find that the diastereoselectivities 
increased greatly from 1:2 to 1:5 solely on exchange of the radical propagator and our desired 
diastereoisomer was still the major product. The reaction also took place in an excellent yield 
of 88%. Part of the reason for this high yield is the stabilization of our radical intermediate 
(Scheme 33). 
 
Reagents and conditions: TTMS (3.2 equiv), AIBN (0.3 equiv), acetone, reflux, 16 h, 152a-14 
%, 152b-74%. 
Scheme 33: Desulphurization of 188a with TTMS and the resonance stabilized radical 
intermediate 
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2.2.3.4.7 Summary of the desulphurization conditions 
For clarity all the desulphurization optimizations are presented in the following table 3. 
 
Entry R =  Method Temperature 
°C 
Yield 
% 
Diastereoselectivity 
7a:7b 
1 Me Raney® nickel 0 0 N/a 
2 Me Raney® nickel 18 0 N/a 
3 Me Raney® nickel Reflux 7 3:1 
4 Ph Raney® nickel 0 0 N/a 
5 Ph Raney® nickel 18 Trace N/a 
6 Ph Raney® nickel 50 37 2:1 
7 Ph Raney® nickel Reflux 42 3:1 
8 Ph AIBN, acetone, Bu3SnH Reflux 93 1:2 
9 Ph AIBN, acetone, TTMS Reflux 88 1:5 
Table 3: Summary of the desulphurization experiments 
2.2.3.4.8 The origin of the desulphurization diastereoselectivity 
Radical intermediates are not planar per se. The unpaired electron is held in a p orbital. The 
conformation of the intermediate adopts an orientation somewhere between an sp2 trigonal 
planar orientation and an sp3 pyramidal; this conformation is known as a shallow based 
pyramid (scheme 34). 
 
Scheme 34: Representation of the conformation of a carbon centred radical 
The energy required to invert this is so small, that rapid interconversion between the two 
states takes place. The radical species can therefore be considered planar, like an sp2 centre. 
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Radical insertion will therefore take place equally at the top or bottom face in achiral 
intermediates. If the radical has another stereocenter however, attack will usually occur from 
the least hindered face. 
Insertion of the thioether groups (scheme 20 and 25) favoured the face opposite the methyl 
ester in each case rather than the iso-butyl. It seems reasonable therefore to assume that the 
methyl ester is the primary directing moiety in our system. This could explain the selectivity 
observed if hydrogen is inserted from the face opposite the methyl ester in our AIBN-initiated 
reactions.  
The factors involved in Raney® nickel desulphurization are far more complex as shown in the 
previous examples (schemes 29, 30 and 31). Although general trends tend to show that 
hydrogen will insert from the least hindered face, the stereochemical outcome is far less 
predictable. Polar groups have been shown to disrupt selectivity104 potentially by 
coordination to the catalyst surface. Both the C5 ester and the C6 hydroxyl could contribute 
to this. 
In Corey’s intermediate, the TBS group and the absence of an iso-butyl means that 
intermediate 31 has a far more well defined sterically hindered face. The TBS group could also 
block potentially competing coordination effects. This could contribute to the high 
diastereoselectivity Corey achieved. Interestingly, during our Raney® nickel thiophenyl 
removal, the selectivity changed from 2:1 to 3:1 on an increase in temperature. Corey’s 
reaction occurred at 0 °C when he obtained the desired diastereoisomer. If our analogue 
underwent epimerization at the α-amide position due to elevated temperatures, this could 
produce the more thermodynamically stable diastereoisomer (preventing hindrance from the 
C7 methyl and the C5 methyl ester) and explain the change of diastereoselectivity at different 
temperatures. Raney® nickel desulphurization can also produce metal salts which could act 
as Lewis acids potentially catalysing this process. Nevertheless, with our advanced 
intermediate 152b in hand we started on the final deprotection steps to produce the 
omuralide analogue. 
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2.2.4 Removal of the PMB and methyl ester groups 
Various methods are available for the removal of PMB groups. CAN is however the most 
commonly used in previous omuralide syntheses. The removal proceeded in fair yield 
(Scheme 35), and NOESY correlations seemed to confirm our previous experiments had 
provided the desired diastereoisomer. 
 
Reagents and conditions: CAN (5.2 equiv), MeCN/H2O (3:1), rt, 62%. 
Scheme 35: Removal of the PMB protecting group 
With all the stereocentres in place and due to the crystalline nature of the product, we 
subjected compound 197 to recrystallization. We successfully obtained a diffractable crystal 
from our racemic series, synthesized for HPLC traces (Figure 5). 
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Figure 5: The X-ray crystal structure of (±)-197 (hydrogen atoms omitted for clarity) 
We were pleased to confirm that our NOESY analysis throughout the synthesis had been 
correct. As in omuralide, the C5 ester, C6 hydroxyl, and the C7 methyl are all cis to each other. 
Our final step involved saponification of the methyl ester to the acid with NaOH. The acid was 
obtained in good yield, and NMR data matched the data from Mereddy,77 confirming that we 
had made the pyroglutamate 174. This had previously been cyclized to 9-deoxy-omuralide 
76c by Mereddy in one step, thus completing a formal synthesis (Scheme 36). 
 
Reagents and conditions: (i) NaOH (0.5 M), 0-5 °C, 86%; (ii) BOPCl, Et3N, DCM, 40%. 
Scheme 36: Saponification of the methyl ester and Mereddy’s formation of the β-lactone 
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2.3 Elaboration of L-serine methyl ester hydrochloride to omuralide 
2.3.1 Choice of amino acid starting material and retrosynthetic analysis 
For our second route we decided to start with L-serine. The primary reason for this is that the 
hydroxyl group will be in place from the beginning of the synthesis; the serine hydroxyl group 
will end up in the C9 position required for elaboration to omuralide (Scheme 37).   
 
Scheme 37: Retrosynthetic analysis of omuralide 
Our target molecule would be Corey’s advanced intermediate 30.29 Not only was this the most 
direct way to confirm that our previously developed methodology could incorporate serine, 
but also this intermediate had previously been used to produce a wide range of C9 omuralide 
analogues.105,37 A suitably protected serine derivative would be coupled to a half malonic 
benzyl ester to form the serine-derived Dieckmann precursor. After the tandem 
cyclization/alkylation procedure to form the serine-derived γ-lactam core, Mander’s reagent 
would again be used to insert the methyl ester to form the serine-derived acylated γ-lactam 
core. Removal of the benzyl ester would allow insertion of the thiomethyl group which along 
with a stereoselective reduction and protecting group removal would provide the advanced 
intermediate 30. 
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2.3.2 Choice of serine O protecting group 
Following the general reaction scheme from our previous work to synthesize 9-deoxy 
omuralide, we had to consider that any protecting group used would have to be stable to 
basic conditions from the acylation with Mander’s reagent, to fluoride sources from the TBAF 
mediated Dieckmann cyclization and potentially to conditions used for the benzyl ester 
hydrogenolysis. Because of these restrictions we decided that an acid-labile protecting group 
would be most suitable. In addition to stability, we also had to consider the steric bulk of the 
protecting group. Our synthesis is based on the amino acid directing the stereochemical 
outcome of the reaction. Serine has very little steric bulk in its structure, and we had already 
found that leucine did not direct our stereochemical outcome as much as we had hoped. We 
therefore aimed to use as bulky protecting group as possible. Two initial protecting groups 
were considered. The first was a tetrahydropyranyl ether. Although it fit all the criteria 
required for our synthesis, the protecting group would insert a second chiral centre. This 
would make full characterization of subsequent intermediates by NMR spectroscopy 
extremely difficult. We settled on a tert-butyl ether protecting strategy. Not only is the tert-
butyl protected serine methyl ester hydrochloride salt commercially available, it is also 
available as the unnatural enantiomer (Figure 6). 
 
Figure 6: Suitable groups for protection of the hydroxyl group 
2.3.3 Synthesis of the serine-derived Dieckmann cyclization precursor 
2.3.3.1 PMB protection of the tert-butyl protected serine 
PMB was once again used for the nitrogen protection. An extensive optimization was carried 
out to find acceptable conditions (Table 4). 
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Table 4: Optimization of the PMB protection of 199 
Our first reaction (Entry 1) involved formation of the imine, with triethylamine (TEA) in 
dichloromethane (DCM), and after evaporation a sodium borohydride reduction. Despite 
good yields, we decided to find an alternative method due to the possibility of racemization 
during imine formation. Reduction of the imine in situ should limit the potential for 
Entry Reagents and conditions Yield % 
1 1) PMB aldehyde (1.5 equiv), TEA (1.2 equiv), DCM 2) NaBH4 (1.6 
equiv), EtOH 
71 
2 p-TSA (1 equiv), PMB aldehyde (10 equiv), NaBH4 (1.1 equiv) N/a 
3 PMB, TEA (1 equiv), NaBH4 (1.2 equiv), MeOH 18 
4 PMB sulphite adduct (1.5 equiv), NaBH3CN (2.7 equiv), MeOH 28 
5 PMB sulphite adduct (3.3 equiv), NaBH3CN (22 equiv), TEA (1 equiv), 
EtOH 
58 
6 PMB sulphite adduct (1.6 equiv), NaBH4 (1 equiv), TEA (1 equiv), 
MeOH 
imine 
7 PMB sulphite adduct (1.6 equiv), NaBH4 (1.7 equiv), TEA (1 equiv), 
EtOH 
imine 
8 PMB sulphite adduct (1.6 equiv), NaBH4 (1.6 equiv), TEA (1 equiv), 
IPA 
N/a 
9 PMB sulphite adduct (1.2 equiv), NaBH3CN (6.3 equiv), pyridine (10 
equiv), MeOH 
24 
10 PMB sulphite adduct (1.5 equiv), NaBH3CN (6.2 equiv), TEA (1 equiv), 
MeOH 
67 
11 PMB sulphite adduct (3.2 equiv), NaBH3CN (13 equiv), TEA (1 equiv), 
MeOH 
85 
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racemization. A solvent-free reaction was attempted based on similar conditions reported by 
Cho et al.106, unfortunately, however, no reaction was observed. Entry 3 shows the yields 
obtained when using conditions analogous to the leucine route, unfortunately however the 
yield was very low. It was possible NaBH4 was reducing the aldehyde, stopping imine 
formation. 
A promising method was found in the paper ‘Direct reductive alkylation of amine 
hydrochlorides with aldehyde bisulphite adducts’107 where the methyl ester hydrochloride of 
phenyl alanine was protected with the bisulphite adduct of PMB in 95% yield. No racemization 
was mentioned, so we decided to attempt this method (Scheme 38). 
 
Reagents and conditions: Na2SO3, EtOH, rt, 16 h, 81%. 
Scheme 38: Formation of the sodium bisulphite adduct of PMB 
The sodium bisulphite adduct of PMB was prepared and isolated in good yield to be used in 
our reductive amination. Unfortunately, in our hands using standard conditions we were only 
able to isolate 28% of the protected amine (Entry 4). Yields were found to drastically increase 
when triethylamine was added. With ethanol as the solvent, yields of 58% were achieved. 
Switching the reducing agent to sodium borohydride did not produce any of the desired 
product. Only the imine could be observed by NMR spectroscopy of the crude material when 
the reaction was carried out in methanol or ethanol, and neither the amine or imine could be 
seen if the reaction was run in iso-propyl alcohol (IPA) (Entries 6,7, and 8). With sodium 
cyanoborohydride as the reducing agent, pyridine was used to catalyse imine formation as it 
has been found to induce much less racemization than triethylamine. Unfortunately, yields 
were greatly reduced (entry 9). Returning to triethylamine but switching the solvent to 
methanol vastly increased yields to 67%, and finally increasing the proportions of the 
aldehyde and reducing agent provided us with the protected amino acid in good yields of 
85%. Unfortunately, we were unable to achieve separation of a synthesized racemate of this 
compound on HPLC using a chiral stationary phase. 
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2.3.3.2 Coupling to the half malonic benzyl ester  
Coupling of the half malonic benzyl ester 146 proceeded in good yield (Scheme 39) in a 
reaction analogous to the leucine route. 
 
Reagents and conditions: i) 146 (2.5 equiv), EDAC.HCl (2.6 equiv), N-MM (2.5 equiv), DMAP 
(0.2 equiv), DCM, 16 h; 73%. ii) 146 (1.6 equiv), NaBH3CN (6.1 equiv), Et3N (0.9 equiv), MeOH, 
0 °C, 16 h (iii) 146 (2.5 equiv), EDAC.HCl (2.7 equiv), N-MM (2.5 equiv), DMAP (0.2 equiv), 
DCM, 16 h; 49% over the 2 steps. 
Scheme 39: Peptide coupling of 146 to 200 
Once again, the Dieckmann cyclization precursor was found to be a pair of rotamers in a 1:5 
ratio. Full coalescence was observed at 100 °C. Analysis on a HPLC using a chiral stationary 
phase in comparison to a synthesized racemic compound found 201 to be 94% ee. It was 
found that there was a degree of variability in this value depending on the room temperature 
at the time of the reductive amination. In light of this, we decided to modify the reductive 
amination to ensure that a cooler temperature was maintained. The crude product from this 
reaction was pure enough to be used in the peptide coupling step without purification by 
column chromatography.  The Dieckmann cyclization precursor 201 could now be isolated in 
good yield over the two steps in 49% yield and 97% ee. 
2.3.4 The Dieckmann cyclization of the serine derived analogue 
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2.3.4.1 Optimization of the Dieckmann cyclization of 201 
 
Entry Conditions Approx. 
Scale (g) 
Yield 
% 
Ratio of 
202a:202b 
ee of 
(202a) 
1 TBAF (3.4 equiv), THF 0.5 h then MeI 
(4.5 equiv) 16 h, rt 
0.1 65 10:1 - 
2 TBAF (4 equiv), THF 0.5 h then MeI (4 
equiv) 16 h 
2.5 31 10:1 - 
3 TBAF (3.7 equiv) THF 2 h then MeI (4.1 
equiv) 2 h 
0.2  62 10:1 44 
4 TBAF (3.6 equiv), THF 0.5 h, MeI (3.9 
equiv), 0 °C to rt over 16 h 
0.2  42 10:1 60 
5 TBAF (3.7 equiv), THF 0.5 h, MeI (3.9 
equiv) 1 h -10 °C 
0.1 Trace - 76 
6 TBAF (3.4 equiv), 0.5 h THF MeI (4.1 
equiv), -15 °C, 64 h 
0.3 30 3:1 76 
7 TBAF (2 equiv), Ether, 5 m, THF MeI (4.3 
equiv), -12 °C, 64 h 
0.2 56 3:1 83 
8 TBAF (2.1 equiv), Ether, 5 m, THF MeI 10 
equiv), -12 °C, 64 h 
1.6 66 3:1 79 
Table 5: Optimization of the cyclization 
Treating the serine-derived Dieckmann precursor 201 under conditions analogous to our 
leucine route provided the isomers 202a and 202b with excellent diastereoselectivity and in 
good yield (Table 5, entry 1).  Unfortunately, we found increasing the scale of this reaction 
resulted in a large drop in yield. We were also surprised to see that the major diastereoisomer 
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produced was that with the methyl and tert-butyl groups cis to each other. We assumed that, 
as we had theorised in the leucine route, the thermodynamically more unstable 
diastereoisomer (202b) was epimerizing to the more stable one (202a).  Due to this resulting 
in racemization during the leucine route, we decided to analyse our reaction further using 
HPLC with a chiral stationary phase. 
Two strategies were considered in an attempt to stop the epimerization: 
1) Epimerization could be reduced with shorter reaction times 
2) Cooling the reaction could stop the epimerization from occurring 
Decreased reaction times provided 202ab in good yield, but the diastereoselectivity remained 
unchanged. The ee was analysed and found to be only 44%, indicating that a similar 
epimerization to our leucine route was occurring. Cooling the reaction to 0 °C led to a slightly 
increased ee of 60%. Cooling to -10 °C increased the ee to 76% but only trace a amount of the 
product was isolated (entry 5). Separation of the cyclization and alkylation steps was also 
attempted along with longer reaction times and cooler temperatures. The diastereoselectivity 
then dropped to 3:1 indicating that the majority of the epimerization had been prevented. 
This was reflected in the ee, which was now 76%. The ee was not improved further at -15 °C, 
leading us to our optimal conditions. Long reaction times and cooling to -12 °C provided a 
yield of 53% and 83% ee. Once again, scaling up the reaction with these conditions decreased 
the yields. Yields could however be increased if a large excess of MeI (10 equiv) was used - 
which provided acceptable yields of up to 66% and with a comparable ee of 79% (Entry 7). 
Unfortunately, the second eluting, minor diastereoisomer 202b could not be successfully 
separated from the major diastereoisomer.  Overlapping peaks in the HPLC chromatograph 
meant accurate information about the enantiopurity could not be obtained. 
The ee could be improved further if necessary by a recrystallization from IPA, providing 
racemic solid and a filtrate of 98% ee. Although we had been able to stop the epimerization 
to a large degree, we were still surprised to find that the major diastereoisomer formed was 
still the diastereoisomer where the methyl and benzyl ester are cis to each other. This result 
is surprising because the expected diastereoselectivity was for the methyl iodide to add 
opposite the bulky amino acid-derived tert-butoxy group. The leucine analogue route had 
shown that the methyl group adds opposite the bulky iso-butyl moiety of the leucine, and we 
expected a similar outcome in our serine derivative. It is possible that the serine tert-butyl 
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group sits too far from the ring to block the top face effectively, unlike the shorter chain iso-
butyl group in leucine, allowing other factors to come into play. Further investigation of the 
cyclization was carried out in order to find a reason for this surprising diastereoselectivity. 
2.3.4.2 Investigation of the unexpected diastereoselectivity 
2.3.4.2.1 Investigation of a chiral relay effect 
2.3.4.2.1.1 Introduction to the chiral relay effect 
In 1998 Davies et al.108 showed that PMB groups, despite not being chiral themselves, were 
capable of relaying chiral information from a valine-derived iso-propyl group around a 
diketopiperazine ring, due to the rotation around the PMB methylene carbon (203). This 
effect could then be used to increase the diastereoselectivity of an alkylation compared to 
using increasingly more rigid methyl groups (205) (Scheme 40). 
 
Reagents and conditions: (i) LiHMDS, THF, -78 °C, MeI (10 equiv). 
Scheme 40: Davies investigation of a chiral relay effect to increase diastereoselectivity 
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It seemed reasonable that similar phenomenon might be occurring in our system. The bulky 
tert-butoxy group could potentially be repelling the PMB group to the opposite face of the 
ring. The methoxy benzyl could now be competing with the tert-butyl group, directing the 
methyl to the same face of the ring as the tert-butoxy group. (Figure 7) 
 
Figure 7: A conformation of our enolate which could potentially exhibit a chiral relay effect 
In order to investigate this, we decided to replace the PMB group with a methyl. The less 
flexible nature of the methyl group would be unable to relay any of the chirality from the 
serine tert-butyl group. We would then expect if this was contributing to our 
diastereoselectivity that the iodomethane might favour addition to the face opposite the tert-
butyl. (Scheme 41) 
 
Scheme 41: A planned synthetic scheme to investigate a possible chiral relay effect 
2.3.4.2.1.2 Attempts to synthesize an N-Me derivative 
Our N-protected serine derivative 206 was methylated using potassium carbonate and MeI 
achieving the product in fair yield. Basic conditions could potentially racemize the amino acid 
therefore analysis of the ee was attempted using HPLC with a chiral stationary phase. 
Unfortunately, we were unable to achieve separation of enantiomers in a synthesized 
racemate. We therefore decided it would be safer to find a non-basic method of methylation. 
Using a modified procedure from Konopelski et al.,109  formaldehyde was used to form an 
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imine, which underwent reduction with sodium cyanoborohydride. Once again, the tertiary 
amine 209 was isolated in good yield; furthermore after work up no further purification was 
necessary. Attempts were then made to cleave the PMB group leaving the methylated serine 
derivative (Scheme 42). 
 
Reagents and conditions: (i) MeI, K2CO3, DMF, rt, 1 h, 62%; (ii) para-Formaldehyde (14 equiv) 
in MeOH, after 5 h NaBH3CN (2.2 equiv), rt, 16 h, 74%; (iii) CAN (5.3 equiv), 3:1 (MeCN/H2O), 
2 h; (iv) Pd/C, H2, MeOH, 16 h; (v) paraformaldehyde (14 equiv), MeOH, NaBH3CN, 2.2 equiv, 
rt, 16 h. 
Scheme 42: Attempts to form the N-methyl serine derivative 206 
Our previous PMB removals had been effective with CAN; unfortunately, however, only traces 
of material could be recovered. Although the NMR spectrum showed promising signals, the 
material was heavily contaminated. We felt the problem could lie in the work-up procedure 
due to the basicity or solubility of the product, and we therefore modified the procedure to 
remove the PMB group with hydrogenolysis conditions, this would only require filtration and 
evaporation. After subjecting 209 to standard benzyl removal conditions however, we were 
still unable to obtain any of the desired product. Whether this is because the product is highly 
volatile or undergoes decomposition is unknown. Reductive amination of the primary amine 
199 also failed to produce the methylated derivative. With the methylated derivative proving 
surprisingly difficult, we decided to exchange the methyl group for a phenyl. This would have 
a similar effect acting as a rigid group, but we hoped would be more stable allowing for easier 
purification.  
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2.3.4.2.1.3 Synthesis of the N-phenylated serine derivative 
There are two common methods for the formation of N-Ar bonds. The Buchwald110-Hartwig111 
method is perhaps the most utilized, but along with potentially expensive ligands, a strong 
base is often required. Due to the possibility of racemization, we decided to avoid this and 
instead use a Chan-Lam coupling (Scheme 43).112 
 
Reagents and conditions: (i) PhB(OH)2 (2 equiv), Et3N (2 equiv), Cu(OAc)2 (1.1 equiv), O2 
balloon, DCM, rt, 3 days, 22%. 
Scheme 43: The Chan-Lam coupling to produce 210 
Coupling the amine hydrochloride salt 199 to benzyl boronic acid produced 210 in poor yield 
(Scheme 43). As only a small amount of material was needed, however, no further 
optimization was attempted. Due to the weakly basic conditions used we decided to check 
for racemization using HPLC with a chiral stationary phase in comparison to a separately 
synthesized racemate. We found that some racemization had occurred at this point to 72% 
ee, but fortunately however, the product could be recrystalized from petroleum ether 
providing crystals of 95% ee and a racemic supernatant. 
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2.3.4.2.1.4 Coupling of 210 to 146 and its cyclization/alkylation 
 
Reagents and conditions: 146 (2.2 equiv), EDAC.HCl (2.7 equiv), N-MM (2.3 equiv), DMAP (0.19 
equiv), DCM, 16 h, rt, 63%. 
Scheme 44: Peptide coupling to form compound 211 
Coupling of 146 to the phenylated serine derivative 211 provided the Dieckmann cyclization 
precursor in fair yield (Scheme 44). The cyclization precursor this time did not appear as a set 
of rotamers in the 1H NMR spectrum, presumably due to the increase in rigidity we had 
introduced in the system compared to the PMB analogues. Analysis of 210 against a 
synthesized racemate HPLC using a chiral stationary phase showed that no further 
racemization had occurred at this point. The phenyl derivative 211 was treated under similar 
conditions to 201 in order to induce the Dieckmann cyclization/alkylation (Scheme 45). 
 
Reagents and conditions: TBAF (2.1 equiv), Ether, 5 m, THF, MeI (4.7 equiv), -12 °C, 64 h, 8%. 
Scheme 45: The Dieckmann cyclization of 211 
Analysis of the 1H NMR spectrum of the crude material showed that poor levels of alkylation 
were observed. There did appear to be a set of diastereoisomers, however, which were 
observed in a 1:5 ratio. Purification by column chromatography allowed isolation of the major 
diastereoisomer as a colourless crystalline solid. Analysis by HPLC using a chiral stationary 
phase in comparison with a synthesized racemate showed that minor amounts of 
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epimerization had occurred during the cyclization, providing 212a with an ee of 87%. NOESY 
experiments were inconclusive as to which diastereoisomer this was, fortunately a crystal was 
able to be obtained of 212a suitable for analysis by X-ray diffraction (Figure 8).  
 
 
Figure 8: The X-ray structure of 212a (hydrogens omitted for clarity) 
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To our surprise, however, we found that once again the major product was the 
diastereoisomer with the methyl and tert-butoxy group cis. This showed that the PMB group 
was not causing a chiral relay as we had expected. Furthermore, the diastereoisomeric ratio 
had even increased. 
2.3.4.2.1.5 Investigation into the effect of the benzyl ester 
Our observations suggested that the PMB group was not the primary reason for the observed 
diastereoselectivity. A chiral relay effect could still be the cause, but instead of the PMB group 
rotating away from the tert-butoxy group, it could be the benzyl ester. This could then hinder 
attack of the methyl iodide at the face opposite the tert-butoxy group accounting for the 
unexpected diastereoselectivity (Figure 9).  
 
Figure 9: A conformation of the benzyl ester which could hinder attack of the methyl iodide 
on the face opposite the tert-butyl group 
In order to test this, we decided to once again to replace the potentially rotatable group due 
to the methylene with a rigid group. We chose a methyl group due to this being the smallest 
possible group to limit other potential steric effects (Scheme 46). 
 
Scheme 46: Planned route for investigation of the effect of the benzyl ester on 
diastereoselectivity 
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2.3.4.2.1.6 Synthesis of a methyl ester Dieckmann cyclization precursor 
The mono potassium salt 215 of dimalonic methyl ester was formed through a saponification 
with potassium hydroxide (Scheme 47). 
 
Reagents and conditions: (i) KOH (1.2 equiv), MeOH, rt, 51%; (ii) 215 (2.4 equiv), EDAC.HCl 
(2.9 equiv), DMAP (0.18 equiv), N-MM (2.4 equiv), rt, 24 h, 73%. 
Scheme 47: Synthesis of the half malonic methyl ester salt and its coupling to amine 200 
Using once again EDAC.HCl to couple the salt to the secondary amine, the Dieckmann 
cyclization precursor 213 was produced, appearing on 1H NMR spectroscopy as a set of 
rotamers. Unfortunately, we were unable to check for possible epimerization as we were 
unable to separate the enantiomers of a synthesized racemate of 213 by HPLC using a chiral 
stationary phase. However, because we had previously not observed racemization during the 
coupling, we assumed that 213 was unlikely to have lost any enantiopurity and remained at 
97% ee. 
2.3.4.2.1.7 The Dieckmann cyclization and identification of products 
Treatment of Dieckmann precursor 213 under our optimized conditions provided a 3:1 
mixture of diastereoisomers as observed in 1H NMR spectroscopic analysis of the crude 
material (Scheme 48). 
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Reagents and conditions: (i) TBAF (1 M in THF), ether, 5 m, then MeI, THF, 58 h, -12 °C, 87% 
3:1 mixture of diastereoisomers (by crude 1H NMR analysis); (ii) CAN (5 equiv), 3:1 
(MeCN/H2O), 1.5h, 57%. 
Scheme 48: The cyclization of 213 and removal of the PMB groups 
We found, however, that upon column chromatography the diastereoisomers 214ab could 
degrade into a complicated mixture of products. Furthermore the diastereoisomers were 
obtained as an inseparable oil from which no NOESY correlations could be used to assign 
relative stereochemistry. We found that acceptable levels of purification could be achieved 
by pouring the crude reaction mixture onto a silica gel column and rapidly washing through 
with ethyl acetate until the product stopped eluting. This technique provided the inseparable 
mix of diastereoisomers in acceptable levels of purity. Removal of the PMB group with CAN 
seemed to increase stability, allowing for the major isomer 216a to be partially separated 
from the minor isomer 216b. The major diastereoisomer was isolated as a solid from which a 
crystal could be obtained, allowing for structure determination through X-ray diffraction 
(Figure 10). 
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Figure 10: X-ray crystal structure of 216a 
Once again, the methyl group was introduced at the face opposite the tert-butoxy. It 
appeared therefore that rotation around the methylene carbon of the benzyl ester was also 
not a cause of the unusual diastereoselectivity. However, the increased yield of our cyclization 
step does indicate that the benzyl ester hinders attack to an extent. 
2.3.4.2.2 Pyramidalization of the amide 
Our original stereochemical reasoning, where methyl iodide would add opposite the bulky 
tert-butoxy group was based on the assumption that the gamma lactam intermediate (figure 
11) would be planar. This seemed plausible due to the sp2 hybridized nature of the C6 ketone 
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and C8 carbonyl groups inducing planarity in the nitrogen in the form of an amide. 
Furthermore, once the C7 position was deprotonated to the enolate, four out of the five 
atoms of the lactam ring would be planar. 
 
Figure 11: The pre-alkylated cyclization intermediate 
However, on further contemplation we felt it was possible that this would not always be the 
case. Amides are planar due to the resonance of the nitrogen lone pair with the carbonyl, 
forming the imidic acid form (or lactim in a lactam). Once C7 deprotonation had occurred 
however, the amide would be partially in the enolate form, meaning that the nitrogen lone 
pair is less available to be involved in resonance (scheme 49). The result of this could be that 
the nitrogen becomes partially pyramidal. This has been observed computationally and in 
crystal structures of amide enol ethers.113 
 
Scheme 49: Restricted resonance in amide enolates 
The increase in flexibility in the lactam ring could allow the PMB group on the nitrogen to 
orientate away from the tert-butoxy group to release steric strain, again, hindering the face 
opposite the tert-butoxy group (figure 12). This could explain not only the outcome for the 
major diastereoisomer but also the increase in diastereoselectivity when the PMB group was 
replaced with a phenyl.  
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Figure 12: Potential conformations of the pre-alkylated cyclized intermediate from 201 and 
211 showing a pyramidalized amide 
Similar systems have been studied both computationally and experimentally.114,115 
Calculations performed by Mayers et al. on simple pyrrolidone enolates have shown that 
pyramidalization of the nitrogen does occur in enolate formation, and that 1,2 interaction 
from the methyl substituent favours the second conformation shown in Figure 13, directing 
the N substituent away from the methyl group. Although Mayers used this to rationalize the 
unusually high trans diastereoselectivity observed in enolate alkylation, it is possible that the 
increased size of our nitrogen substituent could overpower the electronic effect observed by 
Mayers. 
 
Figure 13: Favourable enolate conformations in a simple substituted pyrrolidone 
2.3.4.2.3 Diastereoselectivity reasoning due to transition state 
Another potential cause could be based on the transition states in the approach of the methyl 
iodide from the top or bottom face. An approach from the bottom face could potentially form 
a higher energy transition state compared to a top face approach due to an unfavourable 
clash between the tert-butyl group and the benzyl ester (Scheme 50).  
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Scheme 50: Higher energy transition states affecting diastereoselectivity 
Similar phenomena avoiding high energy transition states are well known, for instance in the 
Fürst-Plattner rule (or trans-diaxial effect) (Scheme 51).116 
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Scheme 51: The Fürst Plattner effect 
The nucleophile could attack either the C3 or C4 position. However, attack at position 3 shown 
by path 1 would mean that the transition state would adopt an unfavourable twist boat 
conformation. Path 2 is therefore dominant. 
2.3.4.2.4 Summary of the investigation into observed diastereoselectivity 
Although we were not able to find a single reason for the unusual diastereoselectivity 
observed, we believe there are several possible plausible explanations and have been able to 
exclude some of the more well-known reasons. Fortunately, however, this unplanned 
stereoselectivity works as an advantage in our synthesis. Whereas in our leucine route we 
synthesized the opposite enantiomer of the analogue with respect to omuralide, the benzyl 
ester should now direct acylation with Mander’s reagent to the face opposite, providing the 
correct stereochemistry (Scheme 52).   
 103 
 
 
Scheme 52: Prediction of absolute stereochemistry after acylation with Mander’s reagent 
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2.3.5 Acylation with Mander’s reagent 
 
Reagents and conditions: LiHMDS (2.2 equiv), DMPU (3 equiv), THF. 
Scheme 53: Acylation of 202a with Mander’s reagent 
Entry Equiv of 
Methyl 
cyanoformate 
Time 
h 
Temperature 
°C 
Yield 
% 
1 3 4 -78 1.7:1 Sm:P 
2 5 4 -78 1.7:1 Sm:P 
3 5 2 -78 1.5:1 Sm:P 
4 5 4 -40 54% 
5 4.5 3 -40 49% 
6 4.5 3 -40 69% (new work 
up) 
Table 6: Optimization of the acylation of 202a with Mander’s reagent 
With the lactam core formed, the next step was to insert the methyl ester moiety, we hoped 
using the benzyl ester to direct the stereochemical course of the reaction (Scheme 53). 
Treatment of lactam 202a under analogous conditions to the leucine route provided a 
complex mixture of products. Analysis of the 1H NMR spectrum of the crude material showed 
the presence of both diastereoisomers 202a and 202b from the previous step along with a 
new compound that we assumed to be the desired acylated lactam 217, in an approximately 
1.7:1 mixture of starting material to product. The observation of an approximately equal 
quantity of the two diastereoisomers despite only starting with one suggested that the 
lithium bis(trimethylsilyl)amide (LiHMDS) was successfully forming the enolate, the problem 
appeared to be with enolate attack at the methyl cyanoformate. Attempted purification of 
crude material was not able to separate the product from the starting material. Increase of 
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the equivalents of methyl cyanoformate from three to five (Table 6, entry 2) provided a 
cleaner crude 1H NMR spectrum of the product mixture, but, the ratio of starting material to 
product was still approximately the same (1.7:1). Retaining the increased number of 
equivalents and reducing the reaction time also led to a cleaner crude 1H NMR spectrum and 
slightly increased the ratio of product (now at 1.5:1). Although still no pure material could be 
recovered, this indicated that the product could be decomposing with longer reaction times 
(Entry 3). 
Running the reaction at increased temperatures (-40 °C) (entry 4) showed complete 
consumption of starting material, allowing the product to be purified and characterized in 
moderate yield. Further optimization of the reaction and modification of the workup 
procedure by removing an evaporation of the quenched reaction mixture led to good yields 
of 217 (69%) (entry 6). The ee of the material was measured at this stage against a synthesized 
racemic compound by HPLC using a chiral stationary phase. We found that a slight drop in 
enantiopurity had occurred during the acylation. We do not believe this is due to racemization 
of the product but rather impurities of the cyclization diastereoisomer 202b in our starting 
material. When using the enriched recrystallized material from the cyclization, an ee of 84% 
was obtained (from 98% ee). Using the non-recrystallized material from the cyclization, the 
ee was 69% (from 79% ee). The product was isolated as a crystalline solid, and therefore we 
attempted to obtain a crystal suitable for X-ray analysis. Even with enantio-enriched material, 
racemic crystals would be preferentially produced over enantiopure crystals. The material 
could therefore be recrystallized from IPA to remove racemic material leading to the 
supernatant containing material of up to 93% ee. The recovery from this was, however, poor, 
but it did allow us to obtain an enantiopure crystal for X-ray analysis. 
Racemic crystals are sometimes more stable and can have an increased density over their 
enantiopure counterparts (Wallach’s rule).117 Our crystals follow this observation due to the 
preferential formation of racemic crystals, and analysis of both crystal structures show that 
the racemate volume is about 3% smaller than that of the enantiopure crystal. This 
phenomenon was found not to be due to any specific interaction between the enantiomers 
of molecules but rather due the increased number of space groups available to racemic 
molecules.118 
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Our enantiopure crystal (Figure 14) confirmed our findings that the methyl group adds to the 
same face as the tert-butoxy group. The methyl ester once again adds opposite the benzyl 
ester, providing the C5 stereochemistry as that required for the natural enantiomer of 
omuralide. 
 
 
Figure 14: X-ray crystal structure of 217 hydrogen atoms removed for clarity (carbonyls 
removed for clarity in chemdraw structure) 
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2.3.6 Hydrogenolysis and thiomethylation of 217 
The acylated product 217 was hydrogenolysed in an identical way to the leucine derivative to 
remove the benzyl ester. Once again, the product was isolated as a mixture of isomers 218ab 
and therefore subjected to the thiomethylation conditions optimized in the leucine route 
without purification (Scheme 54). The inseparable mixture of diastereoisomers 219ab were 
isolated in a 4:1 mixture. Fortunately, the bulkier residue on the amino acid directed the 
thiomethylation far more effectively than in our leucine derivative. NOESY analysis provided 
evidence that the major diastereoisomer was the one required to elaborate to Corey’s 
intermediate 29a. 
 
Reagents and conditions: (i) 1) Pd(OH)2/C (cat), H2, 35 °C, 16 h; ii) 186 (1.7 equiv), Et3N (1.1 
equiv), DCM, 4 h (70% over 2 steps). 
Scheme 54: Benzyl ester removal and thiomethylation of 219ab 
  
 108 
 
2.3.7 Removal of the tert-butyl protecting group from compound 219ab 
 
Reagents and conditions: TFA/DCM, 1:1, 1.5h, 76%. 
Scheme 55: Removal of the tert-butyl group 
The mixture of diastereoisomers was treated with ZnBr2, a methodology reported by Wu et 
al.,119 chosen due to an example given of tert-butyl-O-threonine being deprotected. Also 
attempted was a method reported by Li et al.120 using 85% phosphoric acid. This method had 
also been successful for a deprotection of threonine, and other examples where methyl esters 
were unchanged. Unfortunately, both methods resulted in a complex mixture of products for 
our compound 219ab. Treatment of the mixture of diastereoisomers 219ab with a 1:1 mixture 
of TFA:DCM however resulted in the desired Corey intermediate and diastereoisomers 29ab 
in excellent yield (Scheme 55). To our surprise, the product was isolated after column 
chromatography in a 2:1 mixture of diastereoisomers rather than the original 4:1 ratio. 
Interestingly, the crude material before column chromatography appeared to still be in a 4:1 
ratio. 
2.3.8 Epimerization of the Corey intermediate 29ab 
2.3.8.1 Introduction to the investigation of the epimerization of 29ab 
The most likely reasons for the drop in diastereoisomeric ratio seemed to be either one 
diastereoisomer reacting faster than the other or, one diastereoisomer undergoing 
decomposition faster than the other. An alternative possibility is one or both 
diastereoisomers epimerizing, but this seemed unlikely as both chiral centres were 
quaternary and no obvious mechanism for epimerization could be postulated. It is perhaps 
important to note that despite Corey and Pattenden synthesizing the same compound, 
neither mentioned observing a similar result. Analysis of the 2:1 mixture in comparison with 
a synthesized racemate however showed partial racemization had occurred, the ee dropping 
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from 84% to 58% (major) and 41% (minor) for the two diastereoisomers 29ab respectively. 
This suggested that an epimerization of one of the chiral centres was the reason behind the 
change in diastereoisomer ratio (Scheme 56). 
 
Scheme 56: Summary of the drop in ee 
2.3.8.2 Logical identification of the epimerizing chiral centre 
An epimerization as a mix of diastereoisomers would not necessarily result in a drop in ee. It 
would depend on which of the chiral centres was epimerizing (Scheme 57). This can be seen 
more clearly in the following scheme. Based on the 4:1 ratio of diastereoisomers and the 
original ee of 84%, each isomer has been calculated a % abundance in the diastereoisomeric 
mixture. 
 
Scheme 57: The result of a C5 or C7 epimerization 
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If epimerization were occurring at C7, the diastereoisomeric ratio would change, but ees 
would not change. Both enantiomers would epimerize at the same rate, therefore the ratio 
of enantiomers would stay constant in each mixture, i.e. the minor enantiomer of 
diastereoisomer 1 29a’ would mix with the minor enantiomer of diastereoisomer 2 29b’ and 
the major enantiomer of diastereoisomer 1 29a would mix with the major enantiomer of 
diastereoisomer 2 29b the ee would therefore remain unchanged. If C5 were undergoing 
epimerization, however, the minor enantiomer of diastereoisomer 1 29a’ would mix with the 
major enantiomer of diastereoisomer 2 29b and the major enantiomer of diastereoisomer 1 
29a would mix with the minor enantiomer of diastereoisomer 2 29b’. This would scramble 
the enantiopurity. Using this reasoning we theorised that the C5 centre was epimerizing. 
2.3.8.3 Experimental identification and reasoning of the epimerizing centre 
2.3.8.3.1 Epimerization studies on 172ab 
Not only did we want to confirm which centre was epimerizing, but also which functional 
groups were required for the epimerization to occur, to help elucidate a mechanism. For 
evidence that the hydroxyl group was needed for the epimerization and not the thiomethyl 
we treated our thiomethylated leucine analogue 172ab under identical conditions to our tert-
butoxy deprotection (scheme 58) and purified the reaction mixture using column 
chromatography. Both the ratio of diastereoisomers and the starting material remained 
unchanged as expected. This gave us evidence that any mechanism would probably require 
the hydroxyl group. 
 
Reagents and conditions: (i) TFA:DCM (1:1), 4 h. 
Scheme 58: Attempt to induce a similar epimerization in our leucine series 
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2.3.8.3.2 Synthesis of a gem-dimethylated analogue  
For a final confirmation that the thiomethyl group is not required for the epimerization but 
the hydroxyl group is, a derivative was synthesized by replacing the thiomethylating reagent 
186 with iodomethane. This produced the di-methylated analogue 220 in 46% yield over the 
2 steps in 86% ee, as observed by HPLC using a chiral stationary phase (Scheme 59). 
 
Reagents and conditions: (i) 1) Pd(OH)2/C (cat), H2, 35 °C, 16 h 2) MeI (4 equiv), Et3N (1.8 
equiv), DCM, 4 h (46% over 2 steps). 
Scheme 59: Synthesis of the gem-dimethylated analogue 220 
If 220 racemizes under the tert-butyl deprotection conditions, with only one chiral centre at 
C5, the epimerization at C7 can be ruled out completely, furthermore we can exclude the 
possibility of the thiomethyl group being involved with any possible mechanism. 
 
Reagents and conditions: TFA:DCM, 1:1, 1.5h, 67%. 
Scheme 60: TFA-mediated deprotection of 220 
As expected, treatment of 220 with the TFA:DCM mixture led to 220 in completely racemic 
form (Scheme 60) after purification of column chromatography. Our original experiment with 
the thiomethyl analogues 219ab had shown that the crude material before column 
chromatography had retained the original 4:1 ratio, we therefore decided that the 
epimerization must not be occurring under the reaction conditions but, surprisingly, upon the 
purification. Further evidence of this was found when, instead of using a dry-load technique 
to purify 221 (dissolving the crude material in DCM, adding silica gel and evaporating, 
 112 
 
adsorbing the material onto silica gel), a wet technique was used (dissolving the crude 
material in the petroleum ether/ethyl acetate solvent system and applying the solution to the 
column). The wet technique resulted in no epimerization of the C5 centre, analysis on HPLC 
using a chiral stationary phase showing the ee from compound 221 to be retained. 
With the cause, epimerizing centre, and functional groups involved known, two mechanisms 
were postulated. 
2.3.8.3.3 Potential mechanism for C5 epimerization 
2.3.8.3.3.1 Mechanism 1 
Mechanism one (Scheme 61) involves protonation of the C6 ketone, inducing nucleophilic 
attack from the now deprotected C9 hydroxyl. Reformation of the ketone could break the C6-
C5 bond due to the stabilized nature of the anion through the ester, thus losing the chirality. 
The ester enolate could then attack the newly formed ester, reforming the original 
compound. Both ring-forming reactions would be plausible according to Baldwin rules,121 the 
first being 4-exo-trig and the second 4-enolexo-exo-trig. 
 
Scheme 61: 1st Postulated mechanism for C5 epimerization 
2.3.8.3.3.2 Mechanism 2 
The second mechanism (Scheme 62) involves a retro-aldol type reaction. The removal of the 
hydroxyl group as a formaldehyde cation forms a highly stabilized anion, and thus the 
chirality is lost. Attack of the malonate back at the formaldehyde cation reforms the original 
compound. 
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Scheme 62: 2nd Postulated mechanism for C5 epimerization 
It should be noted, however that the precise role of silica gel and why DCM would induce 
epimerization but not ethyl acetate/petrol is unknown. Both mechanisms postulated would 
seem equally likely under the strong acidic conditions of the TFA:DCM mixture, if not more so 
than under the relative weak acidic conditions of silica gel. However, it is possible the 
epimerization requires a Lewis acid to occur. Trapping experiments with iodomethane were 
carried out (Scheme 63) in an attempt to isolate a possible intermediate of the reaction, such 
as 222 or 223, but unfortunately only starting material was observed. 
 
Reagents and conditions: MeI, DCM, Silica gel, rt, overnight 
Scheme 63: Attempt at trapping an intermediate with MeI 
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2.3.8.3.4 NMR experiments of the mixture in the presence of silica 
Returning to the original thiomethylated compounds, we sought further confirmation that 
silica gel was the cause of the epimerization. A 1H NMR spectrum was taken of the crude 
deprotected 29ab mixture as a control showing the 4:1 ratio of diastereoisomers. A 
microspatula of silica gel was added, and the NMR experiment ran immediately and after 16 
h. The 1H NMR spectrum after treatment with silica gel showed epimerization from 4:1 to 
3:1.3 (<5 mins). Upon being left for 16 h compound continued epimerizing, reaching a 3:2 
ratio. On further inspection, the 16 h experiment also contained a minor signal at δ = 9.73 
ppm which was absent in the control and the initial addition of silica gel experiment. Although 
this by no means confirms the mechanism, this does provide evidence for our second 
mechanism as the signal is consistent with formaldehyde. Interestingly, Dixon et al.122 and 
Massa et al.123 both reported similar observations. Both groups observed decomposition of a 
range of β-hydroxy malonates during chromatographic separation. It is perhaps surprising 
therefore that we were able to isolate the product at all. 
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Reagents and conditions: (i) Silica gel, chloroform, 16 h. 
 
 
 
Figure 15: Inducing of the epimerization with silica and the analysis with NMR 
Crude control 
Initial addition of silica 
16 h after addition of silica 
Potential 
formaldehyde 
peak 
Methyl ester CH3 
tert-Butoxy CH3 
PMB aromatic CH 
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2.3.9 Ketone reduction followed by tert-butyl deprotection strategy  
2.3.9.1 Reduction of the C6 ketone 
With the diastereoisomers of Corey’s intermediate 29ab proving inseparable, we decided to 
attempt an alternative route. Rather than removal of the tert-butyl group followed by 
reduction, we decided to reduce the mixture of diastereoisomers then use our tert-butyl 
removal procedure. Where the previous experiments had been carried out with the 
recrystallized material from the Dieckmann cyclization/alkylation (202a), the following 
procedures were carried out with the un-recrystalized material (69% ee) in the hope we could 
enrich the ee of this material only once at a later stage intermediate. 
Following either postulated mechanism for the epimerization, reduction of the C6 centre 
before deprotection of the hydroxyl group should prevent the epimerization (Scheme 64). 
 
Scheme 64: Rearrangement of the reduction and tert-butyl removal steps 
Our primary concern with the new route was that the bulky tert-butoxy group would direct 
the reduction more than the thiomethyl group. This would decrease the yield of the desired 
diastereoisomer. Reduction with sodium borohydride produced two separable 
diastereoisomers 224a and 224b in an approximately 1:4 ratio along with a small amount of 
starting material. NOESY experiments were carried out for the minor diastereoisomer 
confirming our stereochemical predictions that the hydride would add preferentially to the 
face opposite the thiomethyl group. Unfortunately, due to overlapping 1H NMR signals, the 
necessary interactions could not be seen for the major diastereoisomer. Analysis of both 
diastereoisomers on HPLC using a chiral stationary phase compared to a synthesized 
racemate showed a small drop in ee from 69 to 67% ee. We believe this to be due to minor 
quantities of the unwanted diastereoisomer being formed during the acylation with Mander’s 
reagent. 
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The major diastereoisomer 224a was isolated as a waxy oil (Scheme 65). To our delight, 
recrystallization from IPA produced a solid of 12% ee and a filtrate of 99% ee, as confirmed 
by analysis by HPLC using a chiral stationary phase compared to a synthesized racemate. 
 
Reagents and conditions: (i) 1) Pd(OH)2/C (cat), H2, 35 °C, 16 h 2) 186, Et3N, DCM, 4 h (70% 
over 2 steps) ii) NaBH4 (0.6 equiv), EtOH, 30 m 0 °C, 224a 54%, 224b 13%, 219ab 4%. 
Scheme 65: Thiomethylation and reduction of compound 217 
2.3.9.2 Deprotection of the tert-butyl group 
 
Reagents and conditions: TFA/DCM 1:1, 1.5h, 75%. 
Scheme 66: Deprotection of 224a to produce the Corey intermediate 30a 
Treatment of 224a under the same deprotection conditions as before provided the Corey 
intermediate 30a in excellent yield (Scheme 66). The compound was purified with column 
chromatography by the usual dry load method which previously epimerized the compound, 
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however with C6 now reduced, no epimerization was observed, providing the Corey 
intermediate 30a in 99% ee as confirmed by HPLC with a chiral stationary phase compared 
with a synthesized racemate. The intermediate synthesized is important in omuralide 
analogue synthesis and has been elaborated by Corey to a wide variety of C5 analogues.37  
2.4 Towards the total synthesis of salinosporamide B 
2.4.1 Strategy to salinosporamide B  
With a formal synthesis of omuralide completed and the successful incorporation of 2 amino 
acids into the lactam core using our methodology, we turned our attention to modification of 
the C7 carbon. Our aim was to incorporate longer carbon chains into the lactam core. Our 
target would be to incorporate an ethyl group into the C7 position and then elaborate the 
product to salinosporamide B.42  Although salinosporamide A41 is a more potent proteasome 
inhibitor, we decided to start on the simpler version of the salinosporamide family; there is 
currently no synthesis of salinosporamide B in the literature.  
 
Scheme 67: Retro-synthetic analysis of salinosporamide B 
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Our serine-derived Dieckmann cyclization precursor 201ab would be treated under similar 
conditions to our previous cyclization/alkylations to produce the serine-derived γ-lactam 
ethyl analogue (Scheme 67). An acylation using Mander’s reagent would be used to 
incorporate the methyl ester forming the acylated serine-derived γ-lactam ethyl analogue. 
Removal of the benzyl ester would allow incorporation of the thioether blocking group to give 
salinosporamide B intermediate C, attempts would then be made to reduce the ketone 
diastereoselectively with methyl Grignard reagent, incorporating the C6 methyl group to 
produce salinosporamide B intermediate B. Diastereoselective desulphurization and 
oxidation of the C9 hydroxyl group forming salinosporamide B intermediate A could allow 
for incorporation of the cyclohexene ring using 2-cyclohexyenylzinc chloride, a strategy 
developed by Corey,50 but also used successfully by Danishefsky,124 Hatakeyama,125 
Pattenden126,127 and Romo128 in their respective syntheses. Removal of protecting groups and 
cyclization to the β-lactone could then form salinosporamide B.  
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2.4.2 The Dieckmann cyclization/alkylation using EtI 
 
Entry Conditions Approx. 
Scale g 
Equiv of EtI Yield % 225a:b 
Ratio 
1 TBAF (3.4 equiv), THF 30 
m then EtI 16 h, rt 
0.5 4 19 (with 
inseparable by-
product) 
- 
2 TBAF (2 equiv), THF, 30 
m removal of volatiles, 
THF, 
EtI 16 h, rt 
0.1 2.2 65 1:0.72 
3 “ 1.4 2.2 26 - 
4 TBAF (2 equiv), THF, 5 m 
removal of volatiles, 
THF, 
EtI 20 h, rt 
1.5 2.2 added at 
0 h, 2.2 
added at 
16 h 
43 1:0.4 
5 TBAF (2 equiv), THF, 5 m 
removal of volatiles, 
THF, 
EtI 20 h, 0 °C to rt 
0.6 9 36 1:0.65 
Table 7: Optimization of the Dieckmann cyclization/alkylation using EtI 
Using similar conditions to our leucine cyclization/alkylation procedure (Table 7, Entry 1) 
provided 225ab as a mixture of inseparable diastereoisomers along with another inseparable 
unknown by-product. As our yield for this step was therefore less than 19%, a modification of 
the procedure was required. Using a procedure similar to the one used in our formal synthesis 
of omuralide, where the cyclization and alkylation were separated, provided the mixture of 
diastereoisomers in good yield (Entry 2). Unfortunately, scale up of this reaction to just 1.4 g 
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greatly decreased the yield (Entry 3).  Increasing the equivalents of EtI improved yields slightly 
(Entry 4). Cooling the reaction decreased the diastereoselectivity, presumably, as in our 
previous cyclization due to the cooler temperatures reducing the amount of product from 
epimerization, however, yields dropped to 36% (Entry 5). Unfortunately, at this stage we were 
unable to check to what degree our material had racemized due to the inseparable nature of 
the diastereoisomers. Furthermore, NOESY experiments were inconclusive as to which 
diastereoisomer was in excess. 
2.4.3 Attempted acylation 225ab using Mander’s reagent 
Treatment of the mixture of diastereoisomers under our acylation conditions resulted in a 
complex mixture from which no product could be isolated cleanly (Scheme 68). 
 
Reagents and conditions: LiHMDS (2.1 equiv), DMPU (3.1 equiv), THF, -78 °C, 0.5 h, then 
NCCO2Me (5.1 equiv), (-78 °C, -40 °C, -15 °C), 4 h. 
Scheme 68: Attempted acylation of 225ab with Mander’s reagent 
The high levels of diastereoselectivity we had seen in our previous routes indicated that bulky 
groups in the C7 position are highly effective at blocking addition of the Mander’s reagent. 
The exchange of the methyl group for the ethyl in our starting material could also be hindering 
attack of the methyl cyanoformate, resulting in our complex mixture. Warming the reaction, 
which had helped in our omuralide route, also resulted in complex mixtures. We therefore 
decided to attempt a different strategy to the acylation. 
2.4.4 Acylation following removal of the tert-butyl group 
2.4.4.1 Revised strategy for acylation 
Both the ethyl alkyl chain and the benzyl ester group were necessary in our synthesis and 
therefore could not be removed, but we felt that removal of the tert-butyl group would 
potentially reduce some of the steric hindrance around the C5 position, allowing insertion of 
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the methyl ester. We had previously experienced similar problems when switching from the 
leucine analogue to the tert-butoxy analogue, and we therefore felt that removal could be 
beneficial for the reaction (Scheme 69). 
 
Scheme 69: Removal of the tert-butyl protecting group 
After removal of the tert-butyl group our new strategy (Scheme 70) would involve use of an 
excess of base inducing double deprotonation of both the C5 position, forming the enolate, 
and the hydroxylate group. We theorized (Scheme 70) that addition of Mander’s reagent 
would add first at the most nucleophilic position (the C5 enolate) then at the hydroxyl group, 
re-protecting the hydroxyl group of the newly acylated compound with a methyl carbamate 
protecting group to give 228. 
 
Scheme 70: Removal of the tert-butyl group 
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2.4.4.2 Removal of the tert-butyl group 
Both the inseparable mixture of diastereoisomers from the room temperature cyclization 
(Table 7, entry 4) and the 0 °C cyclization (Entry 5) were treated with TFA under the tert-
butyl ether deprotection conditions previously used to produce 227a and 227b (Scheme 71).  
 
Reagents and conditions: (i) TFA/DCM 1:1, rt. 
Scheme 71: Removal of the tert-butyl group 
Deprotection proceeded in good yield and provided a separable mixture of diastereoisomers 
after column chromatography, furthermore, analysis using HPLC with a chiral stationary 
phase allowed ees to be determined (Table 8). Each diastereoisomer was examined against a 
synthesized racemate. Unfortunately, however, we were still unable through either NOSEY 
experiments or X-ray crystallography to determine which diastereoisomer was in excess. Our 
analysis had, however, shown that cooler temperatures during the cyclization had, as 
expected, improved ees. 
Starting 
material 
Diastereoisomeric 
ratio of starting 
material 
Yield and ee of 
the first eluting 
fraction % 
Yield and ee of the second 
eluting fraction % 
Material from 
table 7 entry 4 
1:0.4 18  
66 ee 
55 
45 ee 
Material from 
table 7 entry 5 
1:0.65 29 
78 ee 
46 
60 ee 
Table 8: Analysis of the deprotected material 227a and 227b 
2.4.4.3 Acylation with Mander’s reagent using the deprotected 227ab 
With the tert-butyl ether removed, 227ab was treated with a modified version of our original 
Mander’s acylation (Scheme 72). Firstly, the quantity of LiHMDS and N,N′-
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dimethylpropyleneurea (DMPU) were increased due to the need for two deprotonations to 
occur; secondly, the reaction required an increase in equivalents of Mander’s reagent 
because the methyl ester was now required to add twice.  
 
Reagents and conditions: (i) LiHMDS (3 equiv), DMPU (30 equiv), THF, −78 °C, 0.5 h, then 
NCCO2Me (4.6 equiv), −78 °C, 3 h, 27%. 
Scheme 72: Attempted acylation of 227ab 
1H NMR spectrum of the crude material after work-up showed a complicated mixture of 
compounds. However, one compound was observed in excess and was isolated by column 
chromatography. Unfortunately, 1H NMR spectroscopic analysis only showed one OMe peak 
corresponding to the para-methoxy benzyl group. Our desired product should have contained 
three. Further analysis by 1H NMR spectroscopy showed a doublet with a J value of 2.3 Hz. 
The chemical shift of this peak (δ-4.53) and its coupling partner (δ-5.21) combined with the 
small J value, pointed towards a terminal alkene 229. We were able to postulate a reason to 
explain the observed elimination. Lactam 227a is likely to have undergone an initial 
deprotonation from the LiHMDS at the hydroxyl position (Scheme 73). 
 
Scheme 73: Mono-deprotonation and acylation of 227a 
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If a second deprotonation does not occur before addition of Mander’s reagent, however, the 
hydroxyl group will become acylated to the carbonate 230 on addition of the reagent. This 
activates the hydroxyl group into a good leaving group, a second deprotonation at the C5 
position therefore would induce an elimination before the second acylation could take place 
(Scheme 74), hence the formation of the enone. 
 
Scheme 74: Mechanism for the formation of 230 from 229 
An analogous reaction was attempted at -40 °C in an attempt to encourage the initial double 
deprotonation but unfortunately decomposition of the starting material occurred. 
2.4.5 Attempted oxidation of the C9 hydroxyl group 
After our failure to incorporate the methyl ester with the hydroxyl group at C9, we devised a 
different approach. Oxidation of the C9 position to the aldehyde would form a malonic carbon 
centre at C5. This would lower the pKa of the C5 proton, potentially allowing a wider variety 
of acylation techniques to be used along with weaker bases, which could be less likely cause 
of decomposition of the product (Scheme 75). The resulting aldehyde could then either be 
protected or utilized to insert the cyclohexene ring earlier than originally intended (Scheme 
67).  
 
Scheme 75: Revised strategy for the insertion of the methyl ester via the malonic 
intermediate 230 
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For the oxidation, we chose to use Dess-Martin periodinane (DMP). DMP 234 is a hypervalent 
iodine species which can be bought commercially or prepared from 2-iodobenzoic acid 232 
(Scheme 76).129 
In 1983 Dess and Martin prepared this reagent and reported its use30 on a range of primary 
and secondary alcohols, oxidising them to aldehydes and ketones respectively. 
 
Scheme 76: Preparation of DMP 234 from 232 
DMP has been shown to not over-oxidize alcohols past the aldehyde and furthermore had 
been used on similar substrates in Corey’s synthesis of omuralide to great effect.29  
 
Reagents and conditions: DMP (2 equiv), DCM, 16 h, rt. 
Scheme 77: Attempted oxidation of 230ab 
Unfortunately, however, after work up, no compound could be observed in the crude 1H NMR 
spectrum or seen on TLC. It is perhaps the case that the malonic product was too unstable 
and therefore underwent decomposition. Due to the significant problems from the beginning 
of this route and time constraints we decided to stop working towards the total synthesis of 
salinosporamide B. 
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2.5 Toward the total synthesis of omuralide and analogues from hydroxy-leucine 
2.5.1 Introduction to β-hydroxy, α-amino acids 
2.5.1.1 β-hydroxy, α-amino acids in natural products 
Of the DNA-encoded 20 amino acids, only two are β-hydroxy, α-amino acids; serine and 
threonine. More unusual β-hydroxy amino acid backbones, however, are found regularly in 
natural products.  
 
Figure 16: An array of β-hydroxy, α-amino acids 
The recently reviewed guanidine-containing amino acid enduracididine has a β-hydroxy 
amino acid form 234 and its epimer, 235.130 Both are found in a group of glycopeptides called 
mannopeptimycins discovered in 2002.130 Mannopeptimycins α-ε were found to be active 
against gram-positive bacteria. Synthesis and a structural revision of the aglycone was 
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reported in 2014.131 Hydroxylated forms of isoleucine 236 and tyrosine 237 have also been 
found in the cyclic peptides ustiloxins132 isolated from false smut balls found on rice,133 and 
were found to have antimitotic properties. β-Hydroxylated forms of asparagine 238, 
phenylalanine 239 and leucine were found in the potent antibiotic lysobactin, discovered in 
1988.134 Full elucidation of the structure of lysobactin was completed in 1989.135 The anti-
cancer drug bleomycin136 contains a substituted β-hydroxy histidine 240 moiety.137 A 
hydroxylated proline derivative 241 is found in the DNA gyrase inhibitor cyclothialidine, both 
discovered138 and structurally determined139 in 1993. Substituted hydroxy-tryptophan 
derivatives 242 were also found in the cyclomarins A-C,140 which display significant anti-
inflammatory properties. The cyclomarins also contained a β-methoxylated phenylalanine. 
Perhaps most famous, however are the chlorohydroxy tyrosine derivatives 243 and 244, due 
to their occurrence in the potent antibiotic vancomycin. Discovered in 1956141 the aglycone 
245 was first synthesized by Evans et al.142 after full structure elucidation.143,144   
 
Figure 17: The aglycone of vancomycin, β-hydroxy, α -amino acids highlighted 
Vancomycin has become the last line of defence in the fight against antibiotic resistance,145,146 
and is listed on the world health organization’s (WHO) list147 of essential medicines. Several 
structural modifications over the years has retained vancomycin at the forefront of 
attention.148 
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2.5.1.2 β-Hydroxy, α-amino acids in pharmaceuticals 
 
Figure 18: β-Hydroxy, α-amino acids in pharmaceuticals 
In addition to natural products, β-hydroxy amino acids and their derivatives also are prevalent 
in drug molecules (Figure 18). ONO-4128 246 was developed by GSK for treatment of HIV.149 
The hypotension drug droxidopa 247149 developed by Sumitomo pharmaceuticals is used 
worldwide, and the antibiotic chloramphenicol 249 which is used to treat a wide variety of 
diseases including the plague. Extracted from bacteria, chloramphenicol (discovered in 
1947150 and structure elucidated151 in 1949) was the first antibiotic to be synthesized.152 Later 
the more potent analogue thiamphenicol 250 was synthesized after replacement of the nitro 
group with a methyl sulphone. Both could be derived from β-hydroxy amino esters after 
reduction. 
2.5.1.3 Hydroxy leucine in natural products 
 
Figure 19: Omuralide, with the motif for hydroxy-leucine highlighted 
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The hydroxy leucine motif is found in omuralide. (Figure 19) The β-hydroxy amino acid and its 
derivatives have been identified in a plethora of natural products, usually with anti-bacterial 
properties. These include; azinothricin153, A83586C154, citropeptin155, the papuamides A-D156, 
verucopeptin,157 kettapeptin,158 polyoxypeptins A and B,159 piplamycin,160 GE3,161 JBIR – 78,162 
JBIR – 95,162 telemycin,163 HV-toxin M,164 leucinostatin,165 scytonemin A,166 and lysobactin.134 
2.5.1.4 Strategies for the synthesis of β-hydroxy, α-amino acids 
2.5.1.4.1 Introduction to β-hydroxy, α-amino acid synthesis 
With the widespread occurrence of the β-hydroxy, α-amino acids backbone and its derivatives 
in natural and synthetic compounds. Methods for the synthesis of these valuable structures 
are important. 
2.5.1.4.2 Synthesis of hydroxy leucine utilizing an aldol reaction 
2.5.1.4.2.1 An aldol reaction employing a chiral auxiliary 
Early work in the asymmetric synthesis of β-hydroxy, α-amino acids was pioneered by Evans. 
Using an oxazolidinone chiral auxiliary attached to halo acetate or glycine derivatives, Evans 
was able to produce anti or syn β-hydroxy, α-amino acids or their derivatives. Evans’ approach 
to syn amino acids used an isocyanate attached to a chiral oxazolidinone via an amide bond 
(251).167 Using an aldehyde and stannous triflate as the Lewis acid, several β-hydroxy, α-
amino acid precursors were synthesized in excellent diastereoselectivity including a precursor 
to hydroxy leucine 252 which was synthesized in 92% yield with a diastereoisomeric ratio (dr) 
of 99:1 (Scheme 78). 
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Reagents and conditions: (i) Sn(OTf)2, iso-Butyraldehyde, N-ethyl piperidine THF, -78 °C, 92%. 
 Scheme 78: Evans approach to syn β-hydroxy, α-amino acids 
Complementary work by Evans168 showed that using an oxazolidinone bonded to a halo 
acetate 253 could produce bromo-hydrins such as 254, which, when bromine was displaced 
with sodium azide (255), could produce anti-β-hydroxy, α-amino acids. Again, hydroxy leucine 
was one of several amino acids synthesized in the work (Scheme 79). 
 
Reagents and conditions: (i) Bu2BOTf, iso-Butyraldehyde, NEt3, DCM, -78 °C – 0 °C, 63% (ii) 
NaN3, DMSO. 
Scheme 79: Evans approach to anti β-hydroxy, α-amino acids 
2.5.1.4.2.2 An aldol reaction using an organocatalyst 
Barbas169 showed in 2004 that proline could be used to catalyse aldol reactions between 
phthalimidoacetaldehyde 256 and various aldehydes. An extensive optimization using iso-
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butyraldehyde was carried out that produced 257 in 93% yield and >99% ee and >100:1 dr, 
which could be elaborated to a derivative of (S,S) hydroxy-leucine 258 (scheme 80). 
 
Reagents and conditions: (i) iso-Butyraldehyde, L-proline, NMP, 4 °C, 6 days, 93%; (ii) 1) 
NaClO2, 2-methyl-2-butene, NaH2PO4, tBuOH-H2O, rt; 2) TMSCHN2, MeOH-toluene-hexane -
20 °C, 73% over the 3 steps. 
Scheme 80: Strategy by Barbas to synthesize β-hydroxy, α-amino acids 
2.5.1.4.2.3 An aldol using a chiral Lewis acid 
Corey was able to produce bromohydrin170 260 using chiral Lewis acid 261. The bromohydrin 
260 (90% yield, 92% ee) was then elaborated to both diastereoisomers of hydroxy leucine 
(scheme 81). 
 
Reagents and conditions: 261, DCM, iso-butyraldehyde, NEt3 -78 °C, 10 h, 90%. 
Scheme 81: Corey’s strategy to produce either hydroxy-leucine diastereoisomer 
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2.5.1.4.3 Synthesis using asymmetric hydrogenation 
The groups of Genet171 and Noyori172 each published asymmetric dynamic kinetic resolutions 
through the hydrogenation of α-amino, β-keto esters using a ruthenium catalyst. This laid the 
foundation for Hamada173 to synthesize all diastereoisomers of hydroxy leucine through 
hydrogenation, producing the anti-diastereoisomer derivative 52, then inverting the β-
hydroxy to produce the syn. Genet174 was later able to report methodology allowing the 
formation of syn or anti-products depending on the nature of the starting material (Scheme 
82). 
 
Reagents and conditions: H2 (100 atm), RuCl2[(S)-binap](dmf)n, DCM, 50 °C, 48 h, 100%. 
Scheme 82: Hamada’s strategy for the synthesis of all stereoisomers of hydroxy leucine 
Later work by Genet175 and Hamada176 developed the methodology further, allowing 
asymmetric hydrogenation of the primary amine salts as opposed to further substituted 
counterparts. 
2.5.1.4.4 Synthesis using Sharpless methodology 
2.5.1.4.4.1 Asymmetric dihydroxylation 
In 1988 Sharpless reported a useful activation of 1,2 diols using a cyclic sulphate. The strategy 
activated the diol much like an epoxide, but the sulphate could undergo displacement by 
nucleophiles far more readily.177 Corey later used this methodology, in combination with the 
Sharpless dihydroxylation reaction, to synthesize the methyl ester of (S,S) hydroxy leucine 265 
(Scheme 83).39 
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Reagents and conditions: (i) (DHQ)2PHAL, K2OsO4, t-BuOH-H2O, 0 °C, 3 days, 92%; (ii) 1) SOCl2, 
Py, CH2Cl2, 0 °C, 10 m, H2SO4; 2) NaIO4, RuCl3, MeCN-CCl4, 97% over 2 steps; (iii) NaN3, 
Acetone, rt, 30 m then H+ (iv) H2, Pd/C, EtOH/EtOAc, 89% over 2 steps. 
Scheme 83: Corey’s synthesis of 265 via a cyclic sulphate 
2.5.1.4.4.2 Asymmetric epoxidation  
Ōmura178 used an asymmetric epoxidation179 to form 266 which after conversion to the cyclic 
carbamate 267 and oxidation to the acid 270, could be converted to (S,S)-hydroxy-leucine. 
Intermediate 270 could also be esterified and epimerized to 271, which could then be 
converted to (R,S)-hydroxy leucine (scheme 84). 
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Reagents and conditions: (i) 1) PhC(Me)2O2H, Ti(O-i-Pr)4, (+)-DIPT, 82%; (ii) NaH, BnNCO, 
THF; (iii) NaH, THF, 75%; (iv) CrO3, Acetone, 100%; (v) 1) KOH (2 M), 2) H2, Pd/C, 98%; (vi) 
CH2N2, Et2O, 86%; (vii) KOH, EtOH, 97%. 
Scheme 84: Ōmura’s synthesis of the hydroxy-leucine using a Sharpless epoxidation 
2.5.1.4.4.3 Asymmetric amino hydroxylation 
Another method developed by Sharpless that has been utilized in the synthesis of β-hydroxy, 
α-amino acids is the amino-hydroxylation, where a double bond can be simultaneously 
hydroxylated and nitrated. 
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Reagents and conditions: (i) p-Bromophenol, DCC, DMAP, CH2Cl2, rt, 12 h 80%; (ii) (DHQ)2-
AQN, K2OsO4, H2NCBz, NaOH, t-BuOCl, n-propanol, 4 h, rt, 60%. (iii) Ti(n-PrO)4, MeOH, 2 h, 
100%; (iv) H2, Pd/C, MeOH, 12 h, 99 %. 
Scheme 85: Panek’s synthesis of 36 
Substrate 274 was found to produce the best regio- and enantioselectivity, allowing 275 to 
be produced in 87% ee, which could be recrystallized to the single enantiomer.32 Exchange of 
the bromo-phenyl to the methyl and protecting group removal then afforded 36 in excellent 
yield. 
2.5.2 Strategy of the synthesis of omuralide from hydroxy leucine  
Although our Corey analogue 19a allowed late stage modification of the C9 position for 
omuralide, the C7 methyl group was installed early on in the synthesis. Ideally, diversification 
of the structure for the synthesis of analogues should be as late in the synthesis as possible 
to reduce the time taken and number of steps required. We therefore decided to design a 
route based around using hydroxy leucine as the starting amino acid. This would install the 
C5 moiety early on in the synthesis, providing a rapid route to omuralide. Furthermore, by 
incorporating much of the stereochemistry and carbon skeleton from the beginning, this 
could allow late stage diversification of the C7 position (Scheme 86). 
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Scheme 86: Outline of a route starting with hydroxy-leucine 
2.5.3 Diastereoisomer of hydroxy leucine required for the synthesis 
Although the synthesis of hydroxy leucine has been well studied, we felt a method where 
either diastereoisomer could be produced from a late stage intermediate would be a valuable 
addition to the literature. We also sought a method which would avoid expensive or unusual 
ligands and proceeded in as few steps as possible, preferably using column chromatography 
to purify intermediates as little as possible. 
Hydroxy leucine is commercially available, however, we were presented with two problems. 
Firstly, hydroxy leucine is very expensive, and we would need multi-gram quantities in order 
to complete our synthesis. Secondly, we were unable to predict which stereochemical course 
our route would take, as the diastereoselectivity during the Dieckmann cyclization had 
switched between the leucine and serine routes. We did know, however, that we required 
the hydroxyl group to be in the S configuration, as in omuralide. 
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*Costs shown are approximate values from Santa Cruz Biotechnology 
https://www.scbt.com/scbt 
We therefore decided to synthesize both of the diastereoisomers of hydroxy leucine. 
Our aim was to synthesize the enone 47 by a Wittig reaction, then use the Sharpless 
dihydroxylation procedure to produce diol 48. The syn diastereoisomer could be synthesized 
utilizing the Sharpless methodology for producing β-acetoxy, α-bromo esters. We would then 
attempt to displace the bromine with a nitrogen-based nucleophile in an SN2 fashion, 
inverting the stereocentre producing the syn diastereoisomer (Scheme 87). The anti-
diastereoisomer could be synthesized using Corey’s methodology as previously described 
(Scheme 83). 
 
Scheme 87: Our planned methodology to synthesize both diastereoisomers of hydroxy 
leucine 
• (S,S) Hydroxy-leucine 
• Anti 
• “Serine route” stereochemical course 
• 1 g = £1180.00* 
 
• (R,S) Hydroxy-leucine 
• Syn 
• “Leucine route” stereochemical course 
• 1 g = £18500.00* 
• Used as an inhibitor of serine protease 
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2.5.4 Synthesis of the enone precursor through a Wittig reaction 
We planned to synthesize the isobutyl enone by a Wittig reation. The methyl acetate 
phosphonium salt was prepared by triphenylphosphine substitution of methyl bromoacetate. 
Deprotonation of the salt with sodium hydroxide produced the ylide 46 in excellent yields 
(scheme 88). 
 
Reagents and conditions: (i) PPh3, EtOAc, 24 h, rt, 80% (ii) DCM, 1 M NaOH Sol, 99%. 
Scheme 88: Synthesis of the Wittig ylide 46 
The α, β-unsaturated ester was synthesized through treatment of the ylide with isobutyl-
aldehyde. The stabilized nature of the ylide provided the product as the E isomer only and 
purification could be completed by Kugelrohr distillation, avoiding the use of column 
chromatography. The ester slowly oxidized upon storage to the γ-peroxidized form through 
an auto-oxidation pathway. Storage under argon and protecting the glassware from light did, 
however, reduce conversion to the peroxidized product (Scheme 89). 
 
Reagents and conditions: (i) iso-butyraldehyde, DCM, 20 h, rt, 63%; (ii) air, hν. 
Scheme 89: Synthesis of enone 47 and its oxidation to 277 
2.5.5 Sharpless asymmetric dihydroxylation 
2.5.5.1 Introduction to the Sharpless asymmetric dihydroxylation 
The reaction between osmium tetroxide and olefins was discovered in 1908.180 Later work by 
Criegee et al. 181 found that reaction rates could be increased with the addition of pyridine. 
This work laid the foundation for Sharpless in 1980 to publish the first asymmetric 
dihydroxylation using chinchona alkaloid ligands.182 Later work by Sharpless et al.183 
developed this asymmetric procedure into a catalytic system, re-oxidizing the osmium with 
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tertiary amine N-oxides, a technique originally discovered by the Upjohn company.184 The 
reaction has since undergone substantial development of both the conditions and ligands 
used. The most important improvement from the previous pseudo-enantiomer ligands,  
quinine and quinidine (providing either enantiomer of the substrate), being the avoidance of 
using stoichiometric ligand through the development of the phthalazine class of ligands 
(Figure 20)185 hydroquinine 1,4-phthalazinediyl diether ((DHQ)2PHAL) and hydroquinidine 
1,4-phthalazinediyl diether ((DHQD)2PHAL), again respectively quinine- and quinidine-
derived, and now the most widely used. These commercially available ligands can be bought 
as pre-mixed powders containing potassium carbonate, potassium osmate dihydrate, the 
oxidant potassium ferricyanide and either ligand depending on the enantiomer required. 
 
Figure 20: Ligands used in asymmetric dihydroxylation 
2.5.5.2 Ligand required for the dihydroxylation 
Sharpless also developed a mnemonic allowing identification of the ligand needed depending 
on the enantiomer of the substrate required. We subjected our substrate to the analysis. As 
mentioned (Chapter 2.5.3), the β-enantiomer would need to have the S stereochemistry as 
found in the C9 position of omuralide. The substrate is orientated so the largest moiety (the 
methyl ester) points to the “southwest” corner and the second largest (the iso-propyl) to the 
“northeast” corner. Once in this position, Sharpless has shown that (DHQD)2PHAL would add 
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the hydroxyl groups from the top face and (DHQ)2PHAL from the bottom face (Figure 21). This 
would provide us with S,R or R,S respectively, allowing us to conclude that the (DHQ)2PHAL 
ligand found in AD-Mix α would be required. 
 
Figure 21: Sharpless mnemonic for choice of ligand required 
2.5.5.3 Asymmetric dihydroxylation of 47 
Enone 47 was treated under standard conditions for asymmetric dihydroxylation. This 
provided 48 in 90% ee, which after recrystallization from petroleum ether/ethyl acetate was 
enriched to 96% ee (Scheme 90). 
 
Reagents and conditions: AD-Mix α, t-BuOH/H2O 1:1, 68% (90% ee). Recrystallization in 
petroleum ether/ethyl acetate (50% overall yield, 96% ee). 
Scheme 90: The dihydroxylation of 47 
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2.5.6 Tandem bromination/esterification of diol 48 
In 1991, Sharpless published “Selective Transformations of threo -2,3-dihydroxy esters”, 
which contained several useful reactions for the transformation of dihydroxylated esters.34 
One of the reported transformations was an α-bromination, β-esterification of α,β diol esters. 
The reaction proceeded through the formation of a cyclic oxocarbenium ion and subsequent 
opening with bromine in an SN2 fashion (Scheme 91). 
 
Reagents and conditions: (i) HBr, AcOH, 40 °C. 
Scheme 91: Regioselective bromination of α,β diol esters 
A modified version of this methodology developed by Adams et al.33 was used for the 
bromination of our diol. A benzoyl cyclic orthoester was formed, catalysed by BF3.OEt2. 
Opening was induced by acetyl bromide, brominating the α-position and forming the benzoyl 
ester on the β-hydroxyl group (Scheme 92). 
 
Reagents and conditions: (i) PhC(MeO)3 (1.3 equiv), BF3.OEt2 (cat), Et3N (cat), DCM 2 h then 
AcBr (1 equiv), 3 h, rt, 91%. 
Scheme 92: Regioselective bromination of 48 
Bromo ester 49 was used without further purification. We decided to attempt to use para-
methoxy benzylamine 278 to displace the bromine. Not only would this provide the amine 
necessary for the amino acid, but also install the PMB protecting group (279), which would 
be required for our omuralide synthesis (Scheme 93). 
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Reagents and conditions: PMBNH2, THF, -78 °C to rt, 64 h, 25%. 
Scheme 93: Attempted displacement of bromine by 278 
To our surprise however, analysis of the 1H NMR spectrum of our product suggested that it 
was aziridine 280 instead of our desired compound. 
A reaction involving α-halo, α,β-unsaturated esters and amines to form aziridines has been 
observed before and is known as the Gabriel-Cromwell reaction.186 The proposed mechanism 
is shown in scheme 94. 
 
Scheme 94: A Gabriel-Cromwell style reaction to produce by-product 280 
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Triethylamine deprotonates the acidic alpha proton and the benzoyl ester is eliminated. A 
Michael type addition from 278 onto the α,β-unsaturated ester forms a secondary amine, 
which can inter-molecularly undergo nucleophilic substitution with the bromine, forming the 
aziridine 280. Although we were only able to isolate the cis diastereoisomer, Gabriel-
Cromwell reactions usually provide an unequal mixture of diastereoisomers187 due to the free 
rotation possible after keto – enol tautomerization.  
2.5.7 Transesterification of the β-ester 
2.5.7.1 Transesterification of the benzoyl ester 
Although substitution of the bromine with PMBNH2 278 had failed, we felt a similar reaction 
was worth pursuing. If we were able to remove the β-ester, leaving the unprotected alcohol 
as in 283, the original elimination shown in scheme 94 would presumably not occur, perhaps 
resulting in the desired substitution. Usually esters are hydrolysed under basic conditions; but 
in our system this would probably lead to the elimination product again. We therefore 
decided to attempt to hydrolyse the ester under acidic conditions. Methanol was chosen as 
the solvent so as not to interfere with the methyl ester in 49. Attempts at removing the benzyl 
ester through a methanolic transesterification failed with (±)-camphorsulphonic acid ((±)-
CSA) at room temperature, (Scheme 95, table 9), providing only starting material after 24 h. 
 
Scheme 95: Attempt at transesterification of the benzoyl ester 133 
Entry Conditions Product and yields % 
1 (±)-CSA (1.4 equiv), MeOH, rt, 24 h  49 92% 
2 p-TSOH (1.1 equiv), rt, overnight 49 
3 p-TSOH (1.1 equiv), reflux, 5 h 49 32% 284 39%. 
Table 9: Attempted acid hydrolysis of 49 
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Increasing the acidity of the organic acid by using p-TsOH also provided only starting material 
at room temperature. Heating this to reflux overnight provided starting material along with 
hydrolysed material, but the hydrolysis had occurred not at the ester but at the bromine, 
providing compound 284. Because of these problems, we decided to modify the method, 
exchanging the benzoate for an acetate in the hope that the decreased size of the ester would 
increase the likelihood of transesterification. 
2.5.7.2 Transesterification of the α-bromo, β-acetoxy ester 
The α-bromo β-acetoxy ester 285 was synthesized in an analogous way to 49 by the exchange 
of trimethoxybenzoate with trimethoxy acetate (Scheme 96). 
 
Reagents and conditions: MeC(MeO)3 (1.7 equiv), BF3.OEt2 (cat), Et3N (cat), DCM 2 h then 
AcBr (3 equiv), 3 h, 91%. 
Scheme 96: Formation of the α-bromo, β-acetoxy ester 285 
Although the compound could be isolated in crude form from the reaction mixture, under 
high vacuum, evaporation appeared to occur, causing purification to be difficult. Because of 
these problems 285 was taken onto the deprotection conditions without further purification. 
Unfortunately stirring with (±)-CSA in methanol also failed to provide the desired 
bromohydrin 283, only starting material being isolated. 
 
Reagents and conditions: i) (±)-CSA, MeOH, rt. 
Scheme 97: Attempt at transesterification of the benzoyl ester 283 
Due to the volatile nature of 285, we decided not to try further deprotection methods for the 
acetoxy group. 
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2.5.7.3 Transesterification of the α-bromo β-formate ester 
One of the most labile ester based protecting groups is a formate ester.188 Due to the difficulty 
in removing our previous esters, we decided to synthesize the α-bromo β-formate ester 286. 
Once again, the reaction proceeded cleanly, and furthermore, no loss of mass was observed 
after extended periods under vacuum (Scheme 98).  
 
Reagents and conditions: HC(MeO)3 (1.4 equiv), BF3.OEt2 (cat), Et3N (cat), DCM then AcBr (1.2 
equiv), 91%. 
Scheme 98: Formation of the α-bromo, β-formate ester 286 
The α-bromo β-formate ester was treated with the acid hydrolysis conditions at room 
temperature, and to our delight this produced the desired bromohydrin 283 in excellent 
yields. Because both our bromination and transesterification appeared to proceed well based 
on crude 1H NMR analysis, a one pot procedure was developed. After bromination, methanol 
and (±)-CSA were added, and the solution stirred vigorously (Scheme 99). The development 
of this one pot procedure only decreased overall yields slightly but removed a step from the 
synthesis. 
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Reagents and conditions: (i) (±)-CSA (1.7 equiv), MeOH, rt 89%. (ii) HC(MeO)3 (1.4 equiv), 
BF3.OEt2 (cat), Et3N (cat), DCM then AcBr (1.1 equiv), MeOH, (±)-CSA (2.6 equiv), 67%. 
Scheme 99: Deprotection of the formate ester 286 and the one pot α-bromination of diol 48 
Although only minor impurities were present, the bromohydrin 283 required purification by 
column chromatography at this stage. However, this was the first column chromotography 
required in our (R,S) hydroxy leucine synthesis. 
2.5.8 Displacement of bromine with para-methoxy benzylamine 278 
Under similar reaction conditions to our previous para-methoxy benzylamine substitution 
attempt (Scheme 93), the bromine displacement reaction was run until full consumption of 
the starting material had occurred (Scheme 100). 
 
Reagents and conditions: PMBNH2 (2 equiv), Et3N (0.9 equiv), THF, overnight, rt, 67%. 
Scheme 100: Attempt to displace the α-bromine position with 278 
One major product was observed in the crude reaction mixture. The major compound was 
active under ultraviolet (UV) light, which indicated the PMBNH2 had been added to the 
molecule, but unfortunately, after purification by column chromatography, analysis of the 1H 
 148 
 
NMR spectrum indicated that the colourless crystalline compound isolated was not our 
desired product. Crucially, only one OMe peak could be observed and a characteristic amide 
peak could be seen. NMR analysis pointed toward α,β-epoxy amide 288. Triethylamine could 
induce a rapid intramolecular cyclization to the epoxide. Substitution at the methyl ester from 
278 would then form the by-product 288. 
Although not our desired product, 288 proved useful in confirming the absolute and relative 
stereochemistry. 
Firstly, the UV active nature of 288 allows measurement by HPLC, due to the method of 
detection used by the instrument. We were able to confirm the ee as 96% using HPLC with a 
chiral stationary phase in comparison with a synthesized racemate. 
Secondly, a crystal structure of the enantiopure product confirmed that the correct 
dihydroxylation ligand had been used, providing our β-hydroxyl group as the S stereocentre. 
Finally, a crystal structure was obtained, which showed the substituents had a trans 
relationship (Figure 22). This provided evidence that the bromohydrin starting material had 
an anti-conformation between the bromine and the hydroxyl group. 
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Figure 22: X-ray crystal structure of 288, hydrogen atoms removed for clarity 
2.5.9 Asymmetric reductive amination 
2.5.9.1 Introduction to asymmetric reductive amination 
With our methods to incorporate the PMB group utilizing an SN2 reaction failing, we decided 
to attempt a different approach. Secondary amines are commonly formed through reductive 
amination. In the last few decades, considerable progress has been made in the formation of 
chiral amines using asymmetric reduction of the imine. In our pursuit of finding a rapid route 
to the synthesis of hydroxy leucine we decided to utilize a method by Saxena et al.,189 who 
developed a one pot oxidation, reductive amination of alcohols. The method utilizes the 
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2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO)/(diacetoxyiodo)benzene (BAIB) oxidation 
developed by Piancatelli.190 The oxidation was chosen by Saxena in part due to the release of 
acetic acid, catalysing the second step of imine formation. TEMPO-based oxidations have 
been reviewed.191 
After oxidation, the imine can be formed with the required primary amine. A chiral Brönsted-
acid, in this case the binol-derived phosphoric acid catalysts such as 290, pioneered by 
Akiyama192 and Terada,193 co-ordinates to the imine creating an environment where the bio-
mimetic reducing agent, Hantzsch ester (289), is able to reduce the imine asymmetrically 
(Scheme 101). Work on asymmetric reductive aminations with similar Brönsted acid-
catalysed systems was initiated by Macmillan.194 
 
Scheme 101: One-pot asymmetric synthesis of amines from alcohols 
We hoped with correct choice of chiral Brönsted acid, either diastereoisomer could be 
synthesized (Scheme 102); however, we needed first to develop a method allowing 
regioselective protection of the β-hydroxyl group in the diol ester 48. 
 151 
 
 
Scheme 102: Strategy for the synthesis of protected hydroxy-leucine from 48 
2.5.9.2 Reigioselective protection of the β-alcohol 
A procedure based on the original bromination from scheme 92 was developed to 
regioselectivly mono-benzoylate the β-hydroxyl group.  Addition of water instead of acetyl 
bromide after formation of the oxocarbenium ion opened the ring, providing a free hydroxyl 
group alpha to the methyl ester and leaving the β-position protected with a benzoyl ester. 
Depending on the mechanism, the α-hydroxyl group could now be anti or syn to the β 
position. Path 1, where the hydroxyl attacks at the α-position of the methyl ester would 
produce the anti-isomer 291, whereas the syn-isomer 284 would be produced by attack at 
the benzoyl carbonyl (path 2) (Scheme 103). 
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Reagents and conditions: (i) PhC(MeO)3 (1.4 equiv), BF3.OEt2 (cat), Et3N (cat), DCM 2 h then 
H2O, rt, 70%. 
Scheme 103: Hydrolysis of the oxocarbenium ion intermediate and potential products 
formed 
Although our next step would oxidize the α-hydroxyl group making its configuration 
irrelevant, we decided to confirm the stereochemistry as the compound was novel. Removal 
of the benzoyl with potassium tert-butoxide in methanol provided our original syn-
dihydroxylated ester 48 (Scheme 104). 
 
Reagents and conditions: KOt-Bu, MeOH, 0 °C, 84%. 
Scheme 104: Removal of the benzoyl ester allowing identification of 284 
This result confirmed the stereochemistry to be syn and the product from scheme 103 to be 
284, meaning the reaction proceeds by path 2, with the hydroxide opening the ring by 
attacking the benzoyl carbonyl. 
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2.5.9.3 Synthesis of the reagents for asymmetric reductive amination 
 
Reagents and conditions: (i) POCl3, Py, 75 °C, 5 h, then H2O, 2 h, rt, 46%. 
Scheme 105: Synthesis of the chiral Brönsted acid 290 
Following a procedure by Zhou et al.195 (S)-binol was converted into the phosphoric acid 
analogue by reacting 292 with phosphoryl chloride. Quenching the mixture provided the 
chiral Brönsted acid 290 after purification by column chromatography (Scheme 105).  
Hantzsch’s ester was synthesised following a procedure by Kumar et al.196 based on the 
Hantzsch dihydropyridine synthesis. This multi-component reaction can be applied to a wide 
variety of aldehydes and malonic keto esters to provide various dihydropyridine derivatives 
(Scheme 106). 
 
Reagents and conditions: (i) Formaldehyde (aq) (1.1 equiv), CH3CO2NH4 (1 equiv), p-TSA (cat), 
16 h, rt, 23%. 
Scheme 106: The Hantzsch dihydropyridine synthesis to 293 
2.5.9.4 Asymmetric reductive amination applied to compound 284 
 154 
 
Our mono-protected diol was treated under the oxidation conditions provided from the 
literature189 until TLC showed that consumption of the starting material had occurred. The 
PMB amine 278 was then added along with 289 and 290 and again left until consumption of 
the starting material had occurred (Scheme 107). Unfortunately, upon work-up we found that 
both by TLC and analysis of the crude 1H NMR spectrum, a complex mixture of products was 
formed. It is possible that the alpha ester ketone is too hindered, the bulky nature of the 
benzoyl ester protecting group in 284 preventing imine formation. Because of this, we 
decided to synthesize a less hindered analogue in the hope the imine could now be formed 
successfully. 
 
Reagents and conditions: (i) BAIB (1.2 equiv), TEMPO (0.2 equiv), DCM, 16 h then 278 (2.3 
equiv), 289 (1.9 equiv), 290 (0.18 equiv), 2.5 h, rt. 
Scheme 107: Attempt at asymmetric reductive amination of 284 
2.5.9.5 Mono-acetate protection of the diol 48 
Diol 48 was treated under an analogous procedure to our mono-benzoate protection 
(Scheme 108) to produce the acetoxy analogue 295. Unfortunately, however, the reaction 
provided two products, the major being our desired β-protected alcohol 295, but significant 
amounts of the α-protected alcohol was also isolated after column chromatography 296. 
 
Reagents and conditions: MeC(MeO)3 (1.3 equiv), BF3.OEt2 (cat), Et3N (cat), DCM 2 h then 
H2O, rt, 150 31% 151 11%. 
Scheme 108: Mono-acetate protection of diol 48 
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During further characterization of the α-protected diol-ester, we found that the acetate 
would migrate to the β-position upon standing in chloroform (Scheme 109), presumably to 
the more stable regioisomer via 297 this migration is potentially due to the acidic content of 
the chloroform. Analysis of the 1H NMR spectrum showed after 16 h a 0.07:1 (295:296) 
mixture would convert to a 3.55:1 mixture of regioisomers. In comparison, conversion of 295 
to 296 was almost negligible, with a 1:0.01 (295:296) mixture of regioisomers converting to a 
1:0.03 mixture after 16 h. 
 
Scheme 109: Equilibrium of 295 and 296 
2.5.9.6 Asymmetric reductive amination applied to compound 295 
The less hindered mono-protected diol ester 295 was treated under similar conditions to our 
previous benzoylated analogue 284 (Scheme 107). Unfortunately, once again a complex 
mixture of products was formed (Scheme 110). A major product was partially isolated, but it 
could not be fully characterized. It appeared that the PMB group had been incorporated, but 
not in the desired fashion. A peak in the 1H NMR spectrum appeared to correspond to an 
amide, which could correspond to a substitution of the methyl ester, suggesting 298. We had 
seen similar reactions occur previously during our attempts to displace the bromine in 
scheme 100. 
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Reagents and conditions: (i) BAIB (1.1 equiv), TEMPO (0.2 equiv), DCM, 16 h, 278 (2 equiv), 
289 (1.2 equiv), 290 (0.15 equiv), 2.5 h, rt. 
Scheme 110: Oxidation/amide formation of 298 
2.5.10 Displacement of bromine with sodium azide 
It seemed that in general PMBNH2 was quite ineffective at displacing bromine and would 
often act as a base rather than a nucleophile. We therefore decided to switch to sodium azide 
which would form 299. Reduction of the azide 299 would then produce the primary amine 
36, providing us with the amino acid for use in our synthesis (Scheme 111). 
 
Scheme 111: Revised strategy for the synthesis of hydroxy-leucine 
To our delight, sodium azide was able to displace the bromine in N,N-Dimethyl formamide 
(DMF). The obtained product appeared pure by analysis of the 1H NMR spectrum and 
therefore 299 could be used in the next step without further purification. 
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Reagents and conditions: (i) NaN3 (3.4 equiv), DMF, 20 h, 80%. 
Scheme 112: Displacement of bromine in 283 by sodium azide 
2.5.11 Reduction of azide 137 and amine HCl salt formation 
Reduction of the azide to 36 appeared to proceed as observed by TLC. Unfortunately, 
however, analysis of the crude 1H NMR spectrum showed a mixture of compounds. We 
theorized that co-ordination between the amine and various impurities (potentially from the 
celite) were forming complexes, thereby increasing the number of signals present in the 1H 
spectrum. To prevent this, the amine hydrochloride salt 300 was synthesized with methanolic 
HCl (Scheme 113). 
 
Reagents and conditions: (i) H2, Pd/C, MeOH (quant) (ii) Methanolic HCl (quant) 
Scheme 113: Reduction of the azide 
Clarity of the 1H spectrum increased dramatically, allowing proper characterization of the salt. 
In addition to the enantiomeric product, a racemic series has also been synthesized, (±)-300 
was obtained as crystalline solid from which a crystal was obtained for analysis by X-ray 
diffraction.  
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Figure 23: X-ray crystal structure of 300, hydrogen atoms removed for clarity 
2.5.12 Synthesis of anti hydroxy leucine from 283 via an epoxide 
2.5.12.1 Introduction to strategy 
With the success of our route to produce the syn amino acid ester, we decided to modify the 
route to form the anti-amino acid ester. Ideally, the routes to the hydroxy leucine 
diastereoisomer would be identical until a late stage modification which would allow either 
diastereoisomer required to be formed. The route planned involved bromohydrin 283, which 
would be subjected to conditions which would form the epoxide. Then, sodium azide would 
be added in situ in an attempt to open the epoxide. This strategy would involve 2 SN2 
inversions of the stereochemistry at the alpha position, overall retaining the original anti 
relationship in the final compound 264. 
 
Scheme 114: Strategy for the substitution of bromine by sodium azide via the epoxide  
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Although the reaction sequence appeared to be plausible, there were several possible 
outcomes that could potentially occur which we would have to control. 
Problem 1: Full epoxide conversion not achieved 
If sodium azide was added before full conversion to the epoxide, the azide would displace the 
bromine as we have already shown (Scheme 112). To control this, epoxide formation would 
be followed by TLC and excess time would be provided for epoxide formation to occur 
(Scheme 115). 
 
Scheme 115: Potential side reactions if incomplete conversion to the epoxide occurred 
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Problem 2: Regioselectivity 
After epoxide formation, the azide could potentially attack the epoxide in either the α or β 
position (Scheme 116). Both the iso-propyl and the methyl ester are approximately equal in 
size, suggesting that steric bulk is unlikely to be a factor in the regioselectivity of the reaction.  
We do envisage, however, that the electron-withdrawing properties of the ester will increase 
the δ+ charge on the α position, providing a favourable reaction at the desired α position. 
 
Scheme 116: Potential regioselectivity problems 
Problem 3: Mechanistic path of epoxide opening 
A final potential problem is that the reaction may proceed mechanistically as an SN1 reaction. 
If the epoxide opened first to produce a carbocation which the azide could attack, we would 
be unlikely to see any diastereoselectivity, producing a mixture of diastereoisomers 264 and 
299 (Scheme 117). 
 
Scheme 117: Outcome of an SN1 or SN2 mechanism 
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An SN2 reaction however would be diastereospecific, providing us with only the desired 
diastereoisomer 299. An SN2 reaction is fortunately the most likely route for this reaction. The 
SN1 mechanism would produce an unstable carbocation intermediate due to the electron-
withdrawing nature of the ester. 
2.5.12.2 Epoxide formation and azide opening experiments 
Epoxide formation was originally achieved by use of 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU) as a non-nucleophilic base. DBU was found to achieve full epoxide formation in about 
1-2 h in most solvents used. Later experiments used triethylamine, which was also found to 
work well, but had the added benefit of volatility, allowing easier extraction from the crude 
material. Efficiency of epoxide formation between the two bases was equivalent. 
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Entry Reagents and Conditions (i) Analysis of the 1H 
NMR Spectrum 
Yield of azide 
1 DBU (2 equiv), DMF 2 h, NaN3 
(2.5 equiv), 16 h 
Only epoxide 
observed 
- 
2 DBU (1.9 equiv), DMF 2 h, 
NaN3 (2.2 equiv), 60 °C 16 h 
Complex mixture - 
3 PEG 400, Et3N (1.3 equiv) 1 h 
NaN3 (3.4 equiv) 16 h 
10:1 epoxide to 
azide ratio 
trace 
4 PEG 400, Et3N (1.4 equiv) 1 h 
NaN3 (4.1 equiv) 40 h 
0.5:1 epoxide to 
azide ratio 
9% 
5 DMF, Et3N (1.3 equiv) 4 h 
then PPTS (1.9 equiv), NaN3 
(3.3 equiv), 16 h 
1:0.25 epoxide to 
azide ratio 
- 
6 DMF, Et3N (1.3 equiv) then 
NH4Cl (2.4 equiv), NaN3, 16 h 
Azide observed in 
mixture of 
compounds 
Azide unable to be 
isolated pure from by-
products 
7 H2O/MeCN (1:9), Et3N (1.2 
equiv) then CeCl3 (0.5 equiv), 
NaN3 (1.9 equiv), reflux 3 h 
Mostly epoxide, 
trace azide 
observed 
- 
8 H2O/MeCN (1:9), Et3N (1.1 
equiv) then oxone®(1 equiv) , 
NaN3 (2.3 equiv) 
- - 
9 H2O/MeCN (1:9), Et3N (1.1 
equiv) then CeCl3, NaN3 (3 
equiv), reflux overnight 
Mostly azide 
observed 
19% 
Table 9: In situ epoxide forming/opening reactions. 
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Treatment of the epoxide with sodium azide provided 301 only (Table 1, entry 1). Heating an 
equivalent reaction resulted in a complex mixture from which nothing could be identified or 
isolated (Entry 2), potentially indicating that the epoxide was unstable at higher 
temperatures. With these two results it became clear that the epoxide would probably need 
activation in order to ring open. We had originally sought to avoid activation of the epoxide 
in case it induced an SN1 epoxide opening mechanism. In 2006 Das et al. published “Catalyst-
free highly regio- and stereoselective ring opening of epoxides and aziridines with sodium 
azide using poly(ethylene glycol) as an efficient reaction medium”.197 The authors suggest that 
hydrogen bonding between polyethylene glycol (PEG) and the reactants induces epoxide 
opening; furthermore the epoxides seemed to be shown to open diastereospecifically. After 
reacting the epoxide overnight (Entry 3), analysis of the 1H NMR spectrum of the crude 
mixture showed mostly the epoxide present, along with a small amount of the azido alcohol 
(Entry 3). Purification by column chromatography, however, provided only trace levels of 
material. Increasing reaction times and the amount of sodium azide provided a yield of 9% 
despite conversion looking positive according to the 1H NMR spectrum of the crude material 
(Entry 4). Although this result was encouraging, we decided to attempt alternative methods 
due to the low yields so attained. In 2010 Van Nieuwenhze published a synthesis of ß-hydroxy 
enduracididine in which pyridinium para-toluene sulphonate (PPTS) is used to activate the 
epoxide and induce ring opening (Scheme 118).198 
 
Reagents and conditions: NaN3, DMF, PPTS, 3d, 44%. 
Scheme 118: Opening of epoxide 303 with sodium azide and PPTS 
Unfortunately, with our substrate, we failed to isolate any product (Entry 5). Switching to 
ammonium chloride as the salt also failed to produce any of the desired product cleanly 
enough to isolate (Entry 6). In 2002, Sabitha et al. published a procedure for opening epoxides 
activated by the weakly acidic nature of oxone®.199 Although attempted, in our system no 
product was observed on TLC after 64 h (Entry 8). Finally, substoichiometric cerium chloride 
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heptahydrate was used to activate the epoxide following a procedure once again by Sabitha 
et al.200 The 3 h reflux unfortunately only provided trace amounts of the azido alcohol. Leaving 
the reaction overnight, however, produced the desired product, but unfortunately in poor 
yield (Entries 7 and 9). We believe that the epoxide is too unstable to be effectively opened 
by the azide, usually producing a complex mixture rather than our desired product, if reacting 
at all. We therefore decided to attempt an alternative procedure. 
2.5.13 Nosylation of the α-hydroxyl group 
Also developed by Sharpless, was a method for activating the alpha hydroxyl group of α,β 
dihydroxy esters with ortho-nosyl chloride.34 A range of diol esters were monosylated in the 
alpha position with nosyl chloride and triethylamine in DCM. The surprisingly high 
regioselectivity of this reaction could be due to the greater acidity of the alpha alcohol due to 
the electron withdrawing properties of the ester. The steric bulk of the sulphonate ester could 
be the reason the reaction stops at the mono-substituted product and does not react further 
to the bis. This methodology has been utilized in the synthesis of a hydroxy tyrosine 
derivative201 and ß-hydroxy enduracididine.198 Following treatment of 48 with nosyl chloride, 
the desired product 305 was obtained in fair yield (Scheme 119). 
 
Reagents and conditions: (i) ortho-Nosyl chloride (1.3 equiv), NEt3 (1 equiv), DCM, 3 h, rt, 
62%. 
Scheme 119: ortho-Nosylation of the α-position in 48 
Column chromatography was necessary in order to separate the excess nosyl chloride. 
Analysis by HPLC with a chiral stationary phase was used to ensure that no racemization had 
occurred; 305 was found to have consistent ee with by-product 288 (Scheme 100) at 96%. 
With the alpha position now activated, sodium azide should be able to efficiently displace the 
nosyl group. 
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2.5.14 Sodium azide displacement of the nosyl group 
Stirring the monosylated diol ester 305 with sodium azide produced a clean displacement. 
Analysis of the 1H NMR spectrum after work up showed that no by-products had been formed 
(Scheme 120). The 1H NMR spectra of the azide matched the 1H NMR spectra of Corey’s 
(Scheme 83), completing our route to the valuable intermediate 264.39 
 
Reagents and conditions: NaN3 (2.9 equiv), DMF, 20 h, rt, 95% 
Scheme 120: Displacement of the nosyl group with sodium azide 
2.5.15 Azide reduction and formation of the hydrochloride salt 
Although we had been able to synthesize an advanced known intermediate of anti-hydroxy 
leucine, we desired a crystal structure of the final compound for completion. Reduction of the 
azide with Pd/C produced the free amine as an oil. The hydrochloride salt was also formed in 
the hope of forming a solid, but unfortunately we were unable to produce crystallizable 
material. 
 
Reagents and conditions: (i) H2, Pd/C, MeOH, 41%; (ii) Methanolic HCl (quant). 
Scheme 121: Reduction of azide 264 and formation of the amine hydrochloride salt 306 
Due to time constraints we were unable to take the amino acids through our methodology to 
synthesize omuralide and analogues. Nevertheless, we had been able to synthesize both of 
the diastereoisomers of hydroxy leucine methyl ester through a short and simple method. 
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2.6 Conclusion and future work 
2.6.1 L-Leucine as a starting material 
We have successfully been able to incorporate leucine into a γ-lactam core, producing to date 
the shortest route to the full carbon skeleton of omuralide (4 steps). This lactam has been 
elaborated to provide a formal synthesis of the omuralide analogue C9-deoxyomuralide in 
the shortest non-racemic route to date (Scheme 122). The previous enantioselective route 
was completed by Corey in a total of 19 steps and overall yield of 10%, our synthesis took only 
11 steps, unfortunately however, the yield was lower at 0.6%. During this route, a 
diastereoselective desulphurization to 152b has been extensively studied and optimized. We 
believe this desulphurization will be an important step in our future work on the synthesis of 
omuralide and analogues. 
Although vast improvements have been made to the enantioselectivity of this route, our final 
ee of 77% could potentially be improved by either further optimization of the Dieckmann 
cyclization step, or recrystallization to enrich ee. Further improvements to our synthesis 
which could be addressed include the production of unwanted diastereoisomers such as 148a 
and the thiophenylated analogue, resulting in large quantities of 188b being isolated. 
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Reagents and conditions: (i) 1) p-Methoxybenzaldehyde (1.1 equiv), Et3N (1 equiv), MeOH, 
NaBH4 (1.9 equiv), 0 °C to rt, 76%; 2) 146, EDAC.HCl (2.6 equiv), DMAP (0.25 equiv), N-MM 
(2.3 equiv), DCM, 93%; (ii) TBAF in THF (3.6 equiv), THF, rt, 0.5 h, then MeI (4 equiv), 0 °C to 
rt, 16 h, 57 %, Ratio 1:2 by crude NMR analysis; (iii) LiHMDS (2.1 equiv), DMPU (2.2 equiv), 
THF, −78 °C, 0.5 h, then NCCO2Me (3.2 equiv), −78 °C, 4 h, 70%; (iv) 1) H2, Pd(OH)2/C, THF, 30 
°C, 12 h; 2) 189 (2.9 equiv), Et3N (1.6 equiv), CH2Cl2, rt, mixture of 187ab, 67% over the 2 steps. 
3) NaBH4 (0.7 equiv), EtOH, −10 °C, 0.5 h, 188a-30% and 188b-35%; (v) TTMS (3.2 equiv), AIBN 
(0.3 equiv), acetone, reflux, 16 h, 152a-14 %, 152b-74%; (vi) 1) CAN (5.2 equiv), MeCN/H2O 
(3:1), rt, 62%; 2) NaOH (0.5 M), 0-5 °C, 86%. 
Scheme 122: Our final route to the formal synthesis of C9-deoxy omuralide 
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2.6.2 L-Serine as a starting material 
In addition to L-leucine, L-serine has been incorporated into the lactam core in an analogous 
fashion (Scheme 123). Although some changes to our methodology were required, the overall 
procedures remained the same. Diasteroselectivity during the Dieckmann cyclization step was 
investigated due to a surprising change from our leucine route. This change, however, worked 
to our advantage, allowing the natural enantiomer of omuralide to be synthesized. 
 
Reagents and conditions: (i) 1) PMB sulphite adduct (1.6 equiv), NaBH3CN (6.1 equiv), Et3N 
(0.9 equiv), MeOH, 0 °C, 16 h 2) 146 (2.5 equiv), EDAC.HCl (2.7 equiv), N-MM (2.5 equiv), 
DMAP (0.2 equiv), DCM, 16 h; 49% over the 2 steps. (ii) TBAF (2.1 equiv), Ether, 5 m, THF, MeI 
(10 equiv), -12 °C, 64 h 66%, ratio 3:1 by crude NMR analysis; (iii) LiHMDS (2.2 equiv), DMPU 
(3 equiv), THF, -40 °C 30 m then NCCO2Me (4.5 equiv), 3 h, 69%; (iv) 1) Pd(OH)2/C (cat), H2, 35 
°C, 16 h; 2) 186 (1.7 equiv), Et3N (1.1 equiv), DCM, 4 h (70% over 2 steps); 3) NaBH4 (0.6 equiv), 
EtOH, 30 m 0 °C, 224a 54%, 224b 13%, 219ab 4%. (v) TFA/DCM 1:1, 1.5 h, 75%. 
Scheme 123: Our final route to the formal synthesis of omuralide 
The lactam core was elaborated to an advanced intermediate of the synthesis of Corey, 
completing a formal synthesis. Although synthesized in an equal number of steps (8 steps),29 
our route’s initial chirality is derived from cheap amino acid precursors. Corey required an 
enzymatic reaction with PLE, potentially providing our method with a considerable cost 
advantage. Corey’s route however was higher yielding with 47% overall yield compared to 
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our 5%. The analogue produced has been elaborated by Corey to a library of C5 and C9 
analogues.37 In recent years, this position has received renewed interest due to the discovery 
of the salinosporamides41 and cinnabaramides.44  
Work has also been initiated towards the synthesis of salinosporamide B; unfortunately it 
appeared that our lactam core was too sterically congested to allow acylation at the C5 
position, leading us to abandon our attempts. Future work should concentrate on 
modification of the serine protecting group, potentially allowing access to this position. 
2.6.3 The synthesis of hydroxy leucine 
We have also developed a new method to provide either diastereoisomer of hydroxy leucine. 
Correct choice of ligand during the dihydroxylation should also allow the opposite 
enantiomers to be synthesized. In the future, work should concentrate on the incorporation 
of these into the lactam core, potentially providing a rapid route to omuralide. We hope that 
this methodology could also be applied to other α,β unsaturated esters to synthesize other 
β-hydroxy amino acids (Scheme 124) for incorporation into the lactam to produce a wider 
array of analogues. 
 
Scheme 124: Potential method to synthesize various β-hydroxy, α-amino acids. 
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2.6.4 Application of our methodology to new natural product targets 
 
Figure 24: The structure of Hoshinolactam 
We believe our methodology is not only useful in the synthesis of omuralide analogues but 
could also be applied to other γ-lactam natural products. In 2007, the discovery and structure 
elucidation by total synthesis of hoshinolactam 133 was reported.139 Hoshinolactam was 
found to have potent antitrypanosomal activity without cytotoxicity against human fetal lung 
MRC-5 cells.  Despite these promising results, however, a SAR study has currently not yet 
been reported nor the cellular target of hoshinolactam identified. Structurally, hoshinolactam 
has a strikingly similar core to many of our intermediates, particularly in our route to C9-
deoxyomuralide. For example, intermediate 148b has the potential to be elaborated into the 
lactam core of hoshinolactam in four steps. 
 
Scheme 125: Synthesis of the lactam core of hoshinolactam from 148b 
Depending on the method used, coupling this core to the known acid 311 could produce 
either hoshinolactam or the un-synthesized epimer 312. 
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Scheme 126: Potential synthesis of hoshinolactam from lactam 310 
Modification of the amino acid starting material, and the alkylation agent during the 
Dieckmann cyclisation, should produce a wide array of analogues which could be used to 
further study the interesting properties of hoshinolactam (Scheme 127). 
 
Scheme 127: Potential route to a library of hoshinolactam analogues 
To summarize, our studies have developed methodology allowing amino acids to be 
incorporated into γ-lactam rings. This procedure has been used to produce formal syntheses 
of C9-deoxyomuralide and omuralide. The reactions developed in this not only are useful in 
the synthesis of omuralide analogues but are also applicable in other γ-lactam natural 
products. When combined with the methodology developed to produce β-hydroxy, α-amino 
acids, this should allow access to a wide variety of biologically relevant natural product cores 
and their derivatives. 
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3.0 Experimental 
3.1 General experimental 
3.1.1 Preparation of glassware, solvents and reagents 
Reactions requiring anhydrous conditions were carried out under a nitrogen atmosphere, 
unless otherwise stated, using flame-dried glassware. Reaction solvents were dried using the 
following methods: dichloromethane was distilled over calcium hydride, tetrahydrofuran and 
diethyl ether were distilled under an argon atmosphere from the sodium/benzophenone ketyl 
radical and if anhydrous acetone was required, an unopened bottle was used. 
3.1.2 Analysis of compounds 
The infrared spectra was recorded using, a PerkinElmer Spectrum 100 IR spectrophotometer 
and the sample ran as a thin film of their evaporated solution from CH2Cl2 or CHCl3 on sodium 
chloride plates. A PerkinElmer spectrum 2 was used if the data states the sample was ran as 
a solid. 1H and 13C NMR spectra were measured respectively at 500 and 126 MHz using a 
Bruker Ascend 500 or at 400 and 100 MHz using a Bruker Ultrashield 400 Plus instrument. The 
solvent used for NMR spectroscopy was deuteriated chloroform unless stated otherwise, 
using tetramethylsilane as the internal reference or the residual deuterated solvent peak. For 
13C experiments run in deuterium oxide, methanol was added and the resulting peak at δc 
49.50 was used as the reference. Chemical shifts are given in parts per million, and J values 
are given in hertz. Mass spectra were recorded by the EPSRC Mass Spectrometry Service at 
the University of Swansea; the ionization and detection technique is stated alongside the 
data. HPLC was carried out on a VWR Elite Lachrom instrument. Separation was achieved by 
either an AD-H Chiralpak column (4.6 mm × 250 mm 5 μm) or Eurocel 01 Knauer (4.6 mm × 
250 mm 5 μm) under the stated conditions. Melting points were recorded using a Büchi B-
545 melting point instrument. Optical rotation values were measured with a Bellingham and 
Stanley ADP-440 instrument, operating at λ = 589 nm, corresponding to the sodium D line, at 
the temperatures indicated. Spectrophotometric grade chloroform was used for these 
measurements unless otherwise stated; solutions for these measurements were prepared in 
a 1 mL volumetric flask for maximum accuracy of the solvent volume used. 
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3.1.3 Chromatographic techniques 
All chromatographic manipulations used silica gel as the adsorbent. Reactions were 
monitored using thin layer chromatography (TLC) on aluminum with Merck Kieselgel 60 F254 
silica gel. TLC plates were visualized by UV radiation at a wavelength of 254 nm or stained by 
exposure to an ethanolic solution of phosphomolybdic acid or aqueous potassium 
permanganate, followed by heating at 220 °C. Purification by column chromatography used 
Material Harvest silica gel 60.  
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3.2 Individual experimental procedures and characterization 
3.2.1 Experimental for procedures starting from L-leucine  
2-(4-Methoxy-benzylamino)-4-methyl-pentanoic acid methyl ester 14578,75 
 
Unintentional, racemic synthesis using the Dean-Stark apparatus: 
Leucine methyl ester hydrochloride 144 (9.96 g, 55 mmol) and p-methoxybenzaldehyde (7.4 
mL, 61 mmol, 1.1 equiv) were dissolved in toluene (100 mL). Acetic acid (2 mL, 35 mmol) was 
added and the solution heated to vigorous reflux with a well-insulated Dean−Stark apparatus 
overnight. The resulting solution was evaporated to dryness to produce a thick red/brown oil, 
which was dissolved in methanol (130 mL). Acetic acid was added (2.8 mL, 50 mmol, 0.9 equiv) 
and the reaction mixture cooled to 0 °C. Sodium cyanoborohydride (6.9 g, 110 mmol, 2 equiv) 
was added in small portions and the reaction stirred for 30 m. The solution was allowed to 
reach room temperature and stirred for a further 5 h. A few drops of water were added, and 
the solution was evaporated to dryness. The resulting oil was dissolved in dichloromethane 
(150 mL) and washed twice each with equal amounts of water, brine, and aqueous sodium 
carbonate. The organic layer was dried over magnesium sulphate, filtered, and evaporated to 
dryness to produce compound 145 as a red-brown oil (14 g, 96%), which was used without 
further purification. 
Non-racemizing synthesis: 
Leucine methyl ester hydrochloride 144 (0.19 g, 1.05 mmol) was dissolved in methanol (10 
mL). To this solution was added Et3N (0.15 mL, 1.0 mmol), and p-methoxybenzaldehyde (0.15 
mL, 1.2 mmol). The mixture was stirred for 90 m, cooled to 0 °C, and sodium borohydride 
(0.82 g, 2.0 mmol) was added in portions over 30 m. The mixture was stirred for a further 30 
m. The solvents were removed under reduced pressure and the resulting oil was dissolved in 
ethyl acetate (approximately 50 mL). The organic solution was washed twice each with equal 
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amounts of water, brine, and aqueous sodium carbonate. The aqueous layer was extracted 
with ethyl acetate, and the organic fractions were combined, dried over magnesium sulphate, 
filtered and the solvents removed under reduced pressure. The resulting residue was purified 
by column chromatography on silica gel using petroleum ether (40-60 °C)/ethyl acetate (2:1) 
as the eluent to afforded 145 as a colourless oil (0.21 g, 76%). [α]D 25 = −40.3 (c 1.3, CHCl3), 
(lit78 [α]D 27 = −31.2 (c 1.5, CHCl3)); max (neat)/cm-1: 3331 N-H (b), 2997 C-H (s), 2955 C-H (s), 
1736 C=O (s); 1H NMR (500 MHz, CDCl3) δH 7.23 (d, J = 8.5 Hz, 2H, H10), 6.84 (d, J = 8.6 Hz, 
2H, H9), 3.78 (s, 3H, H12), 3.73 (d, J = 12.7 Hz, 1H, H7), 3.71 (s, 3H, H1), 3.54 (d, J = 12.7 Hz, 
1H, H7), 3.29 (t, J = 7.3 Hz, 1H, H3), 1.81 – 1.69 (m, 2H, H3), 1.46 (td, J = 7.3, 2.0 Hz, 2H, H4), 
0.90 (d, J = 6.6 Hz, 3H, H6), 0.84 (d, J = 6.6 Hz, 3H, H6); 13C NMR (126 MHz, CDCl3) δC 176.6 C2, 
158.8 C11, 129.6 C10, 113.9 C9, 59.2 C3, 55.4, 51.7 C7, 51.7 C1, 42.9 C4, 25.0 C5, 22.9 C6, 22.3 
C6; one peak unobserved in 13C NMR spectrum. Determined by HPLC to be >99.5% ee.  
Determination of ee was found by HPLC using an AD-H Chiralpak column 95:5 hexane/IPA, 
230 nm, 0.8 mL/min, 25 °C. 
Intentional racemic synthesis:  
Acetyl chloride (3.3 mL, 46.41 mmol, 3 equiv) was added to methanol (60 mL) at 0 °C and the 
solution left for 40 m. L-D leucine (2.003 g, 15.26 mmol) was added in one portion. The 
solution was allowed to stir at 0 °C for a further 30 m, then heated to reflux overnight. The 
solvents were evaporated under reduced pressure to provide L-D leucine methyl ester 
hydrochloride 144 (2.748 g, quant) which was used without further purification. 
LD - Leucine methyl ester hydrochloride 144 (1.819 g, 10.01 mmol) was dissolved in methanol 
(71 mL). To this solution was added Et3N (1.4 mL, 9.96 mmol, 1 equiv), and p-
methoxybenzaldehyde (1.3 mL, 10.65 mmol, 1.1 equiv). The mixture was stirred for 90 m, 
cooled to 0 °C, and sodium borohydride (0.751 g, 19.85 mmol, 2 equiv) was added in portions 
over 30 m. The mixture was stirred for a further 30 m. The solvents were removed under 
reduced pressure and the resulting oil was dissolved in ethyl acetate (approximately 250 mL). 
The organic solution was washed twice each with equal amounts of water, brine, and aqueous 
sodium carbonate. The aqueous layer was extracted with ethyl acetate, and the organic 
fractions were combined, dried (magnesium sulphate), filtered, and the solvents removed 
under reduced pressure. The resulting residue was purified by column chromatography on 
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silica gel using petroleum ether (40-60 °C)/ethyl acetate (2:1) as eluent to afforded 145 as a 
colourless oil (1.806 g, 68%). 
 
Potassium benzyloxycarbonyl acetate 14667 
 
Malonic acid 176 (24.9 g, 0.24 mol, 1 equiv), benzyl alcohol (53 mL, 0.5 mol 2.1 equiv) and p-
TsOH (0.475 g, 2.75 mmol, 0.01 equiv) were dissolved in toluene (250 mL) and heated to reflux 
using a Dean-Stark apparatus overnight. The resulting solution was evaporated to produce an 
orange oil. A solution of KOH in benzyl alcohol (1 M) (240 mL) was added forming a pale-
yellow solid, which was collected by vacuum filtration. The solid was washed with ether and 
transferred to a vacuum oven to produce 146 as a white solid. (41.2 g, 74%). Mp 197-199 °C 
(lit2b 201 °C); max (solid)/cm-1 3035 CH unsaturated (s), 1721 C=O (s), 1599, 1370; 1H NMR 
(500 MHz, D2O) δH 7.51 – 7.40 (m, 5H), 5.22 (s, 2H), 3.36 (s, 2H); 13C NMR (126 MHz, D2O) δC 
173.9 C1, 171.1 C2, 135.8 Ar, 128.9 Ar, 128.6 Ar, 128.3 Ar, 67.3 C4, 44.7 C2. 
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2-{(4-Methoxy-benzyl)-[2-(benzyloxycarbonyl)-acetyl]-amino}-4-methyl-pentanoic acid 
methyl ester 14775 
 
Compound 145 (1.38 g, 5.19 mmol), N-methylmorpholine (1.3 mL, 11.82 mmol, 2.3 equiv), 
benzyl malonic half ester 146 (2.54 g, 10.95 mmol, 2.1 equiv), EDAC.HCl (2.63 g, 13.75 mmol, 
2.6 equiv) and 4-dimethylaminopyridine (0.16 g, 1.3 mmol, 0.25 equiv) were dissolved in 
anhydrous dichloromethane (40 mL). The mixture was stirred for 20 h under a nitrogen 
atmosphere. Aqueous HCl (1 M, 1.5 mL) was added, and the reaction mixture stirred for a 
further 5 m, then washed with water (2 x 50 mL), and the organic layer dried (magnesium 
sulphate), filtered, and evaporated under reduced pressure. The resulting oil residue was 
purified by column chromatography using petroleum ether (40-60 °C)/ethyl acetate as the 
eluent, to provide the product 147 as a yellow oil (2.128 g, 93%). [α]D 26 = –46.42 (c 1.12, CHCl3) 
max (neat)/cm-1: 3472, 2956 CH (s), 1740 C=O (s), 1651 C=O (s, Amide); 1H NMR (500 MHz, 
CDCl3) Major rotamer: δH 7.40 – 7.31 (m, 5H, H12, 13, 14), 7.15 (d, J = 8.7 Hz, 2H, H18), 6.85 
(d, J = 8.7 Hz, 2H, H17), 5.16 (d, J = 2.4 Hz, 2H, H10), 4.83 (t, J = 6.9 Hz, 1H, H8), 4.55 (d, J = 
17.2 Hz, 1H, H15), 4.42 (d, J = 17.2 Hz, 1H, H15), 3.79 (s, 3H, H1), 3.58 (s, 3H, H3), 3.48 (d, J = 
3.6 Hz, 2H, H3), 1.90 – 1.77 (m, 1H, H4), 1.62 – 1.49 (m, 2H, H5), 0.88 (d, J = 6.4 Hz, 3H, H6), 
0.80 (d, J = 6.4 Hz, 3H, H6); 13C NMR (126 MHz, CDCl3) δ 171.8, 167.3, 167.3, 159.3, 135.5, 
128.7, 128.5, 128.5, 128.1, 114.3, 67.3, 56.2, 55.5, 52.2, 50.1, 41.8, 38.4, 25.2, 22.7, 22.4; one 
peak unobserved in 13C NMR spectrum.  Determined by HPLC to be >99.5% ee. Determination 
of ee was found by HPLC using an AD-H Chiralpak column 90:10 hexane/IPA, 230 nm, 0.8 
mL/min, 25 °C. 
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(3S,5S)-N-(4’-Methoxybenzyl)-3-methyl-5-(2’-methylpropyl)-pyrrolidin-2,4-dione-3-
carboxylic acid benzyl ester 148a2a and (3R,5S)-N-(4’-methoxybenzyl)-3-methyl-5-(2’-
methylpropyl)-pyrrolidin-2,4-dione-3-carboxylic acid benzyl ester 148b75 
 
Tetrabutylammonium fluoride (1 M solution in THF, 11.5 mL, 11.5 mmol, 3.6 equiv) was added 
to a solution of 147 (1.442 g, 3.2 mmol) in THF (72 mL) at room temperature under a nitrogen 
atmosphere. The mixture was stirred for 30 m and cooled to 0 °C using an ice bath. 
Iodomethane (0.81 mL, 13 mmol, 4 equiv) was added and the reaction mixture stirred 
overnight being allowed to reach room temperature. Water (4 mL) was added, and the 
solvents were removed under reduced pressure. The resulting residue was dissolved in 
dichloromethane (50 mL) and washed with water (50 mL). The organic layer was dried over 
magnesium sulphate and the solvents removed under reduced pressure. The resulting residue 
was purified and partially separated by column chromatography, using petroleum ether 
(40−60 °C)/ethyl acetate (9:1) as the eluent to afford the diastereoisomers 148ab in a 1:2 ratio 
(0.78 g, 57%). Data for the minor, first eluting diasteroisomer 148a: (Yield 16%), [α]D 26 = 
+14.54 (c 0.44, CHCl3) (9% ee); max (thin film)/cm−1 2959 C-H (s), 1777 C=O (s), 1747 C=O (s), 
1696 C=O (s); 1H NMR (500 MHz, CDCl3) δH 7.37 – 7.34 (m, 3H, H18, 20), 7.24−7.21 (m, 2H, 
H19), 7.01 (d, J = 8.7 Hz, 2H, H11), 6.59 (d, J = 8.7 Hz, 2H, H10), 5.42 (d, J = 15.0 Hz, 1H, H16 or 
8), 5.19 (d, J = 12.3 Hz, 1H, H16 or 8), 5.10 (d, J = 12.3 Hz, 1H, H16 or 8), 3.84 (dd, J = 7.8, 3.9 
Hz, 1H, H4), 3.80 (d, J = 15.0 Hz, 1H, H16 or 8), 3.73 (s, 3H, H13), 1.81−1.80 (m, 1H, H6), 
1.66−1.61 (m, 1H, H5), 1.58 (s, 3H, H15), 1.54−1.50 (m, 1H, H5), 0.87 (d, J = 6.7 Hz, 3H, H7), 
0.76 (d, J = 6.5 Hz, 3H, H7); 13C NMR (126 MHz, CDCl3) δC 206.1 C3, 169.7 C14, 165.7 C1, 159.4 
Ar, 134.9 Ar, 129.5 Ar, 128.8 Ar, 128.7 Ar, 128.3 Ar, 126.3 Ar, 114.2 Ar, 68.3 C16, 62.5, 58.8, 
55.4 C13, 43.4 C8, 38.0 C5, 24.7 C6, 23.4 C7, 22.5 C7, 16.2 C15. Determined by HPLC to be 9% 
ee. Data for the major, second eluting diastereoisomer 148b: (Yield 41%), [α]D 26 = −17.14 (c 
0.98, CHCl3) (79% ee); max (thin film)/cm−1 2958 C-H (s), 1775 C=O (s), 1746 C=O (s), 1696 C=O 
(s); 1H NMR (500 MHz, CDCl3) δH 7.30−7.18 (m, 5H, H18-20 ), 7.05 (d, J = 8.7 Hz, 2H, H11), 6.76 
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(d, J = 8.7 Hz, 2H, H10), 5.18 (d, J = 12.1 Hz, 1H, H16 or 8), 5.11 (d, J = 14.9 Hz, 1H, H16 or 8), 
5.01 (d, J = 12.1 Hz, 1H, H16 or 8), 3.94 (d, J = 14.9 Hz, 1H, H16 or 8), 3.71 (s, 3H, H13), 3.60 (t, 
J = 6.9 Hz, 1H, H4), 1.71−1.63 (m, 1H, H6), 1.46 (s, 3H, H15), 1.42 (t, J = 6.7 Hz, 2H, H5), 0.65 
(d, J = 6.6 Hz, 3H, H7), 0.62 (d, J = 6.6 Hz, 3H, H7); 13C NMR (126 MHz, CDCl3) δC 205.7 C3, 
169.4 C14 or 1, 165.7 C14 or 1, 159.5 Ar, 134.8 Ar, 129.5 Ar, 128.8 Ar, 128.7 Ar, 128.5 Ar, 127.2 
Ar, 114.4 Ar, 68.3, 62.5, 58.7, 55.4 C13, 43.6 C8, 39.0 C5, 24.5 C6, 23.1 C7, 22.0 C7, 16.7 C15. 
Determined by HPLC to be 79% ee. Determination of ee was found by HPLC using an AD-H 
Chiralpak column 95:5 hexane/IPA, 230 nm, 0.8 mL/min, 25 °C. 
 
Benzyl (3S,5S)-3-methyl-5-(2-methylpropyl)-2,4-dioxopyrrolidine-3-carboxylate 179 
 
Lactam 148a (1.2023 g, 2.83 mmol) was dissolved in a MeCN/water mixture (3:1, 27.6 mL). 
CAN (8.3 g, 14.22 mmol, 5 equiv) was added and the solution stirred until complete 
consumption of the starting material had occurred (approx. 2 h). The solution was diluted 
with water (150 mL) and extracted with ethyl acetate (150 mL x 3). The organic layers were 
combined and washed with brine (100 mL x 2), dried (sodium sulphate), filtered, and the 
solvents were removed under reduced pressure. The resulting residue was purified by column 
chromatography using petroleum ether (40-60 °C)/ethyl acetate (8:2) as the eluent to 
produce 179 as a white crystalline solid. (0.725 g, 84%). Mp 118-124 °C; [α]D 24 = +11.6 (c 2.3, 
CHCl3) (9% ee); max (thin film)/cm-1:   3209, 2960 CH (s), 1781 C=O (s), 1748 C=O (s), 1705 C=O 
(s); 1H NMR (500 MHz, CDCl3) δH 7.38-7.30 (m, 3H, H14, 12), 7.29−7.23 (m, 2H, H13), 7.02 – 
6.60 (m, 1H, H15), 5.24 - 511 (m, 2H, H10), 4.18 (dd, J = 9.5, 3.5 Hz, 1H, H4), 1.78−1.68 (m, 2H, 
H5), 1.53 (s, 3H, H8), 1.43 (m, 1H, H7), 0.96 (d, J = 6.2 Hz, 3H, H7), 0.94 (d, J = 6.2 Hz, 3H, H7); 
13C NMR (126 MHz, CDCl3) δC 206.7, 171.9, 165.5, 135.0, 128.8, 128.6, 127.9, 68.1 C10, 61.4, 
58.6, 41.3 C5, 25.2 C6, 23.2 C7, 21.5 C7, 15.9 C8; HRMS (NSI-FTMS) m/z [M + NH4]+ calcd for 
[C17H25N2O4]+ 321.1809, found 321.1812. 
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Benzyl (3R,5S)-3-methyl-5-(2-methylpropyl)-2,4-dioxopyrrolidine-3-carboxylate 178 
 
Lactam 148b (0.1174 g, 0.277 mmol) was dissolved in a MeCN/water mixture (3:1, 2.8 mL). 
CAN (0.1634 g, 0.29 mmol, 1 equiv) was added and the solution stirred for 3 h. A further 
portion of CAN was added (0.6482 g, 1.18, 4.3 equiv) and the solution stirred until complete 
consumption of the starting material had occurred. The solution was diluted with water (50 
mL) and extracted with ethyl acetate (50 mL x 3). The organic layers were combined and 
washed with brine (50 mL), dried (magnesium sulphate), filtered and the solvents were 
removed under reduced pressure. The resulting residue was purified by column 
chromatography using petroleum ether (40-60 °C)/ethyl acetate (9:1 to 2:1) as the eluent to 
produce 178 as a grey oil (0.0526 g, 63%). [α]D 22 = -34.3 (c 0.7, CHCl3) (79% ee); max (thin 
film)/cm-1:  3215, 2959 C-H (s), 1779 C=O (s), 1748 C=O (s), 1703 C=O (s); 1H NMR (500 MHz, 
CDCl3) δH 7.37-7.31 (m, 3H, H14, 12), 7.28−7.25 (m, 2H, H13), 6.67 (d, J = 38.5, 1H, H15), 5.22 
(d, J = 12.2, 1H, H10), 5.10 (d, J = 12.2, 1H, H10), 4.00 (dd, J = 9.7, 4.4 Hz, 1H, H4), 1.70−1.56 
(m, 2H, H5), 1.55 (s, 3H, H8), 1.47 (m, 1H, H6), 0.87 – 0.83 (m, 6H, H7); 13C NMR (126 MHz, 
CDCl3) δC 206.8, 171.5, 165.5, 134.8, 128.8, 128.8, 128.4, 68.4 C10, 61.1 C2 or 4, 58.2 C2 or 4, 
41.7 C5, 25.2 C6, 23.0 C7, 21.5 C7, 16.3 C8; HRMS (NSI-FTMS) m/z [M + Na]+ calcd for 
[C17H21N1O4Na]+ 326.1363, found 326.1363. 
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(3R,5R)-N-(4′-Methoxybenzyl)-3-methyl-5-(2′-methylpropyl)pyrrolidin-2,4-dione-3,5 
dicarboxylic Acid 3-Benzyl Ester 5-Methyl Ester 14975 
 
Compound 148b (1.747 g, 4.125 mmol) was dissolved in anhydrous THF (70 mL) in a flame 
dried flask and the solution cooled to −78 °C. DMPU (1.5 mL, 9.2 mmol) was added followed 
by LiHMDS (1 M in THF, 8.5 mL, 8.5 mmol) and the mixture stirred at −78 °C for 30 m under 
an atmosphere of nitrogen. Methyl cyanoformate (1.1 mL, 13 mmol) was added and the 
mixture stirred for a further 4 h at −78 °C. Saturated aqueous ammonium chloride was added 
(2 mL) at −78 °C, the mixture was allowed to warm to room temperature, and the organic 
solvents were removed under reduced pressure. The residue was dissolved in ethyl acetate 
and the solution washed with water (2 × 100 mL) and brine (2 × 100 mL). The organic layer 
was dried (sodium sulphate), filtered, and evaporated under reduced pressure. The residue 
was purified by column chromatography using petroleum ether (40−60 °C)/ethyl acetate (4:1) 
as the eluent to yield 149 as a waxy solid (1.985 g, 70%). [α]D 21 = −20.35 (c 1.12, CHCl3) (79% 
ee); max (thin film)/cm−1 2959 C-H (s), 1783 C=O (s), 1752 C=O (s), 1698 C=O (s); 1H NMR (500 
MHz, CDCl3) δH 7.38 – 7.28 (m, 5H, H20, 21, 22), 7.19 (d, J = 8.7 Hz, 2H, H13), 6.77 (d, J = 8.7 
Hz, 2H, H12), 5.19 (d, J = 12.1 Hz, 1H, H18), 5.14 (d, J = 12.1 Hz, 1H, H18), 4.89 (d, J = 15.1 Hz, 
1H, H10), 4.15 (d, J = 15.1 Hz, 1H, H10), 3.77 (s, 3H, H15), 3.23 (s, 3H, H6), 2.14 (dd, J = 15.2, 
5.5 Hz, 1H, H7), 1.86 (dd, J = 15.2, 6.3 Hz, 1H, H7), 1.72 (s, 3H, H16), 1.44 (d, J = 6.5 Hz, 1H, 
H8), 0.64 (d, J = 6.6 Hz, 3H, H9), 0.52 (d, J = 6.6 Hz, 3H, H9); 13C NMR (126 MHz, CDCl3) δC 
201.9, 170.9, 167.7, 165.3 Ar, 159.3 Ar, 134.6 Ar, 130.4 Ar, 128.8 Ar, 128.7 Ar, 128.7 Ar, 127.7 
Ar, 113.9 Ar, 76.2 C18, 68.6, 58.5, 55.4 C15, 53.1 C6, 44.0 C10, 38.8 C7, 24.3 C8, 23.5 C9, 23.1 
C9, 19.1 C16.  
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S-Methyl 4-methylbenzene-1-sulfonothioate 18685 
 
Sodium p-toluenesulphinate 185 (9.930 g, 55.7 mmol, 3.1 equiv) was dissolved in DCM, 
(SMe)2 (1.6 mL, 17.7 mmol, 1 equiv) was added with iodine (8.988 g, 35 mmol, 2 equiv) and 
the reaction stirred vigorously. The reaction was left stirring overnight at room temperature. 
Saturated sodium thiosulphate solution was added until the iodine colour was removed. The 
reaction was them washed with an equal amount of water and the organic layer was dried 
(sodium sulphate), filtered and evaporated. Sulphonothioate 186 was obtained as a yellow 
crystalline solid which could be used without further purification (5.47 g, 76%). Mp 56−57 °C, 
(lit85 54-55 °C); max (thin film)/cm−1 2996 C-H (s), 2926 1593; 1H NMR (500 MHz, CDCl3) δH 
7.81 (d, J = 8.4 Hz, 2H, H3), 7.35 (d, J = 8.0 Hz, 2H, H4), 2.50 (s, 3H, H5), 2.46 (s, 3H, H1); 13C 
NMR (126 MHz, CDCl3) δC 144.9 Ar, 141.1 Ar, 130.0 Ar, 127.3 Ar, 21.8 C1, 18.2 C5. 
 
S-Phenyl 4-Methylbenzene-1-sulfonothioate 18996 
 
Sodium p-toluenesulfinate 185 (1.20 g, 6.7 mmol, 1.2 equiv) and iodine (0.74 g, 2.9 mmol, 0.5 
equiv) were dissolved in DCM (15 mL). Diphenyl disulfide (0.55 g, 2.9 mmol, 0.5 equiv) was 
added with vigorous stirring, and the mixture stirred overnight. Aqueous sodium thiosulfate 
(1 M) was added until the iodine colour was removed. The mixture was washed with water 
(100 mL x 2), dried (sodium sulphate), filtered, and the solvents were removed under reduced 
pressure to give an oil that crystallized on cooling, to afford 189 as a colourless solid (1.0 g, 
67%). Mp 71−75 °C, (lit202 74–75 °C); max (thin film)/cm−1 3063, 1594; 1H NMR (500 MHz, 
CDCl3) δH 7.50−7.30 (m, 7H, H9, 8, 7, 3), 7.20 (d, J = 8.0 Hz, 2H, H4), 2.42 (s, 3H, H1); 13C NMR 
(126 MHz, CDCl3) δC 144.8 Ar, 140.5 Ar, 136.7 Ar, 131.4 Ar, 129.5 Ar, 129.5 Ar, 128.2 Ar, 127.8 
Ar, 21.8 C1. The product was sufficiently pure to be used without further purification. 
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(2S,4S)-Methyl 2-Isobutyl-1-(4-methoxybenzyl)-4-methyl-3,5-dioxo-4-
(phenylthio)pyrrolidine-2-carboxylate 172a75 and (2S,4R)-Methyl 2-Isobutyl-1-(4-
methoxybenzyl)-4-methyl-3,5-dioxo-4-(phenylthio)pyrrolidine-2-carboxylate  172b75 
 
Lactam 149 (0.4377 g, 0.53 mmol) was dissolved in THF (1.3 mL). A catalytic amount of 
Pd(OH)2/C was added, the mixture was stirred overnight under a static pressure of hydrogen 
at 35 °C and filtered through celite. The solvents were removed under reduced pressure. The 
crude material was dissolved in anhydrous dichloromethane (1.8 mL) and heated to at 20 °C 
under a nitrogen atmosphere. Triethylamine (0.09 mL, 0.64 mmol, 1.2 equiv) and S-methyl p-
toluenethiosulfonate 186 (0.18 g, 0.89 mmol, 1.7 equiv) were added. The mixture was stirred 
overnight at room temperature. The solvent was removed under reduced pressure and the 
resulting residue purified by column chromatography on silica gel using petroleum ether 
(40−60 °C)/ethyl acetate (9:1) as the eluent, to yield diastereoisomers 172ab as an 
inseparable mixture in a 1:2 ratio (0.142 g, 68%).  Data for the minor diastereoisomer 172b: 
1H NMR (500 MHz, CDCl3) δH 7.26 (d, J = 8.5 Hz, 2H, H13), 6.83 (d, J = 8.0 Hz, 2H, H12), 4.79 
(d, J = 15.1 Hz, 1H, H10), 4.42 (d, J = 15.5 Hz, 1H, H10), 3.77 (s, 3H, H15), 3.44 (s, 3H, H6), 2.24 
(dd, J = 15.5, 7.0 Hz, 1H, H7), 2.14 (s, 3H, H17), 1.95 (dd, J = 15.5, 6.5 Hz, 1H, H7), 1.57 (s, 3H, 
H16), 1.35− 1.29 (m, 1H, H8), 0.74 (d, J = 4.5 Hz, 3H, H9), 0.73 (d, J = 4.5 Hz, 3H, H9); 13C NMR 
(126 MHz, CDCl3) δ 200.4, 171.8, 168.2, 159.2, 130.0, 128.7, 113.9, 75.5, 55.4, 53.0, 49.4, 45.0, 
40.1, 24.0, 23.9, 23.6, 17.0, 12.4. Data for the major diastereoisomer 172a: 1H NMR (500 
MHz, CDCl3) δH 7.23 (d, J = 8.7 Hz, 2H, H13), 6.81 (d, J = 8.6 Hz, 2H, H12), 4.95 (d, J = 14.9 Hz, 
1H, H10), 4.02 (d, J = 14.9 Hz, 1H, H10), 3.77 (s, 3H, H15), 3.15 (s, 3H, H6), 2.27 (s, 3H, H17), 
2.23 (dd, J = 15.2, 5.4 Hz, 1H, H7), 1.97 (dd, J = 15.2, 6.2 Hz, 1H, H1), 1.76- 1.71 (m, 1H, H8), 
1.66 (s, 3H, H16), 0.92 (d, J = 6.6 Hz, 3H, H9), 0.86 (d, J = 6.7 Hz, 3H, H9); 13C NMR (126 MHz, 
CDCl3) δC 202.7, 172.5, 168.1, 159.4, 130.8, 127.6, 113.9, 75.3, 55.4, 52.9, 48.3, 43.8, 38.4, 
24.7, 24.0, 23.8, 18.6, 11.7. Data for the mixture 172ab: max (thin film)/cm−1 2957 C-H (s), 
1767 C=O (s), 1745 C=O (s), 1698 C=O (s). 
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(3S,4S,5R)-N-(4′-Methoxybenzyl)-3-methyl-3-(methylsulfanyl)-4-hydroxy-5-(2′-
methylpropyl)pyrrolidin-2-one-5-carboxylic Acid Methyl Ester 173a75 and (3R,4R,5R)-N-(4′-
Methoxybenzyl)-3-methyl-3-(methylsulfanyl)-4-hydroxy-5-(2′-methylpropyl)pyrrolidin-2-
one-5-carboxylic Acid Methyl Ester 173b75 
 
The mixture of diastereoisomers 172ab (0.4842, 1.23 mmol) was dissolved in ethanol (25 mL) 
and the solution stirred at -10 °C. NaBH4 was added (0.026, 0.68 mmol, 0.55 equiv) and the 
mixture stirred for 30 m. The solvents were removed under reduced pressure and the residue 
dissolved in ethyl acetate (100 mL). The organic solution was washed with water (50 mL x 2) 
and brine (50 mL x 2), dried (sodium sulphate), filtered, and the solvents removed under 
reduced pressure. The resulting pale yellow residue was purified by column chromatography 
using petroleum ether (40-60 °C)/ethyl acetate (3:1) as the eluent to provide 173a as the first 
eluting diastereomer (0.0815 g, 17%) and 173b as the second (0.222 g, 46%), each as 
colourless oils. Data for the minor, first eluting diastereoisomer 173a: [α]D 22 = -2.1 (c 1.6, 
CHCl3) (77% ee); max (thin film)/cm−1 3425 O-H (b), 2957 C-H (s), 2927, 1739 C=O (s), 1697 
C=O (s); 1H NMR (500 MHz, CDCl3) δH 7.15 (d, J = 8.7 Hz, 2H, H13), 6.82 (d, J = 8.7 Hz, 2H, H12), 
4.83 (d, J = 15.9 Hz, 1H, H10), 4.46 (s, 1H, H18), 4.36 (d, J = 15.9 Hz, 1H, H10), 4.03 (s, 1H, H3) 
3.78 (s, 3H, H15), 3.65 (s, 3H, H6), 2.15 (s, 3H, H17), 1.84 (dd, J = 14.5, 6.0 Hz, 1H, H7), 1.74 (d, 
J = 6.5 Hz, 1H, H7), 1.66−1.63 (m, 1H, H8), 1.62 (s, 3H, H16), 0.81 (d, J = 6.5 Hz, 3H, H9), 0.70 
(d, J = 6.6 Hz, 3H, H9); 13C NMR (126 MHz, CDCl3) δC 173.3, 173.2, 158.6 Ar, 130.7 Ar, 128.3 
Ar, 113.9 Ar, 76.1 C3, 71.7 C2 or 4, 57.6 C2 or 4, 55.4 C15, 52.5 C6, 45.4 C10, 40.8 C7, 24.3 C9, 
24.3 C9, 23.6 C8, 22.1 C16, 12.8 C17. Determined by HPLC to be 77% ee.  Determination of ee 
was found by HPLC using an AD-H Chiralpak column 95:5 hexane/IPA, 230 nm, 0.8 mL/min, 
20 °C. Data for the major, second eluting diastereoisomer 173b: [α]D 26 = −17.3 (c 1.1, CHCl3); 
max (thin film)/cm−1 3386 O-H (s), 2957 C-H (s), 1736 C=O (s), 1679 C=O (s); 1H NMR (500 MHz, 
CDCl3) δH 7.14 (d, J = 8.7 Hz, 2H, H13), 6.81 (d, J = 8.7 Hz, 2H, H12), 4.88 (d, J = 16.0 Hz, 1H, 
H10), 4.46 (s, 1H, H3), 4.43 (d, J = 16.0 Hz, 1H, H10), 3.77 (s, 3H, H15), 3.69 (s, 3H, H6), 3.24 (s, 
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1H, H18), 2.15 (s, 3H, H17), 1.88 (dd, J = 13.7, 6.4 Hz, 1H, H7), 1.83 – 1.67 (m, 2H, H8), 1.49 (s, 
3H, H16), 0.90 (d, J = 6.6 Hz, 3H, H9), 0.76 (d, J = 6.5 Hz, 3H, H9); 13C NMR (126 MHz, CDCl3) 
δC 174.7, 173.2, 158.8, 130.3, 128.8, 113.9, 81.4 C3, 67.5 C2 or 4, 55.4 C2 or C4, 52.8 C15, 
51.6 C6, 44.9 C10, 44.1 C7, 24.5 C9, 24.0 C9, 23.6 C8, 21.9 C16, 11.6 C17. 
(2S,4S)-Methyl 2-Isobutyl-1-(4-methoxybenzyl)-4-methyl-3,5-dioxo-
4(phenylthio)pyrrolidine-2-carboxylate 187a and (2S,4R)-Methyl 2-Isobutyl-1-(4-
methoxybenzyl)-4-methyl-3,5-dioxo-4-(phenylthio)pyrrolidine-2-carboxylate 187b 
 
Lactam 149 (0.4377 g, 0.70 mmol) was dissolved in THF (2.2 mL). A catalytic amount of 
Pd(OH)2/C was added, the mixture was stirred overnight under a static pressure of hydrogen 
at 35 °C. The solution was then filtered through celite, and the solvents were removed under 
reduced pressure. The resulting oil was dissolved in anhydrous dichloromethane (3.1 mL), and 
S -phenyl 4-methylbenzene-1-sulfonothioate 189 (0.481 g, 2 mmol, 2.9 equiv) and 
triethylamine (0.15 mL, 1.1 mmol, 1.6 equiv) were added. The mixture was stirred under an 
atmosphere of nitrogen for 5 h, the solvents were removed under reduced pressure, and the 
resulting pale yellow residue was purified by column chromatography using petroleum ether 
(40−60 °C)/ethyl acetate (9:1) as the eluent, yielding diastereoisomers 187ab as an 
inseparable mixture in a 0.9:1 ratio as a pale yellow oil (0.281 g, 67% over the two steps). Data 
for the minor diastereoisomer 187a: 1H NMR (500 MHz, CDCl3) δH 7.50 (dd, J = 8.2, 1.3 Hz, 
2H, H19), 7.48−7.31 (m, 3H, H20, H18), 7.28 (d, J = 8.7 Hz, 2H, H13), 6.84 (d, J = 8.8 Hz, 2H, 
H12), 4.85 (d, J = 15.2 Hz, 1H, H10), 4.41 (d, J = 15.2 Hz, 1H, H10), 3.79 (s, 3H, H15), 3.44 (s, 
3H, H6), 2.26 (dd, J = 15.2, 6.8 Hz, 1H, H7), 1.95 (dd, J = 15.2, 5.6 Hz, 1H, H7), 1.45 (s, 3H, H16), 
1.29 (d, J = 6.7 Hz, 1H H8), 0.73 (d, J = 6.7 Hz, 3H, H9), 0.70 (d, J = 6.6 Hz, 3H, H9); 13C NMR 
(126 MHz, CDCl3) δC 200.4, 171.8, 168.0, 159.2, 137.9, 130.6, 130.1, 129.0, 128.6, 128.2, 
113.9, 75.7, 55.4, 53.1, 53.0, 45.0, 40.1, 24.0, 23.7, 18.3; one peak unobserved in 13C NMR 
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spectrum.  Data for the major diastereoisomer 187b: 1H NMR (500 MHz, CDCl3) δH 7.61 (d, J 
= 7.0 Hz, 2H, H8), 7.47−7.31 (m, 3H, H20, 18), 7.22 (d, J = 8.7 Hz, 2H, H13), 6.81 (d, J = 8.8 Hz, 
2H, H12), 4.96 (d, J = 15.0 Hz, 1H, H10), 4.04 (d, J = 15.0 Hz, 1H, H10), 3.77 (s, 3H, H15), 3.15 
(s, 3H, H6), 2.14 (dd, J = 15.0, 5.7 Hz, 1H, H7), 1.74 (d, J = 6.5 Hz, 1H, H8), 1.60 (dd, J = 15.0, 
6.5 Hz, 1H, H7), 1.54 (s, 3H, H16), 0.95 (d, J = 6.6 Hz, 3H, H9), 0.85 (d, J = 6.6 Hz, 3H, H9); 13C 
NMR (126 MHz, CDCl3) δC 204.2, 172.6, 168.0, 159.4, 137.8, 130.8, 130.4, 129.0, 128.3, 127.8, 
113.9, 74.9, 55.4, 53.2, 52.9, 43.0, 38.4, 24.6, 23.9, 20.8;  one peak unobserved in 13C NMR 
spectrum. Data for the mixture of diastereoisomers 187ab: max(thin film)/cm−1 2957 C-H (s), 
1771 C=O (s), 1745 C=O (s), 1700 C=O (s); HRMS (ASAP-TOF) m/z [M + H]+ calcd for 
[C25H30NO5S]+ 456.1845, found 456.1854. 
 
(2S,3S,4S)-Methyl 3-Hydroxy-2-isobutyl-1-(4-methoxybenzyl)-4-methyl-5-oxo-4-
(phenylthio)pyrrolidine-2-carboxylate 188a and (2S,3R,4R)-Methyl 3-Hydroxy-2-isobutyl-1-
(4-methoxybenzyl)-4-methyl-5-oxo-4-(phenylthio)-pyrrolidine-2-carboxylate 188b 
 
The mixture of diastereoisomers 187ab (0.2059 g, 0.45 mmol) was dissolved in ethanol (9 mL) 
and the solution cooled to −10 °C. Sodium borohydride (0.012 g, 0.3 mmol, 0.7 equiv) was 
added and the mixture stirred for 30 m before being quenched by addition of water (1 mL). 
The solvents were removed under reduced pressure, and the residue was dissolved in 
dichloromethane. The organic layer was washed twice each with water (20 mL) and brine (20 
mL). The organic layer was dried (sodium sulphate) and filtered, and the solvents were 
removed under reduced pressure. The resulting residue was purified by column 
chromatography using petroleum ether (40−60 °C)/ethyl acetate (6:1) as the eluent to give 
188a and 188b as colourless oils. Data for the minor, first-eluting diastereoisomer 188a: 
(yield 0.063 g, 30%) max (thin film)/cm−1 3423 O-H (b), 2957 C-H (s), 1740 C=O (s), 1701 C=O 
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(s); [α]D 22 = −60.0 (c 0.34, CHCl3); 1H NMR (500 MHz, CDCl3) δH 7.55 (d, J = 6.9 Hz, 2H, H19), 
7.40−7.28 (m, 3H, H20, 18), 7.18 (d, J = 8.7 Hz, 2H, H13), 6.81 (d, J = 8.7 Hz, 2H, H12), 4.71 (d, 
J = 15.7 Hz, 1H, H3), 4.52−4.45 (m, 2H, H21, 10), 4.09 (d, J = 10.3 Hz, 1H, H10), 3.78 (s, 3H, 
H15), 3.66 (s, 3H, H6), 1.95 (dd, J = 14.6, 6.1 Hz, 1H, H7), 1.78 (d, J = 6.4 Hz, 1H, H8), 1.66 (dd, 
J = 14.6, 5.0 Hz, 1H, H7), 1.44 (s, 3H, H16), 0.87 (d, J = 6.6 Hz, 3H, H9), 0.76 (d, J = 6.6 Hz, 3H, 
H9); 13C NMR (126 MHz, CDCl3) δC 174.1, 173.6, 158.8 Ar, 137.5 Ar, 130.0 Ar, 129.5 Ar, 129.2 
Ar, 129.1 Ar, 128.8 Ar, 113.8 Ar, 80.3 C3, 68.0 C4 or 2, 56.0 C4 or 2, 55.4 C15, 52.7 C6, 44.8 
C10, 43.7 C7, 24.5 C9, 24.1 C9, 23.6 C8, 23.2 C16; HRMS (ASAP-TOF) m/z [M + H]+ calcd for 
[C25H32NO5S]+ 458.2001, found 458.2003. Data for the major second-eluting 
diastereoisomer 188b: (yield 0.073 g, 35%); max (thin film)/cm−1 3405, 2957, 2930, 1736, 
1683; [α]D 19 = −5.8 (c 13.1, CHCl3); 1H NMR (500 MHz, CDCl3) δH 7.63 (d, J = 6.7 Hz, 2H, H19), 
7.42−7.33 (m, 3H H20, 18), 7.15 (d, J = 8.7 Hz, 2H, H13), 6.83 (d, J = 8.7 Hz, 2H, H12), 4.92 (d, 
J = 16.1 Hz, 1H, H10), 4.44 (d, J = 16.1 Hz, 1H, H10), 4.41 (d, J = 3.8 Hz, 1H, H3), 3.79 (s, 3H, 
H15), 3.67 (s, 3H, H6), 3.65 (d, J = 3.9 Hz, 1H, H21), 1.93-1.86 (m, 1H, H7), 1.81−1.72 (m, 2H, 
H7,8), 1.29 (s, 3H, H16), 0.93 (d, J = 6.5 Hz, 3H, H9), 0.76 (d, J = 6.3 Hz, 3H, H9); 13C NMR (126 
MHz, CDCl3) δ 173.4, 173.2, 158.6 Ar, 136.4 Ar, 130.5 Ar, 129.5 Ar, 129.3 Ar, 128.7 Ar, 128.3 
Ar, 113.9 Ar, 75.4 C3, 71.8 C4 or 2, 62.3 C4 or 2, 55.4 C15, 52.5 C6, 45.4 C10, 41.3 C7, 24.3 C9, 
24.2 C9, 23.7 C8, 22.4 C16; HRMS (FTMS-NSI) m/z [M + H]+ calcd for [C25H32NO5S]+ 458.1996, 
found 458.1987. 
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(2S,3R,4S)-Methyl-3-Hydroxy-2-isobutyl-1-(4-methoxybenzyl)-4-methyl-5-oxopyrrolidine-2 
carboxylate 152a and (2S,3R,4R)-Methyl 3-Hydroxy-2-isobutyl-1-(4-methoxybenzyl)-4-
methyl-5-oxopyrrolidine-2-carboxylate 152b 
 
Desulphurization by treatment with Raney® nickel where R = Me 
Raney® nickel 2800 grade was washed with ethanol and dried under an atmosphere of argon. 
A micro spatula portion was added to a solution of 173a (0.02 g, 0.05 mmol) in ethanol (2.3 
mL). The mixture was heated to reflux for 4 h. The Raney® nickel was removed by filtration, 
and solvent was removed under reduced pressure. The residue was purified by column 
chromatography on silica gel using petroleum ether (40−60 °C)/ethyl acetate (3:1) as the 
eluent, to give 152a and 152b as a 3:1 mixture of diastereoisomers (5.7 mg, 7%). 
Desulphurization by treatment with Raney® nickel where R = Ph 
Raney® nickel 2800 grade was washed with ethanol and dried under an atmosphere of argon. 
A portion was added to a solution of 188a (0.0237 g, 0.05 mmol) in ethanol (1 mL). The 
mixture was heated to reflux for 4 h. The Raney® nickel was removed by filtration, and the 
solvent was removed under reduced pressure. The residue was purified by column 
chromatography on silica gel using ethyl acetate/petroleum ether (40−60 °C) (1:1) as the 
eluent, affording 152a and 152b as a 3:1 mixture of diastereoisomers (7.4 mg, 42%). 
Desulphurization by treatment with AIBN/organotin where R = Ph 
Lactam 188a (0.057 g, 0.12 mmol) and AIBN (0.0042 g, 0.026 mmol, 0.2 equiv) were dissolved 
in anhydrous acetone (0.9 mL). Tributyl-tinhydride (0.11 mL, 0.41 mmol, 3.4 equiv) was 
added, and the mixture was heated to reflux under a nitrogen atmosphere overnight. The 
solvents were removed under reduced pressure, and the residue was purified by column 
chromatography using ethyl acetate/petroleum ether (40−60 °C) (1:3) as the eluent, and a 
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90:10 silica/potassium carbonate mix as the stationary phase, to afford 152ab as a colourless 
oil in a 1:2 mixture of diastereoisomers (0.0405 g, 93%). 
Desulphurization by treatment with AIBN/TTMS where R = Ph 
Lactam 188a (0.064 g, 0.14 mmol) and AIBN (0.007 g, 0.043 mmol) were dissolved in 
anhydrous acetone (1 mL). Tris(trimethylsilyl)silane (0.14 mL, 0.45 mmol, 3.2 equiv) was 
added, and the mixture was heated to reflux under a nitrogen atmosphere overnight. The 
solvents were removed under reduced pressure, and the residue was purified by column 
chromatography using ethyl acetate/petroleum ether (40−60 °C) (1:1) as the eluent, to afford 
152a as a colourless oil (0.007 g, 14%) and 152b as a colourless oil (0.036 g, 74%). Data for 
the first-eluting diastereoisomer 152a: [α]D 19 = +7.4 (c 0.42, CHCl3); max (thin film)/cm−1 
3356, 2957, 2918, 1741, 1673 δH 7.16 (d, J = 8.7 Hz, 2H, H13), 6.81 (d, J = 8.7 Hz, 2H, H12), 
4.69 (d, J = 15.3 Hz, 1H, H10), 4.17 (d, J = 15.3 Hz, 1H, H10), 3.90 (t, J = 9.8 Hz, 1H, H3), 3.78 (s, 
3H, H15), 3.34 (s, 3H, H6), 2.84 (d, J = 9.8 Hz, 1H, H17), 2.71 (dq, J = 9.6, 7.0 Hz, 1H, H2), 2.15 
(dd, J = 14.4, 7.5 Hz, 1H, H7), 1.92−1.81 (m, 1H, H8), 1.55 (dd, J = 14.5, 4.5 Hz, 1H, H7), 1.32 
(d, J = 7.0 Hz, 3H, H16), 0.97−0.88 (m, 6H, H9); 13C NMR (126 MHz, CDCl3) δC 175.5, 172.4, 
159.0 Ar, 129.7 Ar, 129.4 Ar, 113.9 Ar, 79.4 C3, 69.1 C4, 55.4 C2,  52.1 C15, 43.4 C6, 43.3 C10, 
41.9 C7, 24.7 C8, 24.0 C9, 23.5 C9, 13.7 C16; HRMS (NSI-FTMS) m/z [M + H]+ calcd for 
[C19H28NO5]+ 350.1962, found 350.1964. Data for the second-eluting diastereoisomer 152b: 
[α]D 22 = −27 (c 0.67, CHCl3); max (thin film)/cm−1 3374 O-H (b), 2956 C-H (s), 1742 C=O (s), 
1672 C=O (s); 1H NMR (500 MHz, CDCl3) δH 7.17 (d, J = 8.8 Hz, 2H, H13), 6.81 (d, J = 8.8 Hz, 
2H, H12), 4.67 (d, J = 15.4 Hz, 1H, H10), 4.47−4.36 (m, 2H, H10, 3), 3.77 (s, 3H, H15), 3.46 (s, 
3H, H6), 3.03 (d, J = 7.6 Hz, 1H H17), 2.76 (d, J = 7.5 Hz, 1H, H2), 1.99 (dd, J = 14.4, 6.1 Hz, 1H, 
H7), 1.77−1.67 (m, J = 12.9, 6.5 Hz, 1H, H16), 1.61 (dd, J = 14.4, 6.0 Hz, 1H, H7), 1.27 (d, J = 7.6 
Hz, 3H, H16), 0.88 (d, J = 6.6 Hz, 3H, H9), 0.84 (d, J = 6.6 Hz, 3H, H9); 13C NMR (126 MHz, CDCl3) 
δC 176.6, 172.3, 158.7 Ar, 130.1 Ar, 128.9 Ar, 113.8 Ar, 73.4 C3, 72.5 C4, 55.4 C2, 52.2 C15, 
44.7 C6, 43.3 C10, 39.9 C7, 24.3 C8, 24.1 C9, 24.0 C9, 9.5 C16; HRMS (NSI-FTMS) m/z [M + H]+ 
calcd for [C19H28NO5]+ 350.1962, found 350.1964. 
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(2S,3R,4S)-Methyl 3-Hydroxy-2-isobutyl-4-methyl-5-oxopyrrolidine-2-carboxylate 197 
 
Lactam 152b (0.036 g, 0.10 mmol) was dissolved in a 3:1 mixture of acetonitrile/water (1 mL). 
CAN (0.287 g, 0.52 mmol, 5.2 equiv) was added and the mixture stirred at room temperature 
until TLC showed the reaction was complete. The mixture was extracted with ethyl acetate (3 
× 20 mL), the combined organic layers were washed with brine (20 mL), dried (sodium 
sulphate), filtered, and the solvents were removed under reduced pressure. The residue was 
purified by column chromatography using ethyl acetate/petroleum ether (40−60 °C) (9:1) as 
the eluent, affording 197 as a colourless solid (0.023 g, 62%). Mp 147-156 °C max (thin 
film)/cm−1 3434 O-H (b), 2959 C-H (s), 2079, 1725 C=O (s), 1641 C=O (s); [α]D 23 = −2.85 (c 0.42, 
CHCl3); 1H NMR (500 MHz, CDCl3) δH 8.20 (s, 1H, H12), 5.09 (d, J = 11.6 Hz, 1H, H3), 4.06 (dd, 
J = 11.4, 5.1 Hz, 1H, H2), 3.83 (s, 3H, H6), 2.72−2.65 (m, 1H, H11), 2.00 (dd, J = 13.8, 8.7 Hz, 
1H, H7), 1.78−1.68 (m, 1H, H8), 1.51 (dd, J = 13.8, 5.1 Hz, 1H, H7), 1.18 (d, J = 7.3 Hz, 3H, H10), 
0.96 (d, J = 6.7 Hz, 3H, H9), 0.87 (d, J = 6.6 Hz, 3H, H9); 13C NMR (126 MHz, CDCl3) δC 178.1, 
174.2, 78.9 C3, 72.0 C4, 52.8 C2, 43.5 C6, 40.1 C7, 25.0 C8, 24.0 C9, 21.9 C9, 7.7 C10; HRMS 
(NSI-FTMS) m/z [M + H]+ calcd for [C11H20NO4]+ 230.1387, found 230.1388. 
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(2S,3R,4S)-3-Hydroxy-2-isobutyl-4-methyl-5-oxopyrrolidine-2-carboxylic Acid 17477 
 
Lactam 197 (0.01 g 0.04 mmol) was dissolved in aqueous sodium hydroxide (0.5 M, 0.86 mL) 
and kept at 4 °C. The progress of the reaction was monitored by TLC. When all the starting 
material was consumed (approximately 24 h), the solution was acidified to pH 3 with HCl (1 
M), and the solvents were removed under reduced pressure. The residue was dissolved in hot 
THF and filtered through cotton wool. The solvents were removed under reduced pressure. 
The residue was purified by column chromatography using a 
dichloromethane/methanol/acetic acid (90:9:1) mixture as the eluent affording 174 as a pale 
brown residue (0.078 g, 86%): max (thin film)/cm−1 3405 O-H (b), 2923 C-H (s), 1725 C=O (s), 
1686 C=O (s); [α]D 20 = −10 (c 0.28, MeOH); 1H NMR (500 MHz, CD3OD) δH 4.10 (d, J = 5.2 Hz, 
1H, H3), 2.79−2.71 (m, 1H, H2), 1.94 (dd, J = 13.8, 8.3 Hz, 1H, H7), 1.76−1.65 (m, 1H, H8), 1.57 
(dd, J = 13.8, 4.7 Hz, 1H, H7), 1.11 (d, J = 7.2 Hz, 3H, H10), 0.95 (d, J = 6.7 Hz, 3H, H9), 0.92 (d, 
J = 6.7 Hz, 3H, H9); 13C NMR (126 MHz, CD3OD) δC 180.0 C4, 175.4 C1, 78.1 C3, 45.2 C5, 41.4 
C2, 25.9 C6, 24.8 C7, 23.0 C8, 20.8 C8, 8.4 C10; HRMS (NSI-FTMS) m/z [M + H]+ calcd for 
[C10H18NO4]+ 214.1084, found 214.1085. 
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3.2.2 Experimental for procedures starting from L-serine 
3.2.2.1 Experimental toward the synthesis of omuralide 
Sodium hydroxy(4-methoxyphenyl)methanesulfonate107 
 
p-Methoxybenzaldehyde (20 mL, 0.164 mol, 1.2 equiv) was stirred in ethanol (330 mL). An 
aqueous solution of sodium sulphite (17.56 g, 0.139 mol in 34 mL) was slowly added forming 
a cloudy precipitate. This solution was stirred for 16 h at 30 °C then stirred in an ice bath for 
2 hours allowing further precipitation. The resulting suspension was filtered, washed with 
hexane and dried in a vacuum oven to yield the PMB sulphite adduct as a fluffy white solid 
(33.72 g, 81%). Mp 166-168 °C (decomp.) (lit203 155-157 °C (decomp.); max (solid)/cm-1 3226 
O-H (b), 1516, 1249; 1H NMR (500 MHz, DMSO) δH 7.34 (d, J = 8.3 Hz, 2H, Ar), 6.79 (d, J = 8.8 
Hz, 2H, Ar), 5.56 (d, J = 5.0 Hz, 1H, H1), 4.87 (d, J = 5.0 Hz, 1H, H1), 3.72 (s, 3H, H6), hydroxyl 
proton unobserved in 1H NMR spectrum; 13C NMR (126 MHz, DMSO) δC 158.6 Ar, 131.6 Ar, 
129.1 Ar, 112.6 Ar, 84.7 C1, 55.2 C6. 
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(S)-methyl 3-(tert-butoxy)-2-((4-methoxybenzyl)amino)propanoate 200 
 
t-Bu-O-Serine methyl ester hydrochloride 199 (5.00 g, 23.61 mmol) was dissolved in methanol 
(250 mL). The PMB sulphite salt (9 g, 37.46 mmol, 1.6 equiv) was added along with 
triethylamine (3 mL, 21.52 mmol 0.9 equiv). The stirred solution was cooled with an ice bath 
and sodium cyanoborohydride (9.09 g, 144 mmol, 6.1 equiv) was added in small portions. The 
suspension was left overnight and allowed to reach room temperature. The solution was 
evaporated and dissolved in ethyl acetate (200 mL). The organic solution was washed with 
equal amounts of brine, saturated sodium sulphite solution and water, then dried 
(magnesium sulphate), filtered, and evaporated under reduced pressure to produce 5.92 g of 
crude 200, which was used in the next step with no further purification. For analytical 
purposes a portion was purified by column chromatography on silica gel using petroleum 
ether (40-60 °C)/ethyl acetate (9:1) to yield 200 as a colourless oil. [α]D 24 = –23.61 (c 1.05, 
CHCl3) max (thin film)/cm-1: 3434 N-H (s), 2974 C-H (s), 1743 C=O (s); 1H NMR (500 MHz, CDCl3) 
δH 7.25 (d, J = 7.5 Hz, 2H, H10), 6.85 (d, J = 8.7 Hz, 2H, H9), 3.83 (d, J = 12.8 Hz, 1H, H7), 3.79 
(s, 3H, H12), 3.72 (s, 3H, H1), 3.65 (d, J = 12.8 Hz, 1H, H7), 3.60 (dd, J = 8.7, 5.3 Hz, 1H, H4), 
3.55 (dd, J = 8.7, 4.9 Hz, 1H, H4), 3.43 (t, J = 5.1 Hz, 1H, H3), 2.14 (s, 1H), 1.14 (s, 9H, H6); 13C 
NMR (126 MHz, CDCl3) δC 174.1 C2, 158.8 Ar, 132.1 Ar, 129.7 Ar, 113.9 Ar, 73.3 C5, 63.3 C4, 
61.1 C3, 55.4 C2, 51.8 C3, 51.5 C7, 27.5 C6; HRMS (NSI-FTMS) m/z [M+H]+ Calcd for 
[C16H26NO4]+ 296.1856 found 296.1859. 
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(S)-benzyl 3-((3-(tert-butoxy)-1-methoxy-1-oxopropan-2-yl)(4-methoxybenzyl)amino)-3-
oxopropanoate 201 
 
Crude amine 200 (5.92 g, 20.05 mmol) was dissolved in anhydrous DCM (182 mL) in a flame 
dried flask. The benzyl malonic half ester 146 (11.59 g, 49.89 mmol, 2.5 equiv) was added 
along with EDAC.HCl (10.30 g, 53.72 mmol 2.7 equiv), DMAP (0.5 g, 4.1 mmol, 0.2 equiv) and 
N-methyl morpholine (5.5 mL, 50 mmol, 2.5 equiv). The solution was stirred for 16 h under 
an atmosphere of nitrogen. HCl (1 M aq solution) (6 mL) was added, the solution transferred 
into a separating funnel, and washed with equal amounts of water and brine. The organic 
layer was dried (magnesium sulphate), filtered and evaporated under reduced pressure to 
form 201 as a yellow oil, which was purified by column chromatography on silica gel using 
petroleum ether (40-60 °C)/ethyl acetate (8:2) as the eluent, to produce a pale-yellow oil. 
(5.49 g, 49% over the 2 steps) [α]D 24 = –23.61 (c 1.05, CHCl3) (97% ee); max (neat)/cm-1: 3434, 
2974 C-H (s), 1743 C=O (s); 1H NMR (500 MHz, CDCl3) (major conformation) δH 7.40 – 7.29 (m, 
5H H12, 14, 16), 7.24 (d, J = 8.8 Hz, 2H, H20), 6.86 (d, J = 8.7 Hz, 2H, H19), 5.15 (s, 2H, H8 or 
H10), 4.69 (s, 2H, H8 or 10), 4.58 (dd, J = 7.5, 3.4 Hz, 1H, H4), 3.90 (dd, J = 9.7, 7.6 Hz, 1H, H4), 
3.80 – 3.74 (m, 4H, H22 and 3), 3.67 (s, 3H, H1), 3.51 (d, J = 15.4 Hz, 1H, H17), 3.43 (d, J = 15.4 
Hz, 1H, H17), 1.06 (s, 9H, H6); 13C NMR (126 MHz, CDCl3) δC 169.7, 167.3, 167.2, 159.1, 128.8, 
128.6, 128.4, 128.1, 114.2, 73.4, 67.1, 60.7, 59.7, 55.4, 52.3, 52.1, 41.5, 27.3, two peaks 
unobserved in 13C NMR spectrum; HRMS (NSI-FTMS) m/z [M+H]+ Calcd for [C26H34NO7]+ 
472.2330 found 472.2325. Determined by HPLC to be 97% ee. Determination of ee was found 
by HPLC using an AD-H Chiralpak column 90:10 hexane/IPA, 230 nm, 0.8 mL/min, 15 °C. 
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(3S,5S)-benzyl 5-(tert-butoxymethyl)-1-(4-methoxybenzyl)-3-methyl-2,4-dioxopyrrolidine-
3-carboxylate 202a and (3R,5S)-benzyl 5-(tert-butoxymethyl)-1-(4-methoxybenzyl)-3-
methyl-2,4-dioxopyrrolidine-3-carboxylate 202b 
 
The cyclization precursor 201 (1.605 g, 3.4 mmol) was dissolved in ether (9.8 mL), TBAF (1 M 
in THF) (7 mL, 7 mmol, 2.1 equiv) was added and the solution was stirred for 10 m, evaporated 
under reduced pressure, and placed under high vacuum for approximately 2 h. To the 
resulting white solid was added THF (9.8 mL) and the solution was cooled to -12 °C. MeI (2.1 
mL, 34 mmol, 10 equiv) was added and the solution stirred for 72 h. Water (approximately 3 
mL) was added and the solution was allowed to warm to room temperature where the 
solution was dissolved in ethyl acetate (100 mL) and washed with equal amounts of water 
and brine. The organic layer was dried (magnesium sulphate), filtered, and evaporated. The 
resulting brown oil was purified by column chromatography on silica gel using petroleum 
ether (40-60 °C)/ethyl acetate (9:1) as the eluent, to produce 202ab as a 3:1 ratio of 
diastereoisomers (1.0273 g, 67%)  as a clear oil which could be partially separated Data for 
the major, first eluting diastereoisomer 202a: (Yield 0.491 g, 32%), [α]D 19.5 = –91.3 (c 1.06, 
CHCl3) (98% ee) max (neat)/cm-1: 2934 C-H (s), 1781 C=O (s), 1749 C=O (s), 1698 C=O (s); 1H 
NMR (400 MHz, CDCl3) δH 7.39 – 7.33 (m, 3H, H13, 11), 7.28 – 7.23 (m, 2H, H12), 7.01 (d, J = 
8.4 Hz, 2H, H18), 6.60 (d, J = 8.7 Hz, 2H, H17), 5.38 (d, J = 15.1 Hz, 1H, H9), 5.21 (d, J = 12.3 Hz, 
1H, H15), 5.10 (d, J = 12.3 Hz, 1H, H15), 3.86 (t, J = 2.3 Hz, 1H, H4), 3.83 (d, J = 15.1 Hz, 1H, 
H9), 3.74 (s, 3H, H20), 3.58 (dd, J = 9.9, 2.1 Hz, 1H, H5), 3.53 (dd, J = 9.9, 2.4 Hz, 1H, H5), 1.56 
(s, 3H, H14), 1.12 (s, 9H, H7); 13C NMR (126 MHz, CDCl3) δC 205.0, 170.3, 166.0, 159.3 Ar, 
135.0 Ar, 129.3 Ar, 128.8 Ar, 128.6 Ar, 128.4 Ar, 126.7 Ar, 114.3 Ar, 73.9 C5, 68.2 C9, 65.2 C6, 
58.8 C2, 57.2 C4, 55.4 C20, 43.1 C15, 27.3 C7, 15.3 C14; HRMS (NSI-FTMS) m/z [M+H]+ Calcd 
for [C26H32NO6]+ 254.2224 found 454.2218. Determined by HPLC to be 79% ee recrystalization 
in IPA was found to have an enriched supernatent of 98% ee. Determination of ee was found 
by HPLC using an AD-H Chiralpak column 80:20 hexane/IPA, 230 nm, 0.8 mL/min, 25 °C. Data 
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for the partially purified, minor, second eluting diastereomer 202b: (Yield 0.416 g, 35%), 1H 
NMR (400 MHz, CDCl3) δH 7.38 – 7.28 (m, 5H, H16, 14, 12), 7.22 (d, J = 8.6 Hz, 2H, H20), 6.82 
(d, J = 8.7 Hz, 2H, H19), 5.25 – 5.16 (m, 2H H9-15), 5.11 (d, J = 12.2 Hz, 1H, H9-15), 4.31 (d, J = 
14.3 Hz, 1H, H9 or 15), 3.87 (dd, J = 7.2, 2.6 Hz, 1H, H5 or 4), 3.78 (s, 3H, H20), 3.59 (dd, J = 
9.7, 2.5 Hz, 1H, H5 or 4), 3.48 (dd, J = 9.7, 7.1 Hz, 1H, H5 or 4), 1.52 (s, 3H, H14), 1.02 (s, 9H, 
H7); 13C NMR (101 MHz, CDCl3) δ 204.0, 169.6, 165.6, 159.4 Ar, 135.0 Ar, 130.0 Ar, 128.8 Ar, 
128.7 Ar, 128.3 Ar, 128.0 Ar, 114.2 Ar, 74.0 C6, 68.2 C5, 65.5 C9, 62.8 C4, 58.5 C2, 55.4 C20, 
44.5 C15, 27.2 C7, 16.7 C14. 
(2R,4S)-4-benzyl 2-methyl 2-(tert-butoxymethyl)-1-(4-methoxybenzyl)-4-methyl-3,5-
dioxopyrrolidine-2,4-dicarboxylate 217 
 
Lactam 202a (0.1125 g, 0.25 mmol), in a flame dried flask, was dissolved in anhydrous THF 
(4.5 mL) and cooled to -40 °C and placed under an atmosphere of nitrogen. LiHMDS (1 M in 
THF/ethylbenzene) (0.56 mL, 0.56 mmol, 2.2 equiv) was added with DMPU (0.9 mL, 0.75 
mmol, 3 equiv) and the solution left for 0.5 h. Methyl cyanoformate was added (0.09 mL, 1.13 
mmol, 4.5 equiv) and stirring was continued for 3 h. Saturated NH4Cl solution (0.2 mL) was 
used to quench the solution, which was allowed to warm to room temperature. The crude 
solution had water added (20 mL) which was extracted with equal amounts of ethyl acetate 
twice. The combined organic extracts were washed with water (20 mL), and with brine (2 x 
20 mL) before being dried (sodium sulphate), filtered, and evaporated under reduced 
pressure. The resulting residue was purified by column chromatography using a petroleum 
ether (40-60 °C)/ethyl acetate (9:1) as the eluent to yield 217 as a white crystalline solid 
(0.0881 g, 69%). Mp 90-94 °C [α]D 25 = +2.85 (c 1.12, CHCl3) (supernatant of up to 93 % ee could 
be obtained after recrystallization from IPA) max (neat)/cm-1: 3434, 2974 C-H (s), 1743 C=O 
(s); 1H NMR (500 MHz, CDCl3) δH 7.39 – 7.30 (m, 5H, H20, 21, 22), 7.18 (d, J = 8.7 Hz, 2H, H13), 
6.70 (d, J = 8.7 Hz, 2H, H12), 5.24 (d, J = 12.5 Hz, 1H, H18 or 10), 5.16 (d, J = 12.5 Hz, 1H, H18 
or 10), 4.72 (d, J = 15.3 Hz, 1H, H18 or 10), 4.57 (d, J = 15.3 Hz, 1H, H5), 3.83 (d, J = 9.7 Hz, 1H, 
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H15), 3.75 (s, 3H, H5), 3.73 (d, J = 9.7 Hz, 1H, H9), 3.53 (s, 3H, H16), 1.66 (s, 3H, H16), 0.87 (s, 
9H, H7); 13C NMR (126 MHz, CDCl3) δC 199.7, 170.7, 166.3, 165.1 Ar, 159.0 Ar, 135.1 Ar, 129.5 
Ar, 128.7 Ar, 128.6 Ar, 128.5 Ar, 128.0 Ar, 113.7 Ar, 74.1 C5, 68.1 C18, 61.0 C2, 57.7 C4, 55.5 
C15, 53.4 C9, 44.7 C10, 26.8 C7, 18.9 C16, one carbon peak unobserved in 13C spectrum ; (NSI-
FTMS) m/z [M+H]+ Calcd for [C28H34NO8]+ 512.2279 found 512.2271. Determination of ee was 
found by HPLC using an AD-H Chiralpak column 90:10 hexane/IPA, 230 nm, 0.8 mL/min, 25 
°C. 
(S)-methyl 3-(tert-butoxy)-2-((4-methoxybenzyl)(methyl)amino)propanoate 209 
 
Alkylation method: 
Amine 200 (0.1289 g, 0.436 mmol) was dissolved in DMF (6 mL). K2CO3 (0.16 g, 1.16 mmol, 
2.7 equiv) and MeI (0.06 mL, 0.96 mmol, 2.2 equiv) were added and the solution stirred at 
room temperature until TLC showed consumption of the starting material (about 1 h). Water 
(5 mL) was added and all solvents were removed under reduced pressure. The resulting 
residue was dissolved in ethyl acetate (75 mL) and water (75 mL). The aqueous layer was 
removed and the organic washed with a further 75 mL of water and brine (2 x 75 mL). The 
organic solution was dried (magnesium sulphate), filtered, and evaporated under reduced 
pressure to provide 209 as a colourless oil. The oil was purified with column chromatography 
using petroleum ether (40-60 °C)/ethyl acetate (9:1) as the eluent to give 209 (0.0834 g, 62%). 
Reductive amination method: 
Amine 200 (0.1415 g, 0.48 mmol) and para-formaldehyde (0.072 g, 2.38 mmol, 5 equiv) were 
stirred in MeOH (6.6 mL) for 5 h. Sodium cyanoborohydride (0.072 g, 1.14 mmol, 2.4 equiv) 
was added and the solution stirred for 16 h. The solvents were evaporated under vacuum and 
the resulting crude material dissolved in ethyl acetate (75 mL) and water (75 mL). The aqueous 
layer was removed and the organic washed with a further 75 mL of water and brine (2 x 75 
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mL). The organic was dried (magnesium sulphate), filtered, and evaporated under reduced 
pressure, to provide 209 as a colourless oil which could be used without further purification 
(0.1094 g, 74%). For characterization purposes however, a small amount was purified using 
column chromatography.  [α]D 23 = –46.5 (c 1.6, CHCl3); max (neat)/cm-1: 2974 C-H (s), 2951 C-
H (s), 1736 C=O (s), 1612; 1H NMR (500 MHz, CDCl3) δH 7.25 (d, J = 9.6 Hz, 2H, H10), 6.84 (d, J 
= 8.6 Hz, 2H, H9), 3.80 (s, 3H, H10), 3.76 (d, J = 7.6 Hz, 1H, H3), 3.74 (s, 3H, H1), 3.70 (d, J = 
13.3 Hz, 1H, H7), 3.62 (m, 2H, H7 and 4), 3.51 (dd, J = 7.4, 5.7 Hz, 1H, H4), 2.29 (s, 3H, H12), 
1.17 (s, 9H, H8); 13C NMR (126 MHz, CDCl3) δC 172.0, 158.8 Ar, 131.5 Ar, 130.1 Ar, 113.8 Ar, 
73.3 C5, 66.1 C4, 61.3 C3, 58.8 C12, 55.4 C11, 51.2 C1, 39.0 C12, 27.5 C6; HRMS (NSI-FTMS) 
m/z [M + H]+ calcd for [C17H28NO4]+ 310.2013, found 310.2016. 
Methyl (2S)-2-anilino-3-tert-butoxypropanoate 210204 
 
Amine 210 (1.249 g, 5.9 mmol) was dissolved in in anhydrous DCM (40 mL). Phenyl boronic 
acid (1.447 g, 11.94 mmol, 2 equiv) was added, along with Cu(OAc)2 (1.2 g, 6.6 mmol, 1.1 
equiv). Triethylamine (1.65 mL, 11.8 mmol, 2 equiv) and molecular sieve (4 Å, 4.4 g) were also 
added and the reaction was placed under a static atmosphere of oxygen and stirred for 3 
days. Ammonium hydroxide (1 M aqueous solution, 40 mL) was added, the suspension stirred 
for 40 m, filtered through diatomaceous earth and transferred into a separating funnel. The 
organic layer was removed and the aqueous extracted again with an equal portion of DCM. 
The organic layers were combined, washed with water (80 mL) and brine (80 mL), dried 
(magnesium sulphate), filtered and evaporated under reduced pressure. The resulting residue 
was purified by column chromatography using petroleum ether (40-60 °C)/ether 18:1 as the 
eluent to yield 210 as a cream coloured solid (0.319 g, 22%). Recrystallization from petroleum 
ether yielded crystals of 95% ee and a racemic supernatant from 72% ee. Mp 52-59 °C (lit205 
47-50 °C); [α]D 22 = -13.69 (c 1.11, CHCl3) (95% ee) (lit205 [α]D 24 = -10.7 (c 1.1, CHCl3) (71% ee)); 
max (neat)/cm-1: 3398 N-H (b), 2975 C-H (s), 1751 C=O (s); 1H NMR (500 MHz, CDCl3) δH 7.20 
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– 7.14 (m, 2H, H8), 7.75 (td, J = 7.4, 0.8 Hz, 1H, H10), 6.64 (d, J = 8.2 Hz, 2H, H9), 4.62 (s, 1H, 
NH), 4.20 (t, J = 4.1 Hz, 1H, H3), 3.78 (dd, J = 8.8, 4.0 Hz, 1H, H4), 3.73 (s, 3H, H1), 3.69 (dd, J = 
8.8, 4.2 Hz, 1H, H4), 1.17 (s, 9H, H6); 13C NMR (126 MHz, CDCl3) δC 172.0 C2, 146.9 Ar, 129.40 
Ar, 118.5 Ar, 113.8 Ar, 73.70 C5, 62.60 C4, 57.4 C3, 52.3 C1, 27.5 C6. Determination of ee was 
found by HPLC using an Eurocel 01 Knauer column 90:10 hexane/IPA, 230 nm, 0.8 mL/min, 25 
°C. 
 
(S)-benzyl 3-((3-(tert-butoxy)-1-methoxy-1-oxopropan-2-yl)(phenyl)amino)-3-
oxopropanoate 211 
 
Amine 210 (0.2308 g, 0.91 mmol) was dissolved in anhydrous DCM (7 mL) in a flame dried 
flask. The benzyl malonic half ester 146 (0.47 g, 2.02 mmol, 2.2 equiv) was added along with 
EDAC.HCl (0.467 g, 2.4 mmol 2.7 equiv), DMAP (0.021 g, 0.17 mmol, 0.19 equiv) and N-
methylmorpholine (0.23 mL, 2.09 mmol, 2.3 equiv). The solution was stirred for 16 h under a 
nitrogen atmosphere. HCl (0.3 mL, 1 M solution) was added, and the solution diluted with 
DCM (50 mL). The solution was transferred into a separating funnel and washed with equal 
amounts of water and brine. The organic layer was dried (magnesium sulphate), filtered and 
evaporated under reduced pressure, to form 211 as a yellow oil which was purified by column 
chromatography using petroleum ether (40-60 °C)/ethyl acetate (9:1 to 7:3) as the eluent to 
produce clear oil (0.1136 g, 71%). [α]D 23 = +1.48 (c 0.54, CHCl3) (95 % ee); max (neat)/cm-1: 
3022 C-H (unsaturated, s), 2974 C-H (s), 1743 C=O (s), 1663 C=O (s); 1H NMR (500 MHz, CDCl3) 
δH 7.45 (s, 2H, Ar), 7.38 – 7.28 (m, 8H, Ar), 5.10 (s, 2H, H12), 4.69 – 4.64 (m, 1H H3 or 4), 3.81 
– 3.78 (m, 2H, H3 or 4), 3.75 (s, 3H, H1), 3.24 (d, J = 15.8 Hz, 1H, H14), 3.20 (d, J = 15.8 Hz, 1H, 
H14), 1.08 (s, 9H, H6); 13C NMR (126 MHz, CDCl3) δC 169.8, 167.3, 166.4, 141.5 Ar, 135.6 Ar, 
129.6 Ar, 129.5 Ar, 128.8 Ar, 128.6 Ar, 128.5 Ar, 128.4 Ar, 73.5 C14, 67.1 C5, 62.0 C4, 59.2 C12, 
52.4 C3, 42.2 C1, 27.4 C6; (NSI-FTMS) m/z [M+H]+ Calcd for [C24H30NO6]+ 428.2068 found 
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428.2065. Determined by HPLC to be 95% ee. Determination of ee was found by HPLC using 
an AD-H Chiralpak column 80:20 hexane/IPA, 230 nm, 0.8 mL/min, 25 °C. 
(3S,5S)-benzyl 5-(tert-butoxymethyl)-3-methyl-2,4-dioxo-1-phenylpyrrolidine-3-
carboxylate 212 
 
The Dieckmann cyclization precursor 211 (0.104 g, 0.24 mmol) was dissolved in ether (0.67 
mL), TBAF (1 M in THF), (0.5 mL, 0.5 mmol 2.1 equiv) was added and the solution was stirred 
for 10 m, evaporated under reduced pressure, and placed under high vacuum for 
approximately 2 h. To the resulting white solid was added THF (0.67 mL), and the reaction 
was cooled to -12 °C. MeI (0.07 mL, 1.12 mmol, 4.7 equiv) was added and the suspension 
stirred for 72 h. Water (0.1 mL) was added and the solution was allowed to warm to room 
temperature where the solution was dissolved in ethyl acetate (30 mL) and washed with an 
equal amount of water and brine. The organic layer was dried (magnesium sulphate), filtered, 
and evaporated under reduced pressure. The resulting brown oil was purified by column 
chromatography with petroleum ether (40-60 °C)/ethyl acetate (9:1) as the eluent. Only the 
major diastereoisomer 212 could be isolated (0.008 g, 8%) Mp 121-124 °C [α]D 22 = +14.2 (c 
0.81, CHCl3) (87 % ee) max (neat)/cm-1: 2977 C-H (s), 2253, 1782 C=O (s), 1752 C=O (s), 1702 
C=O (s); 1H NMR (500 MHz, CDCl3) δH 7.44 – 7.23 (m, 10H, Ar), 5.18 (s, 2H, H14), 4.57 (t, J = 
2.1 Hz, 1H, H4), 3.68 (dd, J = 9.6, 1.8 Hz, 1H, H5), 3.39 (dd, J = 9.6, 2.4 Hz, 1H, H5), 1.65 (s, 3H, 
H13), 1.02 (s, 9H, H7); 13C NMR (126 MHz, CDCl3) δC 204.5, 169.5, 165.8, 135.8 Ar, 135.2 Ar, 
129.4 Ar, 128.8 Ar, 128.5 Ar, 127.8 Ar, 127.5 Ar, 125.6 Ar, 73.9 C6, 68.8 C5, 68.0 C14, 59.7 C2, 
57.9 C4, 27.2 C7, 15.2 C13; (NSI-FTMS) m/z [M+H]+ Calcd for [C24H28NO5S]+ 410.1962 found 
410.1956. Determined by HPLC to be 87% ee. Determination of ee was found by HPLC using 
an AD-H Chiralpak column 80:20 hexane/IPA, 230 nm, 0.8 mL/min, 25 °C. 
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Potassium 3-methoxy-3-oxopropanoate 215206 
 
KOH (22.06 g, 393.18 mmol, 1.2 equiv) was dissolved in methanol (75 mL). The resulting 
solution was added to a beaker of dimethyl malonate (38 mL, 332.5 mmol) dissolved in 
methanol (85 mL). A white precipitate was formed which was collected by vacuum filtration 
and dried in a vacuum oven to provide (26.35 g 51%) of 215, collected as a white solid. Mp: 
204-209 °C (lit207 204-207 °C); max (solid)/cm-1: 1726 C=O (s), 1595, 1368; 1H NMR (500 MHz, 
D2O) δH 3.75 (s, 3H, H4), 3.34 (s, 2H, H3); 13C NMR (101 MHz, D2O) δC 174.8, 172.6, 53.2 C3, 
45.0 C4. 
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(S)-methyl 3-(tert-butoxy)-2-(3-methoxy-N-(4-methoxybenzyl)-3-
oxopropanamido)propanoate 213 
 
Amine 200 (0.5558 g, 1.88 mmol) was dissolved in anhydrous DCM (17.5 mL) in a flame dried 
flask. The methyl malonic half ester 215 (0.692 g, 4.43 mmol, 2.4 equiv) was added along with 
EDAC.HCl (1.06 g, 5.53 mmol, 2.9 equiv), DMAP (0.0405 g, 0.33 mmol, 0.18 equiv) and N-
methylmorpholine (0.5 mL, 4.54 mmol, 2.4 equiv). The solution was stirred for 24 h under an 
atmosphere of nitrogen. HCl (1 M, 0.5 mL) was added, the solution transferred into a 
separating funnel, and washed with equal amounts of water and brine. The organic layer was 
dried (magnesium sulphate), filtered, and evaporated under reduced pressure to form a 
yellow oil, which was purified by column chromatography using petroleum ether (40-60 
°C)/ethyl acetate (8:2) as the eluent to produce the desired compound 213 as a pale-yellow 
oil (0.54 g, 73%). [α]D 26 = -42.0 (c 1.13, CHCl3); max (neat)/cm-1: 2973 C-H (s), 1744 C=O (s), 
1656 C=O (s), 1514; 1H NMR (400 MHz, CDCl3) δH 7.29 (d, J = 7.5 Hz, 2H, H17), 6.91 (d, J = 8.7 
Hz, 2H, H16), 4.73 (s, 2H, H12), 4.60 (dd, J = 7.6, 3.4 Hz, 1H, H4 or 3), 3.93 (dd, J = 9.7, 7.6 Hz, 
1H, H4 or 3), 3.86 – 3.81 (m, 4H, H19, 3 or 4), 3.74 (s, 3H, H1 or 14), 3.72 (s, 3H, H1 or 14), 
3.50 (d, J = 15.3 Hz, 1H, H7), 3.40 (d, J = 15.3 Hz, 1H, H7), 1.10 (s, 9H, H6); 13C NMR (101 MHz, 
CDCl3) δC 169.7, 167.8, 167.4, 159.2 Ar, 128.8 Ar, 128.1 Ar, 114.2 Ar, 73.5 C5, 60.7 C4, 59.8 
C12, 55.4 C3, 52.5 C19, 52.3 C14 or 1, 52.2 C1 or 14, 41.3 C7, 27.3 C6; (NSI-FTMS) m/z [M+H]+ 
Calcd for [C20H30NO7]+ 396.2017 found 396.2016. 
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(3S,5S)-methyl 5-(tert-butoxymethyl)-1-(4-methoxybenzyl)-3-methyl-2,4-dioxopyrrolidine-
3-carboxylate 214a and (3R,5S)-methyl 5-(tert-butoxymethyl)-1-(4-methoxybenzyl)-3-
methyl-2,4-dioxopyrrolidine-3-carboxylate 214b 
 
The Dieckmann cyclization precursor 213 (0.2219 g, 0.56 mmol) was dissolved in ether (1.6 
mL). TBAF (1 M in THF), (1.6 mL, 1.6 mmol, 3 equiv) was added and the solution stirred for 5 
m. Solvents were removed under reduced pressure to form a brown oil. The oil was dissolved 
in THF (1.6 mL) and cooled to -12 °C, MeI (0.15 mL, 2.4 mmol, 4.3 equiv) was added and the 
suspension stirred for 58 h. The solution was quenched with water (1 mL) and the reaction 
mixture was pipetted crude onto a short silica gel column. The column was washed with ethyl 
acetate until full elution of the product had occurred. The partially purified 3:1 mixture of 
diastereoisomers 214ab was collected as a yellow oil and used onto the next step without 
further purification (0.1832 g, 87%). Data for the major diastereoisomer 214a: 1H NMR (400 
MHz, CDCl3) δH 7.21 (d, J = 8.5 Hz, 2H, H14), 6.87 (d, J = 8.6 Hz, 2H, H13), 5.35 (d, J = 15.0 Hz, 
1H, H11), 3.93 (d, J = 15.0 Hz, 1H, H11), 3.93 (t, J = 2.2 Hz, 1H, H4), 3.80 (s, 3H, H16), 3.73 (s, 
3H, H10), 3.60 (dd, J = 9.8, 2.2 Hz, 1H, H5), 3.56 (dd, J = 9.9, 2.4 Hz, 1H, H5), 1.53 (s, 3H, H8), 
1.11 (s, 9H, H7); 13C NMR (101 MHz, CDCl3) δC 205.0, 170.5, 166.7, 159.5, 129.5, 127.2, 114.4, 
73.9 C6, 65.4 C5, 58.7 C2, 57.4 C4, 55.5 C16, 53.4 C10, 43.4 C11, 27.3 C7, 15.2 C8. Data for 
the minor diastereoisomer 214b: 1H NMR (400 MHz, CDCl3) δH 7.23 (d, J = 6.6 Hz, 2H, H14), 
6.85 (d, J = 7.2 Hz, 2H, H13), 5.27 (d, J = 14.6 Hz, 1H, H11), 4.23 (d, J = 14.5 Hz, 1H, H11), 3.86 
(dd, J = 5.8, 2.7 Hz, 1H, H5), 3.79 (s, 3H, H16), 3.75 (s, 3H, H10), 3.69 (m, 2H, H5, 4), 1.52 (s, 
3H, H8), 1.17 (s, 9H, H7); 13C NMR (101 MHz, CDCl3) δC 204.0, 169.0, 166.3, 159.5, 129.0, 
127.8, 114.3, 74.0 C6, 65.1 C5, 61.3 C2, 58.3 C4, 55.4 C16, 53.4 C10, 44.2 C11, 27.4 C7, 17.4 
C8. Data for both diastereoisomers: max (neat)/cm-1: 2974 C-H (s), 1782 C=O (s), 1750 C=O 
(s), 1698 C=O (s), 1514; (NSI-FTMS) m/z [M+H]+ Calcd for [C20H28NO6]+ 378.1911 found 
378.1913. 
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(3S,5S)-methyl 5-(tert-butoxymethyl)-3-methyl-2,4-dioxopyrrolidine-3-carboxylate 216a 
and (3R,5S)-methyl 5-(tert-butoxymethyl)-3-methyl-2,4-dioxopyrrolidine-3-carboxylate 
216b 
 
The mixture of diastereoisomers 214ab (0.1251 g, 0.331 mmol) was dissolved in a MeCN/H2O 
mixture (3:1) (3.5 mL). CAN (0.9 g, 1.64 mmol, 5 equiv) was added and the solution stirred 
vigorously until consumption of the starting material had occurred (approx 1.5 h). Ethyl 
acetate (25 mL) was added and the solution washed with water (25 mL). The aqueous was re-
extracted with ethyl acetate (25 mL) and both organic layers were combined. The organic 
solution was further washed with water (25 mL) and brine (25 mL). The organic layer was 
dried (magnesium sulphate), filtered, and the solvents removed under reduced pressure. The 
crude material was purified by column chromatography with petroleum ether (40-60 
°C)/ethyl acetate (8:2 – 7:3) as the eluent to provide a mixture of partially separable 
diastereoisomers (0.0483 g, 57% total) from which only 216a could be obtained 
uncontaminated (0.01 g, 12%). Data for the major, first eluting diastereoisomer 216a: Mp 
111-116 °C; [α]D 24 = -46.2 (c 0.91, CHCl3); max (neat)/cm-1: 3234, 2976 C-H (s), 1785 C=O (s), 
1750 C=O (s), 1706 C=O (s); 1H NMR (400 MHz, CDCl3) δH 6.72 (d, J = 39.7 Hz, 1H, H11), 4.18 
(dd, J = 9.2, 3.6 Hz, 1H, H5), 3.77 – 3.69 (m, 4H, H5, 10), 3.53 (t, J = 9.1 Hz, 1H, H4), 1.55 (s, 3H, 
H8), 1.19 (s, 9H, H7); 13C NMR (101 MHz, CDCl3) δC 204.4, 171.4, 166.2 C1, 74.3 C6, 63.4 C5, 
62.4 C2, 58.5 C4, 53.6 C10, 27.5 C7, 16.7 C8; (NSI-FTMS) m/z [M+H]+ Calcd for [C12H20NO5]+ 
258.1336 found 258.1339. Data for the minor, second eluting diastereoisomer 216b: 1H NMR 
(400 MHz, CDCl3) δH 6.73 – 6.31 (m, 1H, H11), 4.31 (t, J = 3.6 Hz, 1H, H4), 3.74 (s, 3H, H10), 
3.61 (d, J = 3.6 Hz, 2H, H4), 1.51 (s, 3H, H8), 1.14 (s, 9H, H7); 13C NMR (101 MHz, CDCl3) δC 
205.2, 172.2, 166.3, 74.1 C6, 63.5 C5, 61.0 C2, 58.6 C4, 53.6 C10, 27.4 C7, 15.1 C8. 
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(2R,4R)-methyl 2-(tert-butoxymethyl)-1-(4-methoxybenzyl)-4-methyl-4-(methylthio)-3,5-
dioxopyrrolidine-2-carboxylate 219a and (2R,4S)-methyl 2-(tert-butoxymethyl)-1-(4-
methoxybenzyl)-4-methyl-4-(methylthio)-3,5-dioxopyrrolidine-2-carboxylate 219b 
 
Methyl ester 217 (0.1426 g, 0.31 mmol) was dissolved in THF (0.7 mL) and heated to 35 °C. A 
micro-spatula full of Pd(OH)2/C was added and the stirred solution was placed under a static 
atmosphere of hydrogen. After 16 h this solution was filtered through diatomaceous earth 
and washed through with DCM. The solution was evaporated to produce a crude foam which 
was dissolved in anhydrous DCM (0.5 mL). Sulphonothioate 186 (0.1090 g, 0.53 mmol, 1.7 
equiv) was added to this along with triethylamine (0.05 mL, 0.35 mmol, 1.1 equiv) in a flame 
dried flask. The solution was stirred at 20 °C for 5 h under an atmosphere of nitrogen then 
evaporated, to a crude yellow oil. Purification was achieved using column chromatography 
with petroleum ether (40-60 °C)/ethyl acetate (9:1) as the eluent to produce a 4:1 (by NMR) 
mixture of inseparable diastereoisomers 219ab as a pale-yellow oil (0.127 g, 70%). Data for 
the major diastereoisomer 219a: 1H NMR (500 MHz, CDCl3) δH 7.26 (d, J = 8.7 Hz, 2H, H13), 
6.82 (d, J = 8.7 Hz, 2H, H12), 4.74 (d, J = 15.2 Hz, 1H, H10), 4.44 (d, J = 15.2 Hz, 1H, H10), 3.89 
(d, J = 9.6 Hz, 1H, H5), 3.78 (s, 3H, H15), 3.72 (d, J = 9.6 Hz, 1H, H5), 3.47 (s, 3H, H9), 2.16 (s, 
3H, H17), 1.57 (s, 3H, H16), 1.01 (s, 9H, H7); 13C NMR (101 MHz, CDCl3) δ 201.6, 172.5, 166.2, 
159.3 Ar, 130.3 Ar, 128.4 Ar, 113.8 Ar, 76.2 C6, 74.3 C5, 60.3 C2 or 4, 55.4 C4 or 2, 52.0 C15, 
49.7 C9, 44.1 C10, 27.1 C7, 18.0 C16, 12.6 C17. Data for the minor diastereoisomer 219b: 1H 
NMR (500 MHz, CDCl3) δC 7.26 (d, J = 8.7 Hz, 2H, H13), 6.82 (d, J = 8.7 Hz, 2H, H12), 4.84 (d, J 
= 15.1 Hz, 1H, H10), 4.36 (d, J = 15.1 Hz, 1H, H10), 4.00 (d, J = 10.2 Hz, 1H, H5), 3.86 (d, J = 10.2 
Hz, 1H, H5), 3.78 (s, 3H, H15), 3.37 (s, 3H, H9), 2.20 (s, 3H, H17), 1.61 (s, 3H, H16), 1.08 (s, 9H, 
H7); 13C NMR (101 MHz, CDCl3) δ 203.4, 172.7, 166.7, 159.3 Ar, 130.4 Ar, 128.0 Ar, 113.8 Ar, 
75.8 C6, 74.4 C5, 59.7 C2 or 4, 55.4 C4 or 2, 53.1 C15, 50.7 C9, 44.2 C10, 27.1 C7, 20.7 C16, 
12.9 C17. Data for both diastereoisomers: max (neat)/cm-1: 3020, 1741 C=O (s), 1699 C=O (s); 
(NSI-FTMS) m/z [M+H]+ Calcd for [C21H30NO6S]+ 424.1788 found 424.1790. 
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(2R,4R)-methyl 2-(hydroxymethyl)-1-(4-methoxybenzyl)-4-methyl-4-(methylthio)-3,5-
dioxopyrrolidine-2-carboxylate 29a76 and (2R,4S)-methyl 2-(hydroxymethyl)-1-(4-
methoxybenzyl)-4-methyl-4-(methylthio)-3,5-dioxopyrrolidine-2-carboxylate 29b 
 
The 4:1 mixture of inseparable diastereoisomers 219ab (0.0297 g, 0.07 mmol) in a flame dried 
flask was dissolved in anhydrous DCM (0.15 mL) and TFA (0.15 mL). The solution was stirred 
under nitrogen for 1.5 h or until TLC showed complete consumption of starting material. The 
solution was diluted with DCM (50 mL), and an equal amount of water was carefully added 
and used to wash the organic layer. The organic solution was further washed with an equal 
amount of a NaHCO3 solution. The organic layer was dried (sodium sulphate), filtered, and 
evaporated to a brown residue. The residue was purified by column chromatography using 
petroleum ether (40-60 °C)/ethyl acetate (2:1) as the eluent to produce 29ab as a 2:1 mixture 
of inseparable isomers (0.0195 g, 76%). Data for the major diastereomer 29a: 1H NMR (400 
MHz, CDCl3) δH 7.33 (d, J = 8.6 Hz, 2H, H9), 6.86 (d, J = 8.6 Hz, 2H, H8), 5.08 (d, J = 15.2 Hz, 1H, 
H6), 4.35 (d, J = 15.2 Hz, 1H, H6), 4.17 (d, J = 12.0 Hz, 1H, H5), 3.79 (d, J = 12.8 Hz, 4H, H5 and 
11), 3.67 (s, 3H, H13), 2.12 (s, 3H, H4), 1.54 (s, 3H, H5), hydroxyl proton unobserved in 1H NMR 
spectrum; 13C NMR (101 MHz, CDCl3) δC 199.1, 172.2, 165.7, 159.7 Ar, 129.9 Ar, 128.8 Ar, 
114.6 Ar, 77.6 C5, 61.8 C2 or 4, 55.4 C2 or 4, 53.4 C11, 49.7 C13, 44.3 C6, 16.9 C15, 12.4 C14. 
Analysis on HPLC determined ee to be 58%. Data for the minor diastereomer 29b: 1H NMR 
(400 MHz, CDCl3) δH 7.27 (d, J = 9.7 Hz, 2H, H9), 6.84 (d, J = 7.2 Hz, 2H, H8), 4.68 (d, J = 15.0 
Hz, 1H, H6), 4.60 (d, J = 15.0 Hz, 1H, H6), 4.20 (d, J = 11.8 Hz, 1H, H5), 4.07 (d, J = 12.6 Hz, 1H, 
H5), 3.77 (s, 3H, H11), 3.42 (s, 3H, H13), 2.17 (s, 3H, C15), 1.61 (s, 3H, C14), hydroxyl proton 
unobserved in 1H NMR spectrum; 13C NMR (101 MHz, CDCl3) δC 200.3, 172.2, 166.7, 159.6 Ar, 
130.3 Ar, 127.9 Ar, 114.3 Ar, 76.6 C5, 62.01 C2 or 4, 55.4 C2 or 4, 53.4 C11, 49.5 C13, 44.4 C6, 
18.1 C15, 12.2 C14. Analysis on HPLC determined ee to be 41% ee. Data for both 
diastereoisomers: max (neat)/cm-1: 3419, 3000, 2932 C-H (s), 1776 C=O (s), 1742 C=O (s), 1699 
C=O (s); (NSI-FTMS) m/z [M+H]+ Calcd for [C17H22NO6S]+ 368.1162 found 368.1165. 
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Determination of ee was found by HPLC using an AD-H Chiralpak column 80:20 hexane/IPA, 
230 nm, 0.8 mL/min, 25 °C.   
(R)-methyl 2-(tert-butoxymethyl)-1-(4-methoxybenzyl)-4,4-dimethyl-3,5-dioxopyrrolidine-
2-carboxylate 220 
 
Methyl ester 217 (0.0832 g, 0.16 mmol) was dissolved in THF (0.5 mL) and the solution heated 
to 35 °C. Pd(OH)2/C (20% nominally on water) (0.604 g) was added and the solution put under 
a static atmosphere of hydrogen. After 16 h this solution was filtered through diatomaceous 
earth and washed through with DCM. The solution was evaporated to produce a crude foam 
which was dissolved in DCM (0.6 mL). The crude compound was stirred under an atmosphere 
of nitrogen and triethylamine was added (0.04 mL, 0.29 mmol, 1.8 equiv). After 15 m MeI was 
added (0.04 mL 0.64 mmol, 4 equiv). The solution was stirred for a further 5 h, diluted with 
DCM (50 mL), and washed with water (50 mL) and brine (50 mL). The organic layer was dried 
(sodium sulphate), filtered, evaporated under reduced pressure and purified with column 
chromatography using petroleum ether (40-60 °C)/ethyl acetate (8:2) as the eluent to 
produce a pink oil. The oil was dissolved in DCM and washed with a saturated sodium 
thiosuphate solution until the organic layer became clear, then, dried with sodium sulphate, 
filtered, and evaporated under reduced pressure to produce 220 as a colourless oil. (0.0286 
g, 46% over the 2 steps). [α]D 22 = +50 (c 0.31, CHCl3) (86% ee); max (neat)/cm-1: 3019, 2978 C-
H (s), 1779 C=O (s), 1742 C=O (s); 1H NMR (500 MHz, CDCl3) δH 7.22 (d, J = 8.7 Hz, 2H, H13), 
6.81 (d, J = 8.7 Hz, 2H, H12), 4.87 (d, J = 15.1 Hz, 1H, H10), 4.19 (d, J = 15.1 Hz, 1H, H10), 3.89 
(d, J = 9.8 Hz, 1H, H5), 3.77 (s, 3H, H15), 3.75 (d, J = 9.8 Hz, 1H, H5), 3.31 (s, 3H, H9), 1.34 (s, 
3H, H16), 1.28 (s, 3H, H16), 1.05 (s, 9H, H7); 13C NMR (126 MHz, CDCl3) δC 209.1, 177.3, 166.9, 
159.3, 130.5 Ar, 128.2 Ar, 113.8 Ar, 75.8 C6, 74.1 C5, 58.9 C2 or 4, 55.4 C4 or 2, 52.8 C15, 46.1 
C9, 43.3 C10, 27.2 C7, 22.2 C16, 20.6 C16; HRMS (NSI-FTMS) m/z [M+H]+ Calcd for [C21H30NO6]+ 
392.2068 found 392.2068. Analysis on HPLC determined ee to be 86% ee.  Determination of 
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ee was found by HPLC using an Eurocel 01 Knauer column 95:5 hexane/IPA, 230 nm, 0.8 
mL/min, 25 °C. 
(R)-methyl 2-(hydroxymethyl)-1-(4-methoxybenzyl)-4,4-dimethyl-3,5-dioxopyrrolidine-2-
carboxylate 221 
 
Lactam 220 (0.0109 g, 0.027 mmol) was dissolved in dry DCM (0.1 mL) and TFA (0.1 mL). The 
solution was stirred under nitrogen for 1.5 h or until TLC showed complete consumption of 
starting material. The solution was diluted up to 50 mL with DCM and an equal amount of 
water was carefully added and used to wash the organic layer. The organic layer was further 
washed with a saturated NaHCO3 solution (50 mL). The organic layer was then dried (sodium 
sulphate), filtered, and evaporated to a white solid. This was purified by column 
chromatography using petroleum ether (40-60 °C)/ethyl acetate (2:1) as the eluent to 
produce the deprotected alcohol 221 as a gummy residue (0.0062 g, 67%). [α]D 24 = -7.74 (c 
0.62, CHCl3) (86% ee); max (neat)/cm-1: 3396 O-H (b), 2919 C-H (s), 1778 C=O (s), 1742 C=O 
(s), 1678 C=O (s); 1H NMR (500 MHz, CDCl3) δH 7.30 (d, J = 8.7 Hz, 2H, H8), 6.86 (d, J = 8.7 Hz, 
2H, H7), 4.89 (d, J = 15.1 Hz, 1H, H5), 4.31 (d, J = 15.1 Hz, 1H, H5), 4.14 (dd, J = 12.3, 8.6 Hz, 
1H, H11), 3.85 (dd, J = 12.3, 4.4 Hz, 1H, H11), 3.79 (s, 3H, H10), 3.55 (s, 3H, H13), 1.35 (s, 3H, 
H14), 1.28 (s, 3H, H14), 1.17 (dd, J = 8.6, 4.5 Hz, 1H, OH); 13C NMR (126 MHz, CDCl3) δC 208.3, 
177.3, 166.4, 159.6 , 130.1 Ar, 128.7 Ar, 114.5 Ar, 77.3 C11, 60.8 C4 or 2, 55.4 C 2 or 4, 53.2 
C10, 46.1 C13, 43.7 C5, 22.0 C14, 20.5 C14; HRMS (NSI-FTMS) m/z [M+H]+ Calcd for 
[C17H22NO6]+ 336.1442 found 336.1443. Determined by HPLC to be 86% ee. Determination of 
ee was found by HPLC using an AD-H Chiralpak column 80:20 hexane/IPA, 230 nm, 0.8 
mL/min, 25 °C. 
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(2R,3R,4R)-methyl 2-(tert-butoxymethyl)-3-hydroxy-1-(4-methoxybenzyl)-4-methyl-4-
(methylthio)-5-oxopyrrolidine-2-carboxylate 224a and (2R,3S,4S)-methyl 2-(tert-
butoxymethyl)-3-hydroxy-1-(4-methoxybenzyl)-4-methyl-4-(methylthio)-5-oxopyrrolidine-
2-carboxylate 224b 
 
The mixture of diastereoisomers 219ab (0.1407 g, 0.33 mmol) was dissolved in ethanol (9 mL) 
and the solution was cooled with an ice bath. Sodium borohydride (0.0073 g, 0.19 mmol, 0.6 
equiv) was added and the reaction was stirred for 20 m. Water (40 mL) was added to quench 
the reaction and the resulting solution was extracted with equal amounts of ethyl acetate (3 
x 40 mL). The combined organic fractions were washed with and equal amount of brine, dried 
(sodium sulphate), filtered and evaporated. The resulting residue was purified using column 
chromatography with petroleum ether (40-60 °C)/ethyl acetate (8:2 - 2:1) as the eluent to 
provide 2 separable diastereoisomers 224a and 224b as gummy oils. The first eluting 
diastereoisomer (0.0764 g, 54%) and the second (0.0181 g, 13%). Analysis on chiral HPLC 
showed the of the diastereoisomers were 67% and 66% ee respectively. Diastereomer 224a 
however upon re-crystalization from IPA gave 0.0511 g of material from the supernatant at 
99% ee. Data for major, first eluting diastereoisomer 224a: [α]D 23 = +6.2 (c 0.71, CHCl3) (99% 
ee); max (neat)/cm-1: 3418, 2973, 2926, 1743, 1697; 1H NMR (500 MHz, CDCl3) δH 7.24 (d, J = 
8.7 Hz, 2H, H13), 6.81 (d, J = 8.7 Hz, 2H, H12), 4.71 (d, J = 15.2 Hz, 1H, H10), 4.46 (d, J = 15.2 
Hz, 1H, H10), 3.99 – 3.87 (m, 2H, H3 and 18), 3.82 (d, J = 9.7 Hz, 1H, H5), 3.78 (s, 3H, H15), 
3.65 (s, 3H, H9), 3.44 (d, J = 9.7 Hz, 1H, H5), 2.12 (s, 3H, H17), 1.60 (s, 3H, H16), 1.04 (s, 9H, 
H7); 13C NMR (126 MHz, CDCl3) δC 173.0, 172.1, 158.9, 130.4 Ar, 129.6 Ar, 113.7 Ar, 77.9 C3, 
74.1 C6, 70.7 C5, 62.8 C4 or 2, 55.4 C2 or 4, 53.4 C15, 52.5 C9, 45.2 C10, 27.2 C7, 22.9 C18, 
12.3 C16; HRMS (NSI-FTMS) m/z [M+H]+ Calcd for [C21H32NO6S]+ 426.1945 found 426.1942. 
Data for the minor, second eluting diastereomer 224b: [α]D 22 = +5.26 (c 0.38, CHCl3) (66% 
ee); max (neat)/cm-1: 3385 O-H (b), 3016, 2975 C-H (s), 1743 C=O (s), 1686 C=O (s);  1H NMR 
(500 MHz, CDCl3) δ 7.18 (d, J = 8.6 Hz, 2H, H13), 6.81 (d, J = 8.7 Hz, 2H, H12), 4.77 (d, J = 15.5 
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Hz, 1H, H10), 4.43 (d, J = 15.5 Hz, 1H, H3), 4.32 (s, 1H, H3), 3.96 (d, J = 9.7 Hz, 1H, H5), 3.77 (s, 
3H, H15), 3.75 (s, 1H, H10), 3.67 (d, J = 9.7 Hz, 1H, H5), 3.64 (s, 3H, H15), 2.19 (s, 3H, H17), 
1.53 (s, 3H, H16), 1.02 (s, 9H, H7);13C NMR (126 MHz, CDCl3) δ 173.8, 171.7, 158.8 Ar, 130.3 
Ar, 128.9 Ar, 113.7 Ar, 78.0 C3, 74.4 C6, 71.6 C5, 62.1 C2 or 4, 55.7 C4 or 2, 55.4 C15, 52.7 C9, 
45.3 C10, 27.1 C7, 22.6 C17, 12.7 C16; HRMS (NSI-FTMS) m/z [M+H]+ Calcd for [C21H32NO6S]+ 
426.1945 found 426.1945. Determination of ee was found by HPLC using an AD-H Chiralpak 
column 90:10 hexane/IPA, 230 nm, 0.8 mL/min, 25 °C. 
 
(2R,3R,4R)-methyl 3-hydroxy-2-(hydroxymethyl)-1-(4-methoxybenzyl)-4-methyl-4-
(methylthio)-5-oxopyrrolidine-2-carboxylate 29a76 
 
Alcohol 224a (0.0427 g, 0.1 mmol) was dissolved in anhydrous DCM (0.21 mL) in a flame dried 
flask. TFA (0.21 mL) was added and the reaction was stirred under an atmosphere of nitrogen 
until TLC showed complete consumption of starting material (about 1.5h). The reaction 
mixture was diluted with DCM (20 mL) and quenched with water (20 mL). The organic layer 
was removed and the aqueous extracted again with DCM (20 mL). The organic layers were 
combined and washed with saturated NaHCO3 and brine (20 mL of each), dried (sodium 
sulphate), filtered, and evaporated under reduced pressure. The resulting residue was 
purified by column chromatography using petroleum ether (40-60 °C)/ethyl acetate 1:1 as the 
eluent to yield 29a as a white solid (0.0279 g, 75%). Mp 128 – 130 °C (lit29 129 °C); [α]D 23 = –
33.84 (c 0.13, CHCl3) (99% ee) (lit29 [α]D 23 = –41.8 (c 0.1, CHCl3)); max (neat)/cm-1: 3416 O-H 
(b), 2925 C-H (s), 2852, 1737 C=O (s), 1675 C=O (s); 1H NMR (500 MHz, CDCl3) δH 7.29 (d, J = 
8.5 Hz, 2H, H9), 6.85 (d, J = 8.7 Hz, 2H, H8), 5.11 (d, J = 15.3 Hz, 1H, H6), 4.13 (d, J = 7.7 Hz, 1H, 
H3 or 5), 4.05 (d, J = 15.3 Hz, 1H, H6), 3.85 – 3.77 (m, 5H, H11 and 3 or 5 or OH), 3.76 (s, 3H, 
H13), 3.67 (d, J = 8.1 Hz, 1H, H3 or 5 or OH), 2.14 (s, 3H, H14), 1.61 (s, 3H, H15); 13C NMR (126 
MHz, CDCl3) δC 173.5, 171.6, 159.5 Ar, 129.8 Ar, 129.6 Ar, 114.6 Ar, 76.8 C3, 72.4 C5, 62.5 C2 
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or 4, 55.4 C4 or 2, 53.4 C11, 52.9 C13, 44.8, 22.9 C14 12.4 C15; HRMS (NSI-FTMS) m/z [M+H]+ 
Calcd for [C17H24NO6S]+ 370.1319 found 370.1320. Analysis on HPLC determined ee to be 99%. 
Determination of ee was found by HPLC using an AD-H Chiralpak column 80:20 hexane/IPA, 
230 nm, 0.8 mL/min, 25 °C. 
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3.2.2.2 Experimental toward the synthesis of salinosporamide B 
(3S,5S)-benzyl 5-(tert-butoxymethyl)-3-ethyl-1-(4-methoxybenzyl)-2,4-dioxopyrrolidine-3-
carboxylate and (3R,5S)-benzyl 5-(tert-butoxymethyl)-3-ethyl-1-(4-methoxybenzyl)-2,4-
dioxopyrrolidine-3-carboxylate 225ab 
 
Cyclization ran at room temperature: 
The cyclization precursor 201 (1.5562 g, 3.3 mmol) was dissolved in ether (9.5 mL), TBAF (1 M 
in THF, 6.6 mL, 6.6 mmol, 2 equiv) was added until a white precipitate formed (<5 m). Solvents 
were removed under reduced pressure and the resulting white solid suspended in THF (9.5 
mL) under a nitrogen atmosphere. EtI was added (0.58 mL, 7.21 mmol, 2.2 equiv) and the 
solution stirred for 15 h. A second aliquot of EtI was added (0.58 mL, 7.21 mmol, 2.2 equiv) 
and the solution stirred for a further 5 h. Water (20 mL) was added and the resulting mixture 
was extracted with DCM (3 x 50 mL). The organic layers were combined and washed with 
water (50 mL), and brine (50 mL). The organic extractions were dried (magnesium sulphate) 
filtered, and evaporated under reduced pressure to provide the crude material as a yellow 
oil. The oil was purified by column chromatography using petroleum ether (40-60 °C)/ethyl 
acetate (9:1) as the eluent to provide 225ab as a 1:0.4 mixture of diastereoisomers through 
NMR as a pale-yellow oil (0.669 g, 43%). 
Cyclization ran at 0 °C to rt: 
The cyclization precursor 201 (0.6304 g, 1.34 mmol) was dissolved in ether (3.8 mL). TBAF (1 
M in THF, 2.7 mL, 2.7 mmol, 2 equiv) was added until a white precipitate formed (<5 m). 
Solvents were removed under reduced pressure and the resulting white solid suspended in 
THF (3.8 mL) under a nitrogen atmosphere. EtI was added at 0 °C (0.95 mL, 11.8 mmol, 8.8 
equiv) and the solution was allowed to warm slowly to room temperature over 20 h. Water 
(20 mL) was added and the resulting mixture was extracted with DCM (3 x 20 mL). The organic 
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layers were combined and washed with water (50 mL) and brine (50 mL). The organic 
extractions were dried (magnesium sulphate), filtered, and evaporated under reduced 
pressure to provide the crude material as a yellow oil. The oil was purified by column 
chromatography using petroleum ether (40-60 °C)/ethyl acetate (9:1) as the eluent to provide 
225ab as a 1:0.65 mixture of diastereoisomers from NMR as a pale yellow oil (0.2236 g, 36%). 
Data for the major diastereoisomer: 1H NMR (400 MHz, CDCl3) δH 7.39 – 7.19 (m, 5H, H21, 
20, 19), 7.03 (d, J = 8.5 Hz, 2H, H11), 6.62 (d, J = 8.7 Hz, 2H, H12), 5.41 (d, J = 15.0 Hz, 1H, H7), 
5.17 (d, J = 10.5 Hz, 1H, H8 or 17), 5.09 (d, J = 12.3 Hz, 1H, H8 or 17), 3.90 (d, J = 15.0 Hz, 1H, 
H8 or 17), 3.83 (t, J = 2.6 Hz, 1H, H4), 3.74 (s, 3H, H13), 3.66 (dd, J = 10.0, 2.5 Hz, 1H, H5), 3.54 
(dd, J = 10.0, 2.8 Hz, 1H, H5), 2.23 (m, 2H, H14), 1.12 (s, 9H, H7), 0.95 (t, J = 7.5 Hz, 3H, H15); 
13C NMR (101 MHz, CDCl3) δC 204.4, 169.2, 165.5, 159.2, 135.0, 129.4, 128.8, 128.3, 126.9, 
114.2, 73.8, 68.0, 64.9, 63.4, 55.4, 43.3, 27.2, 23.8, 8.8, two carbon peaks unobserved in 13C 
spectrum. Data for the minor diastereoisomer: 1H NMR (400 MHz, CDCl3) δH 7.42 – 7.18 (m, 
7H, C21, 20, 19), 6.81 (d, J = 8.7 Hz, 2H, H10), 5.30 – 5.16 (m, 3H, H8 or 17), 4.28 (d, J = 14.3 
Hz, 1H, H8 or 17), 3.79 – 3.74 (m, 4H, H13 and 18 or 17), 3.60 (dd, J = 9.7, 2.5 Hz, 1H, H5), 3.46 
(dd, J = 9.7, 7.1 Hz, 1H, H5), 2.30 – 2.14 (m, 2H, H14), 1.03 (s, 9H, H7), 0.72 (t, J = 7.5 Hz, 3H, 
H15). 13C NMR (101 MHz, CDCl3) δC 204.3, 168.6, 165.1, 159.2, 134.9, 130.2, 128.7, 128.5, 
127.9, 114.0, 73.9, 67.9, 66.2, 63.4, 62.6, 55.3, 44.4, 27.1, 25.5, 8.5, one carbon peak 
unobserved in 13C spectrum. Data for the mix of diastereoisomers: max (neat)/cm-1: 3450, 
2974 C-H (s), 1778 C=O (s), 1747 C=O (s), 1696 C=O (s); HRMS (NSI-FTMS) m/z [M + H]+ calcd 
for [C27H34NO6]+ 468.2381, found 468.2374. 
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(3S,5S)-benzyl 3-ethyl-5-(hydroxymethyl)-1-(4-methoxybenzyl)-2,4-dioxopyrrolidine-3-
carboxylate and (3R,5S)-benzyl 3-ethyl-5-(hydroxymethyl)-1-(4-methoxybenzyl)-2,4-
dioxopyrrolidine-3-carboxylate 
 
The inseparable mixture of diastereoisomers 225ab (0.066 g, 0.14 mmol) of the 1:0.4 mixture 
of diastereoisomers from the room temperature cyclization was dissolved in DCM (0.3 mL) 
with TFA (0.3 mL). The solution was stirred at room temperature under argon until complete 
consumption of the starting material (about 1h) had occurred. DCM (40 mL) was added and 
the organic solution was carefully washed with water (20 mL x 2) and saturated sodium 
hydrogen carbonate solution (20 mL x 2). The organic layer was dried (magnesium sulphate), 
filtered, and evaporated under reduced pressure to produce a colourless residue. The 
diastereoisomers could be separated by column chromatography using petroleum ether (40-
60 °C)/ethyl acetate (8:2) as the eluent, the first eluting diastereoisomer as a colourless oil 
(0.010 g, 18%) and the second as a colourless oil (0.032 g, 55%). The first eluting diastereomer 
was found to have an ee of 66%, the second was found to have an ee of 45%. 
 
The inseparable mixture of diastereoisomers 225ab (0.2236 g, 0.47 mmol) of the 1:0.65 
mixture of diastereoisomers from the 0 °C cyclization was dissolved in DCM (1 mL) with TFA 
(1 mL). The solution was stirred at room temperature under argon until complete 
consumption of the starting material (about 1h) had occurred. DCM (50 mL) was added and 
the organic solution was carefully washed with water (30 mL x 2) and saturated sodium 
hydrogen carbonate solution (30 mL x 2). The organic layer was dried (magnesium sulphate), 
filtered, and evaporated under reduced pressure to produce a colourless residue. The 
diastereoisomers could be separated using column chromatography with petroleum ether 
(40-60 °C)/ethyl acetate as the eluent. The first eluting diastereoisomer as a colourless oil 
(0.058 g, 29%) and the second as a colourless oil (0.0902 g, 46%). The first eluting 
diastereomer was found to have an ee of 78%, the second was found to have an ee of 60%. 
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Data for the first eluting diatereoisomer: [α]D 24 = -34 (c 0.73, CHCl3) (66% ee); max (neat)/cm-
1: 3448 O-H (s), 2939 C-H (s), 1776 C=O (s), 1744 C=O (s), 1682 C=O (s); 1H NMR (500 MHz, 
CDCl3) δH 7.40 – 7.33 (m, 3H, H22, 18, 19), 7.30 (dd, J = 7.6, 1.8 Hz, 2H, H20, 21),  7.20 (d, J = 
8.6 Hz, 2H, H10), 6.81 (d, J = 8.7 Hz, 2H, H9), 5.19 (d, J = 12.2 Hz, 1H, H7 or 16), 5.14 (d, J = 
12.2 Hz, 1H, H7 or 16), 5.13 (d, J = 14.18 Hz, 1H, H7 or 16), 4.30 (d, J = 14.8 Hz, 1H, H7 or 16), 
3.90 (dd, J = 12.2, 3.3 Hz, 1H, H5), 3.78 (s, 3H, H12), 3.75 (dd, J = 7.7, 4.5 Hz, 1H, H5), 3.67 – 
3.64 (m, 1H, H4), 2.36 – 2.18 (m, 2H, H13), 0.81 (t, J = 7.5 Hz, 3H, H14); 13C NMR (101 MHz, 
CDCl3) δC 205.7, 169.0, 165.8, 159.6 Ar, 134.7 Ar, 129.7 Ar, 128.9 Ar, 128.9 Ar, 128.4 Ar, 127.4 
Ar, 114.6 Ar, 68.5 C5, 67.5 C2 or 16, 63.9 C2 or 16, 60.3 C4, 55.4 C12, 44.2 C7, 25.4 C13, 8.7 
C14; HRMS (FTMS-NSI) m/z [M + H]+ calcd for [C23H26NO6]+ 412.1755, found 412.1753. Data 
for the second eluting diastereoisomer: [α]D 24 = -72.4 (c 1.1, CHCl3) (60% ee); max (neat)/cm-
1: 3440 O-H (s), 2940 C-H (s), 2253, 1780 C=O (s), 1747 C=O (s), 1688 C=O (s); 1H NMR (400 
MHz, CDCl3) δH 7.29 – 7.25 (m, 3H, H22, 18, 19), 7.15 – 7.12 (m, 2H, H20, 21), 7.02 (d, J = 8.6 
Hz, 2H, H10),  6.59 (d, J = 8.7 Hz, 2H, H9), 5.14 (d, J = 15 Hz, 1H, H7 or 16), 5.09 (d, J = 12.3 Hz, 
1H, H7 or 16),  5.04 (d, J = 12.3 Hz, 1H, H7 or 16), 4.10 (d, J = 15.0 Hz, 1H, H7 or 16), 3.91 (dd, 
J = 12.0, 2.7 Hz, 1H, H5) 3.81 – 3.78 (m, 1H, H4), 3.72 (dd, J = 12.0, 3.6 Hz, 1H, H5), 3.68 (s, 3H, 
H12), 2.24 – 2.10 (m, 2H, H13), 0.85 (t, J = 7.5 Hz, 3H, H14). 13C NMR (101 MHz, CDCl3) δC 
204.9, 169.2, 165.1, 159.5 Ar, 134.9 Ar, 129.5 Ar, 128.9 Ar, 128.7 Ar, 128.3 Ar, 126.9 Ar, 114.5 
Ar, 68.2 C5, 66.3 C2 or 16, 63.7 C2 or 16, 58.7 C4, 55.4 C12, 43.9 C7, 23.8 C13, 8.8 C14; HRMS 
(FTMS-NSI) m/z [M + H]+ calcd for [C23H26NO6]+ 412.1755, found 412.1752. Determination of 
ee was found by HPLC using an AD-H Chiralpak column 80:20 hexane/IPA, 230 nm, 0.8 
mL/min, 25 °C. 
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Benzyl 3-ethyl-1-(4-methoxybenzyl)-5-methylene-2,4-dioxopyrrolidine-3-carboxylate 229 
 
The racemic mixture of diastereoisomers 227ab (0.0336 g, 0.082 mmol) was dissolved in 
anhydrous THF (1.7 mL) under an atmosphere of nitrogen and cooled to -78 °C. LiHMDS (1 M 
in THF, 0.25 mL, 0.25 mmol, 3 equiv) was added along with DMPU (0.3 mL, 2.48 mmol, 30 
equiv). The solution was stirred for 30 m before methyl cyanoformate (0.03 mL, 0.377 mmol, 
4.6 equiv) was added. The solution was further stirred at -78 °C for 3 h then, saturated 
ammonium chloride solution (0.3 mL) was added and the mixture was allowed to warm to 
room temperature. Ethyl acetate was added (30 mL) and the solution was washed with water 
(30 mL). The aqueous layer was re-extracted with ethyl acetate (30 mL) and the organic 
extractions were combined. The combined organic layers were washed with water (30 mL) 
and brine (30 mL). The organic layer was dried (magnesium sulphate), filtered, and 
evaporated under reduced pressure to provide a pale brown oil. The oil was purified by 
column chromatography using petroleum ether (40-60 °C)/ethyl acetate (9:1) as the eluent 
to provide 229 as a colourless residue, which appeared green in solution (0.0085 g, 27%). max 
(neat)/cm-1: 2936 C-H (s), 1769 C=O (s), 1720 C=O (s), 1631; 1H NMR (500 MHz, CDCl3) δH 7.38 
– 7.30 (m, 3H H19, 17), 7.25 – 7.21 (m, 2H, H18), 7.08 (d, J = 8.8 Hz, 2H, H9), 6.67 (d, J = 8.7 
Hz, 2H, H8), 5.23 – 5.19 (m, 2H, H5, 15 or 6), 5.12 (d, J = 12.4 Hz, 1H, H15 or 6), 5.06 (d, J = 
15.2 Hz, 1H, H15 or 6), 4.61 (d, J = 15.3 Hz, 1H, H15 or 6), 4.53 (d, J = 2.3 Hz, 1H, H5), 3.74 (s, 
3H, H11), 2.30 (q, J = 7.5 Hz, 2H, H12), 0.85 (t, J = 7.5 Hz, 3H, H13); 13C NMR (126 MHz, CDCl3) 
δC 192.7, 169.0, 164.9, 159.3, 141.0, 134.9, 128.8, 128.6, 128.6, 128.1, 126.1, 114.3, 94.2, 
68.2, 62.3, 55.4 C11, 43.6 C6, 24.8 C12, 8.4 C13; HRMS (NSI-FTMS) m/z [M + H]+ calcd for 
[C23H24NO5]+ 394.1649, found 394.1651. 
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3.2.3 Experimental procedures toward the synthesis of hydroxy leucine 
(2-methoxy-2-oxoethyl)triphenylphosphonium bromide208 
 
To triphenylphosphine (5.11 g, 19.48 mmol) was added ethyl acetate (44 mL). Methyl 
bromoacetate (1.85 mL, 19.54 mmol, 1 equiv) was added dropwise and the solution stirred 
for 24 h. The resulting white precipitate was collected through suction filtration, washed with 
ether, and dried in a vacuum oven to provide the phosphonium salt (6.5 g, 80%). Mp 156-158 
°C (lit209 162 °C); max (neat)/cm-1: 3055, 3009, 2954 C-H (s), 2193, 1727 C=O (s); 1H NMR 
(CDCl3, 500 MHz) δH: 7.84 – 7.77 (m, 6H, Ar), 7.74 – 7.69 (m, 3H, Ar), 7.64 – 7.57 (m, 6H, Ar), 
5.45 (d, J = 13.6 Hz, 2H, H2) 3.49 (s, 3H, H4); 13C NMR (CDCl3, 100 MHz) δC 165.0 (d) C3, 135.2 
(d), 133.9 (d), 130.3 (d), 117.7 (d), 53.4 (d) C4, 32.9 (d) C4. 
 
Methyl 2-(triphenylphosphoranylidene)acetate 46208 
 
Methyl acetate phosphonium salt (6.394 g) was dissolved in DCM (40 mL). The solution was 
washed with an NaOH solution (1 M, 30 mL). The organic layer was removed and the aqueous 
re-extracted with DCM (40 mL). The organic layers were combined and washed with an equal 
amount of brine solution. The organic layer was dried (magnesium sulphate), filtered, and 
evaporated to provide 46 as an off-white solid (5.096 g, 99%). Mp 166.5-168 °C (lit209 165 °C); 
max(neat)/cm-1: 3058, 2943 C-H (s), 1619; 1H NMR (CDCl3, 400 MHz) δH: 7.70 – 7.60 (m, 6H, 
H1, Ar), 7.59 – 7.50 (m, 3H, H1, Ar), 7.50 – 7.40 (m, 6H, H1, Ar), 3.53 (bs, 3H, H4) 2.90 (bs, 1H, 
H2); 13C NMR (CDCl3, 100 MHz) δC: 133.1 (d) Ar, 132.1 (d) Ar, 128.9 (d) Ar.  
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(E)-methyl 4-methylpent-2-enoate 4733 
 
Ylid 46 (11.56 g, 34.57 mmol) was dissolved in anhydrous DCM (36 mL) and the solution was 
cooled to 0 °C using an ice bath. iso-Butyraldehyde (2.8 mL, 30.68 mmol, 1.1 equiv) was added 
and the solution stirred for 20 h being allowed to gradually warm to room temperature. The 
DCM was removed under reduced pressure, and the crude olefin was extracted from the 
resulting solid by washing with pentane. The suspension was filtered, and the pentane 
removed under reduced pressure.  The olefin was further purified using Kugelrohr distillation 
apparatus to afford 47 as a colourless liquid (2.81 g, 63%). max(neat)/cm-1: 2964 C-H (s), 2873, 
1727 C=O (s); 1H NMR (CDCl3, 500 MHz) δH: 6.95 (dd, J =  15.7, 6.7 Hz, 1H, H3) 5.77 (dd, J = 
15.7, 1.5 Hz, 1H, H3), 3.72 (s, 3H, H3), 2.50 – 2.41 (m, 1H, H1) 1.06 (d, J = 10 Hz, 6H, H6); 13C 
NMR (CDCl3, 100 MHz) δC: 167.6 C1, 155.9 C3, 118.4 C4, 51.5 C5, 31.1 C1, 21.4 C6 and 7. 
 
Peroxide (E)-methyl 4-hydroperoxy-4-methylpent-2-enoate 277 
 
Conversion of enone 47 to peroxide 277 occurred spontaneously in air and light. 
max(neat)/cm-1: 3386 O-H (b), 2985 C-H (s), 2954, 1706, C=O (s), 1660; 1H NMR (400 MHz, 
CDCl3) δH 7.03 (d, J = 16.1 Hz, 1H, H4), 5.98 (d, J = 16.1 Hz, 1H, H3), 3.75 (s, 3H, H1), 1.38 (s, 
6H, H6); 13C NMR (101 MHz, CDCl3) δC 167.3 C1, 151.5 C3, 120.5 C4, 81.9 C5, 51.9 C1, 24.1 C6 
and 7. m/z (NSI-FTMS) [M+H]+:  calcd for [C7H13O4]+ 161.0808, found 161.0806. 
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(2R,3S)-methyl 2,3-dihydroxy-4-methylpentanoate 4833 
 
Racemic synthesis: 
K2OsO4.2H2O (21.6 mg, 0.058 mmol, 0.008 equiv) was added to a flask with t-butanol (9 mL), 
H2O (5 mL) and N-methylmorpholine N-oxide (50% wt in H2O) (5 mL). Enone 47 (0.8955 g, 6.98 
mmol) was added over 24 h using a syringe pump. The solution was further stirred for 2 days, 
then, sodium sulphite (4 g) was carefully added and the solution was stirred for another hour. 
Water (20 mL) was added and the aqueous layer was extracted with ethyl acetate (20 mL x 
3). The organic layers were combined and washed with a saturated sodium sulphite solution 
(20 mL). The organic layers were dried (sodium sulphate), filtered, and evaporated to yield 
diol 48 as a clear oil which cooled to a waxy white solid (0.872 g, 77%). 
Enantioselective synthesis: 
To a flask containing AD-mix α (31.167 g), was added a t-butanol/water solution (1:1) (220 
mL). The suspension was stirred for 30 m then enone 47 (2.707 g, 21.12 mmol) was slowly 
added and the solution was stirred for 24 h. The solution was carefully quenched with 
saturated sodium sulphite solution and stirred for a further 30 m, then, extracted with ethyl 
acetate (100 mL x 3). The organic layers were combined and washed with a saturated sodium 
sulphite solution (100 mL). The organic layers were dried (magnesium sulphate), filtered and 
evaporated under reduced pressure to yield diol 48 (2.326 g, 68%) at 90% ee. The 
enantiomeric excess was enriched by dissolving the solid in 50 mL of a 9:1 petroleum 
ether/ethyl acetate solution and cooling to -20 °C to yield white waxy crystals (1.717 g, 50%) 
96% ee. max(neat)/cm-1: 3368 O-H (b), 2960 C-H (s), 2874, 1741 C=O (s); [α]D 23 = +22.92 (c 
0.72, CHCl3) (96% ee), (lit33 [α]D 23 = -10.7 (c 1, CHCl3));  1H NMR (500 MHz, CDCl3) δH 4.30 (s, 
1H, H4 or 6), 3.83 (s, 3H, H1), 3.51 (t, J = 7.7 Hz, 1H, H5), 3.01 (s, 1H, H4 or 6), 1.95 – 1.81 (m, 
2H, H7 and 3), 1.05 (d, J = 6.7 Hz, 3H, H8), 0.98 (d, J = 6.7 Hz, 3H, H8); 13C NMR (101 MHz, 
CDCl3) δC 174.8 C2, 78.0 C3, 71.5 C5, 52.9 C1, 31.2 C7, 19.2 C8, 19.1 C8.  
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(2S,3S)-2-bromo-1-methoxy-4-methyl-1-oxopentan-3-yl benzoate 4933 
 
Diol 48 (0.5335 g, 3.29 mmol) was dissolved in anhydrous DCM (7 mL). Trimethyl-
orthobenzoate (0.73 mL, 4.25 mmol, 1.3 equiv) was added with BF3.OEt2 (0.02 mL, 0.16 mmol, 
0.05 equiv) and the solution stirred at room temperature for 2 h. Triethyl amine (0.02 mL) 
was added and the solution evaporated to dryness. The residue was re-dissolved in DCM (7 
mL) and acetyl bromine (0.25 mL, 3.4 mmol, 1 equiv.) was added. After 3 h water was added 
(100 mL) and the solution extracted with DCM (100 mL x 2). The organic layers were combined 
and dried (magnesium sulphate), filtered, and evaporated. The resulting brown oil 49 (0.908 
g, 84%) was pure enough to be used without further purification, but a small portion was 
purified by column chromatography for characterization purposes using petroleum ether (40-
60 °C)/ethyl acetate as the eluent. max(neat)/cm-1: 2967 C-H (s), 1750 C=O (s), 1729 C=O (s), 
[α]D 26 = +34.43 (c 0.73, CHCl3) (94% ee) (lit33 [α]D 25 = +31.1 (c 1.01, CHCl3)); 1H NMR (CDCl3, 
400 MHz) δH: 8.06 – 8.00 (m, 2H, H11), 7.61 – 7.55 (m, 1H, H12), 7.48 – 7.41 (m, 2H, H10), 
5.57 (dd, J = 8.8, 3.9 Hz, 1H, H4) 4.48 (d, J = 8.8 Hz, 1H, H3), 3.68 (s, 3H, H1), 2.51 – 2.39 (m, 
1H, H5), 1.02 (d, J = 6.9 Hz, 6H, H6); 13C NMR (CDCl3, 100 MHz) δC 168.4, 165.4, 133.4, 129.9, 
129.6, 128.6, 77.2 C4, 53.3 C3, 44.5 C1, 29.5 C5, 19.7 C6, 15.9 C6.  
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(2R,3R)-methyl 3-isopropyl-1-(4-methoxybenzyl)aziridine-2-carboxylate 280 
 
Ester 49 0.0566 g (0.17 mmol) was dissolved in dry THF (1.6 mL). p-Methoxybenzylamine (0.03 
mL, 0.229 mmol, 1.35 equiv) was added at -78 °C and allowed to warm to room temperature 
over 3 days. The solution was evaporated and purified by column chromatography using 
petroleum ether (40-60 °C)/ethyl acetate (8:2) as the eluent, to produce (0.0113 g, 25%) of 
aziridine 280 as a clear oil. max(neat)/cm-1: 3432, 2959 C-H (s), 1747 C=O (s); 1H NMR (CDCl3, 
400 MHz) δH: 7.24 (d, J = 8.7 Hz, 2H, H10), 6.85 (d, J = 8.7 Hz, 2H, H9), 3.79 (s, 3H, H12), 3.71 
(s, 3H, H1), 3.54 (d, J = 12.9 Hz, 1H, H7), 3.43 (d, J = 12.9 Hz, 1H, H7) 2.25 (d, J = 6.4 Hz, 1H, 
H3), 1.63 – 1.52 (m, 2H, H4 and 5), 0.89 (d, J = 6.3 Hz, 3H, H6), 0.82 (d, J = 6.4 Hz, 3H, H6); 13C 
NMR (CDCl3, 100 MHz) δC: 170.6, 159.1 Ar, 129.0 Ar, 113.8 Ar, 63.8, 55.4, 53.6, 52.1, 42.7 C7, 
27.5 C5, 21.0 C6, 19.7 C6; one quaternary Ar peak unobserved in 13C NMR spectrum; m/z (NSI-
FTMS) [M+H]+: calcd for [C15H22O3N]+ 264.1594, found 264.1598. 
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(2S,3S)-methyl 3-acetoxy-2-bromo-4-methylpentanoate 285 
 
Ester 48 (0.0367 g, 0.226 mmol) was dissolved in anhydrous DCM (0.5 mL). Trimethyl-
orthoacetate (0.05 mL, 0.39 mmol, 1.7 equiv) was added with 1 drop of BF3.OEt2 and the 
solution stirred at room temperature for 2 h. Triethyl amine (1 drop) was added and the 
solution evaporated to dryness. The residue was then re-dissolved in DCM (0.5 mL) and acetyl 
bromine (0.05 mL, 0.67 mmol, 3 equiv.) was added. After 3 h the reaction was quenched with 
water (20 mL) and the solution extracted with DCM (50 mL x 2). The organic layers were 
combined and dried (magnesium sulphate), filtered, and evaporated. The resulting brown oil 
285 (0.0547 g, 91%) was characterized and used without further purification. max(neat)/cm-
1: 3021, 2970 C-H (s), 1751 C=O (s); [α]D 21 = +10.41 (c 0.48, CHCl3); 1H NMR (500 MHz, CDCl3) 
δH 5.31 (dd, J = 9.0, 3.8 Hz, 1H, H4), 4.29 (d, J = 9.0 Hz, 1H, H3), 3.75 (s, 3H, H1), 2.40 – 2.27 
(m, 1H, H5 and 3), 2.04 (s, 3H, H9), 0.93 (d, J = 6.9 Hz, 3H, H6), 0.90 (d, J = 6.9 Hz, 3H, H6); 13C 
NMR (126 MHz, CDCl3) δC 169.7, 168.4, 76.5 C4, 53.2 C1, 44.3 C3, 29.0 C9, 20.7 C5, 19.5 C6, 
15.5 C6. Unfortunately, although attempted, accurate mass data was unable to be obtained 
for this compound.  
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Two step procedure to 286 from 48: 
 (2S,3S)-methyl 2-bromo-3-(formyloxy)-4-methylpentanoate 286 
 
Ester 48 (0.0731, 0.45 mmol), was dissolved in anhydrous DCM (0.9 mL). Trimethyl-
orthoformate (0.07 mL, 0.63 mmol, 1.4 equiv) was added with 1 drop of BF3.OEt2 and the 
solution stirred at room temperature for 2 h. 1 drop of triethyl amine was added and the 
solution evaporated to dryness. The residue was re-dissolved in DCM (0.9 mL) and acetyl 
bromine (0.04 mL, 0.54 mmol, 1.2 equiv.) was added. After 2 hours water was used to quench 
the reaction (20 mL) and the solution extracted with DCM (50 mL x 2). The organic layers were 
combined and dried (magnesium sulphate), filtered, and evaporated. The resulting brown oil 
286 was purified using column chromatography with petroleum ether (40-60 °C)/ethyl 
acetate (9:1) as the eluent to provide 286 (0.0568 g, 91%). max(neat)/cm-1: 3446, 2969 C-H 
(s), 2881, 1751 C=O (s), 1732 C=O (s); [α]D 25 = −13.36 (94% ee) (c 1.01, CHCl3); 1H NMR (500 
MHz, CDCl3) δH 8.08 (s, 1H, H9), 5.40 (dd, J = 9.2, 3.3 Hz, 1H, H4), 4.32 (d, J = 9.2 Hz, 1H, H3), 
3.77 (s, 3H, H1), 2.40 (dtd, J = 13.7, 6.9, 3.6 Hz, 1H, H3), 0.97 (d, J = 6.9 Hz, 3H, H6), 0.93 (d, J 
= 6.8 Hz, 3H, H6); 13C NMR (101 MHz, CDCl3) δC 168.3, 159.8, 76.6 C4, 53.4 C1, 43.5 C3, 28.9 
C5, 19.6 C6, 15.3 C6. Unfortunately, although attempted, accurate mass data was unable to 
be obtained for this compound. 
 
(2S,3S)-methyl 2-bromo-3-hydroxy-4-methylpentanoate 286 
 
The bromo-formate ester 48 (0.2751 g, 1.09 mmol) was dissolved in MeOH (13.5 mL). (±)-CSA 
(0.338 g, 1.46 mmol, 1.3 equiv) was added, and the solution stirred for 5 h. A further portion 
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of (±)-CSA (0.1 g, 0.43 mmol, 0.4 equiv) was added and the reaction left until TLC showed 
complete consumption of the starting material had occurred. The solvents were removed 
under reduced pressure and the residue dissolved in ether (75 mL). The organic layer was 
washed with water (50 mL) and saturated NaHCO3 solution (50 mL). The organic layer was 
dried (magnesium sulphate), filtered, and evaporated under reduced pressure. To provide 
bromo-hydrin 286 (0.217 g, 89%) which could be used without further purification. 
 
Two step procedure to 286 from 48 
(2S,3S)-methyl 2-bromo-3-hydroxy-4-methylpentanoate 286 
 
Diol 48 (0.537 g, 3.31 mmol), was dissolved in anhydrous DCM (6.5 mL). Trimethyl-
orthoformate (0.5 mL, 4.57 mmol, 1.4 equiv) was added with BF3.OEt2 (0.02 mL, 0.16 mmol, 
0.05 equiv) and the solution stirred at room temperature for 2 h. Triethyl amine (0.02 mL) 
was added and the solution evaporated to dryness. The residue was re-dissolved in DCM (6.5 
mL) and acetyl bromine (0.28 mL, 3.78 mmol, 1.1 equiv) was added. After 2 h methanol (3.9 
mL) and (±)-CSA (2.00 g, 8.6 mmol, 2.6 equiv) was added and the solution was left to stir for 
a further 2 hours. The solution was diluted with DCM (50 mL). Water (50 mL) was added and 
the organic layer was separated. The aqueous later was extracted again with DCM (50 mL). 
The organic layers were combined, washed with saturated NaHCO3 solution (50 mL) and dried 
(magnesium sulphate), filtered, and evaporated. The resulting brown oil was purified using 
column chromatography with petroleum ether (40-60 °C)/ethyl acetate (9:1) as the eluent to 
provide 286 (0.4952 g, 67%). max(neat)/cm-1: 3455 O-H (b), 2962 C-H (s), 2877, 1736 C=O (s); 
[α]D 24 = −34.6 (96% ee) (c 0.75, CHCl3); 1H NMR (500 MHz, CDCl3) δH 4.22 (d, J = 8.2 Hz, 1H, 
H4), 3.87 (ddd, J = 8.3, 6.2, 3.9 Hz, 1H, H3), 3.81 (s, 3H, H1), 2.50 (d, J = 6.3 Hz, 1H, OH), 2.14 
(dtd, J = 13.7, 6.9, 3.9 Hz, 1H, H5), 1.02 (d, J = 6.9 Hz, 3H, H6), 0.92 (d, J = 6.8 Hz, 3H, H6); 13C 
NMR (126 MHz, CDCl3) δC 170.4 C2, 76.4 C4, 53.2 C1, 45.4 C3, 29.5 C5, 19.0 C6, 15.0 C6. 
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Unfortunately, although attempted, accurate mass data was unable to be obtained for this 
compound. 
(2R,3S)-3-isopropyl-N-(4-methoxybenzyl)oxirane-2-carboxamide 288 
 
Bromohydrin 283 (0.1053 g, 0.47 mmol) was dissolved in THF (4.4 mL). p-
Methoxybenzylamine (0.12 mL, 0.91 mmol, 2 equiv) was added with triethylamine (0.06 mL, 
0.43 mmol, 0.9 equiv) and the solution was stirred overnight. The solution was evaporated, 
dissolved in ethyl acetate and washed with equal amounts of water (x2) and brine (x2). The 
organic layer was dried (magnesium sulphate), filtered, and evaporated. The resulting residue 
was purified by column chromatography using petroleum ether (40-60 °C)/ethyl acetate (8:2) 
as the eluent to provide epoxy amide 288 as a white crystalline solid (0.078 g, 67%). Mp 75-
77 °C max (neat)/cm-1: 3321, 2964 C-H (s), 2934, 1655 C=O (s), 1534, 1514; [α]D 22 = −3.5 (c 1, 
CHCl3); 1H NMR (400 MHz, CDCl3) δH 7.17 (d, J = 8.8 Hz, 2H, H3), 6.86 (d, J = 8.7 Hz, 2H, H4), 
6.34 (s, 1H, H7), 4.35 (d, J = 5.9 Hz, 2H, H6), 3.80 (s, 3H, H1), 3.31 (d, J = 2.2 Hz, 1H, H9), 2.75 
(dd, J = 6.4, 2.2 Hz, 1H, H10), 1.72 – 1.60 (m, 1H, H11), 1.01 (d, J = 4.2 Hz, 3H, H12), 1.00 (d, J 
= 4.3 Hz, 3H, H12); 13C NMR (101 MHz, CDCl3) δC 168.6 C8, 159.3, 129.8, 129.3, 114.3, 64.8 
C9, 55.5 C10, 54.7 C1, 42.5 C6, 30.3 C11, 18.6 C12, 18.2 C12; m/z (NSI-FTMS) [M+H]+ calcd for 
250.1438 [C14H20NO3]+ found 250.1440. Determination of ee was found by HPLC using an AD-
H Chiralpak column 80:20 hexane/IPA, 230 nm, 0.8 mL/min, 25 °C. 
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(2R,3S)-2-hydroxy-1-methoxy-4-methyl-1-oxopentan-3-yl benzoate 284 
 
Diol 48 (0.274 g, 1.69 mmol) was dissolved in dry dichloromethane (3.4 mL). Trimethoxy 
orthobenzoate (0.4 mL, 2.3 mmol, 1.4 equiv) was added along with 1 drop of BF3.OEt2. The 
solution was stirred for 2 h. Water (1 mL) was added and the solution vigorously stirred for a 
further 1 h. The solution was diluted with water (approximately 20 mL) and extracted twice 
with equal amounts of dichloromethane. The organic was dried (magnesium sulphate), 
filtered, and evaporated. Purification using column chromatography with petroleum ether 
(40-60 °C)/ethyl acetate as the eluent provided 284 as a clear oil (0.317 g, 70%). max 
(neat)/cm-1: 3490 O-H (b), 2968 C-H (s), 1744 C=O (s), 1721 C=O (s), 1272; [α]D 19 = −45.1 (c 
0.51, CHCl3), (94 % ee); 1H NMR (CDCl3, 400 MHz) 1H NMR (500 MHz, CDCl3) δH 8.01 (dd, J = 
8.4, 1.3 Hz, 2H, H13 and 14), 7.61 – 7.52 (m, 1H, H15), 7.43 (t, J = 7.8 Hz, 2H, H12 and 11), 5.14 
(dd, J = 9.1, 2.0 Hz, 1H, H5), 4.46 (dd, J = 7.9, 1.9 Hz, 1H, H3), 3.71 (s, 3H, H1), 3.02 (d, J = 8.0 
Hz, 1H, H4), 2.40 – 2.25 (m, 1H, H6), 1.09 (d, J = 6.8 Hz, 3H, H7 or 8), 0.99 (d, J = 6.8 Hz, 3H, H8 
or 7); 13C NMR (CDCl3, 100 MHz) δC: 173.6, 166.0, 133.3, 129.9, 129.8, 128.6, 79.6 C3, 70.6 
C5, 52.9 C1, 29.3 C6, 19.0 C7 or 8, 19.0 C7 or 8; m/z (TOF-ASAP) [M+H]+ calcd for 267.1233 
[C14H19O5]+ found 267.1227. 
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(2R,3S)-methyl 2,3-dihydroxy-4-methylpentanoate 48 
 
Benzoyl ester 284 (0.036 g, 0.135 mmol) was dissolved in methanol. The solution was cooled 
with an ice bath and potassium tert-butoxide (0.019 g, 0.17 mmol, 1.3 equiv) was added. After 
1 h, the solution was neutralised with amberlite resin H+ 120. After neutralisation the solution 
was filtered, evaporated, and purified by column chromatography, using petroleum ether (40-
60 °C)/ethyl acetate as the eluent to provide diol 48 as a waxy white solid (0.018 g, 84%). 
 
(2R,3S)-methyl 3-acetoxy-2-hydroxy-4-methylpentanoate 295 and (2R,3S)-methyl 2-
acetoxy-3-hydroxy-4-methylpentanoate 296 
 
Diol 48 (0.0881 g, 0.54 mmol) was dissolved in dry dichloromethane (1.2 mL). Trimethoxy 
orthoacetate (0.09 mL, 0.7 mmol, 1.3 equiv) was added along with 1 drop of BF3.OEt2. The 
solution was stirred for 2 h. Water (0.3 mL) was added and the solution vigorously stirred for 
a further 1 h. The solution was diluted with water (approximately 20 mL) and extracted twice 
with equal amounts of dichloromethane. The organic solution was dried (magnesium 
sulphate), filtered, and evaporated. Purification by column chromatography using petroleum 
ether (40-60 °C)/ethyl acetate (9:1) as the eluent provided 295 as a clear oil (0.0344 g, 31%) 
and 296 as a clear oil (0.0125 g, 11%), which rapidly converted to 295 upon standing in 
chloroform. First eluting regioisomer 295: max(neat)/cm-1: 3491 O-H (b), 2966 C-H (s), 1748 
C=O (s), 1272; [α]D 24 = −115.1 (c 0.76, CHCl3); 1H NMR (CDCl3, 400 MHz) δH: 4.85 (dd, J = 9.3, 
1.8 Hz, 1H, H6), 4.33 (d, J = 1.6 Hz, 1H, H3), 3.73 (s, 3H, H1), 2.86 (bs, 1H, H7), 2.21 – 2.08 (m, 
1H, H8), 2.03 (s, 3H, H5), 1.01 (d, J= 6.8 Hz, 3H, H9), 0.91 (d, J= 6.7 Hz, 3H, H9); 13C NMR (CDCl3, 
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100 MHz) δC 173.7, 170.4, 79.1 C3, 70.2 C6, 52.8 C1, 28.9 C5, 20.7 C8, 19.0 C9, 18.8 C9; m/z 
(FTMS-NSI) [M+Na]+ calcd for 227.0895 [C14H19O5]+ found 227.0891. Second eluting 
regioisomer 296: 1H NMR (CDCl3, 400 MHz) δH: 5.21 (d, J = 2.6, 1H, H3), 3.77 (s, 3H, H1), (dd, 
J = 8.5, 2.6 Hz, 1H, H6), 2.18 (s, 3H, H5), 1.96 (bs, 1H, OH), 1.85 – 1.70 (m, 1H, H8), 1.05 (d, J= 
6.7 Hz, 3H, H9), 0.90 (d, J = 6.8 Hz, 3H, H9); 13C NMR (CDCl3, 100 MHz) δC 170.3, 169.5, 76.8 
C6 or 3, 73.3 C3 or 6, 52.7 C1, 31.2 C5, 20.7 C8, 19.1 C9, 18.9 C9. 
(S)-1-((4-methoxybenzyl)amino)-4-methyl-1,2-dioxopentan-3-yl benzoate 289196 
 
Formaldehyde (aqueous 37%), (0.81 mL, 10.8 mmol, 1.1 equiv), methanol (15 mL), ethyl 
acetoacetate (2.7 mL, 21.16 mmol, 2.1 equiv), ammonium acetate (0.77 g, 9.98 mmol), p-
toluenesulphonic acid monohydrate (0.049 g, 0.28 mmol, 0.028 equiv) were stirred at room 
temperature for 16 h. The resulting suspension was evaporated to a crude yellow solid which 
was recrystalized twice with methanol to provide Hantzsch’s ester 289 as a yellow solid (0.57 
g, 23%). Mp 160-167 °C  (lit210 164-166 °C); max(neat)/cm-1: 3349 N-H (b), 2987 C-H (s), 1694 
C=O (s), 1657 C=O (s);  1H NMR (400 MHz, CDCl3) δH 5.11 (s, 1H, H1), 4.17 (q, J = 7.1 Hz, 4H, 
H6), 3.26 (s, 2H, H8), 2.19 (s, 6H, H3), 1.28 (t, J = 7.1 Hz, 6H, H7); 13C NMR (101 MHz, CDCl3) 
δC 168.2 C5, 144.9 C4, 99.7 C2, 59.8 C6, 24.9 C8, 19.4 C3, 14.6 C7. 
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(11bS)-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine 4-oxide 290195 
 
S-Binol 292 (1.021 g, 3.57 mmol) was dissolved in dry pyridine (7.1 mL). POCl3 (0.67 mL, 6.43 
mmol, 1.8 equiv) was added and the mixture was heated to 75 °C. After 5 h the mixture was 
cooled and water (7.2 mL) was added and the solution was stirred for a further 2 h. DCM (150 
mL) was added and the pyridine was removed with HCl (4 M, 150 mL). The organic layer was 
dried (sodium sulphate), filtered, and evaporated under reduced pressure to afford a crude 
which was purified by column chromatography using DCM/MeOH (9:1) as the eluent to afford 
290 as a beige solid (0.576 g, 46%). Mp >300 °C (lit211 236-239 °C) [α]D 23 = +583 (c 0.18, CHCl3) 
(lit212 [α]D 20 = +607 (c 1, MeOH)); max (neat)/cm-1: 1237, 1096; 1H NMR (500 MHz, DMSO) δH 
8.05 (dd, J = 19.7, 8.1 Hz, 4H), 7.46 (d, J = 6.6 Hz, 4H), 7.38 – 7.27 (m, 2H), 7.22 (d, J = 8.1 Hz, 
2H); 13C NMR (126 MHz, DMSO) δC 146.1, 131.9, 130.5, 130.1, 128.5, 126.3, 126.1, 124.7, 
122.3, 121.6. 
(2R,3S)-methyl 2-azido-3-hydroxy-4-methylpentanoate 264 
 
Bromohydrin 283 (0.1469 g, 0.65 mmol) was dissolved in DMF (5.8 mL). Sodium azide (0.144 
g, 2.21 mmol, 3.4 equiv) was added and the solution was stirred for 20 h. The DMF was 
evaporated under reduced pressure and the resulting residue dissolved in ethyl acetate (50 
mL) and water (25 mL). The aqueous layer was removed and the organic layer washed again 
with brine (25 mL). Both aqueous layers were removed and extracted with ethyl acetate (50 
mL). The organic layers were dried (sodium sulphate), filtered, and evaporated under reduced 
pressure. The azide 264 was produced as a clear oil (0.098 g, 80%). Although the product was 
used without purification, a small portion was purified by column chromatography for 
characterization purposes using petroleum ether (40-60 °C)/ethyl acetate (8:2) as the eluent. 
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max(neat)/cm-1: 3483 O-H (b), 2963 C-H (s), 2876, 2117, 1747 C=O (s), 1438; [α]D 25 = +36.7 (c 
0.64, CHCl3); 1H NMR (500 MHz, CDCl3) δH 4.03 (d, J = 2.9 Hz, 1H, H3), 3.84 (s, 3H, H1), 3.70 
(dd, J = 8.4, 2.9 Hz, 1H, H4), 1.96 (s, 1H, H6), 1.91 – 1.81 (m, 1H, H7), 1.05 (d, J = 6.7 Hz, 3H, 
H7), 0.95 (d, J = 6.7 Hz, 3H, H7). 13C NMR (101 MHz, CDCl3) δC 170.2 C2, 78.0 C4, 64.2 C3, 53.0 
C1, 31.4 C5, 19.1 C7, 18.7 C7; m/z (ASAP-TOF) [M+H-N2]+ calcd for 160.0974 [C7H14NO3]+ found 
160.0975. 
(2R,3S)-methyl 2-amino-3-hydroxy-4-methylpentanoate 36 
 
The azido alcohol 264 (0.0853 g, 0.45 mmol) was dissolved in MeOH (0.5 mL) and the solution 
gassed with nitrogen. Pd/C (0.0210 g, 10% by weight) was added and the suspension placed 
under a static atmosphere of hydrogen. The suspension was stirred overnight, filtered 
through celite, and washed with methanol. The resulting solution was evaporated under 
reduced pressure to produce the amino ester 36, which was used onto the next step without 
further purification (0.0734 g, quant). 
 
(2R,3S)-3-hydroxy-1-methoxy-4-methyl-1-oxopentan-2-aminium chloride 300 
 
The amino acid ester 36 (0.0128 g, 0.079 mmol) was dissolved in MeOH (0.54 mL) a solution 
of methanolic HCl (3 M, 0.54 mL) was added and stirred for 3 h. The solution was evaporated 
to produce 300 as a waxy yellow residue (0.0155 g, quant). max(neat)/cm-1: 3423 O-H (b), 
2965 C-H (s), 2929, 2027, 1743 C=O (s); [α]D 24 = -4.8 (c 1.7, CHCl3); 1H NMR (400 MHz, CDCl3) 
δH 8.35 (s, 3H, H4), 4.26 (s, 1H, H5), 4.39 – 3.64 (m, 5H, H3, 1, 6), 1.99 (s, 1H, H7), 1.11 – 0.91 
(m, 6H, H8 and 9); 13C NMR (101 MHz, CDCl3) δC 169.4 C2, 75.1 C5, 56.6 C3, 53.9 C1, 30.4 C7, 
19.8 C9 or 8, 17.5 C8 or 9. 
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 (2R,3S)-methyl 3-hydroxy-4-methyl-2-(((2-nitrophenoxy)sulfonyl)oxy)pentanoate 305 
 
Diol 48 (0.4589 g, 2.83 mmol) was dissolved in anhydrous DCM (22 mL). 2-Nosyl chloride 
(0.728 g, 3.82 mmol, 1.3 equiv) was added in one portion, triethyl amine (0.4 mL, 2.86 mmol, 
1 equiv) was slowly added over 0.5 h. The solution was stirred for 3 h. HCl (1 M, 1 mL), was 
added with DCM (75 mL) and the solution was washed with an equal portion of brine. The 
organic layer was dried (magnesium sulphate), filtered, and evaporated to dryness. The 
resulting yellow oil was purified by column chromatography using petroleum ether (40-60 
°C)/ethyl acetate (7:3) as the eluent to provide 305 as a pale-yellow oil. (0.605 g, 62 %). 
max(neat)/cm-1: 3544 O-H (b), 3101, 2964 C-H (s), 1766 C=O (s), 1547; [α]D 26 = −23.3 (c 0.73, 
CHCl3) (96% ee); 1H NMR (500 MHz, CDCl3) δH 8.19 (dd, J = 7.3, 1.2 Hz, 1H, Ar), 7.85 – 7.75 (m, 
3H, Ar), 5.24 (d, J = 3.0, 1H, H3), 3.75 – 3.68 (m, 4H, H4 and 1), 2.00 – 1.80 (m, 2H, H6 and 5), 
1.05 (d, J = 6.7 Hz, 3H, H7), 0.98 (d, J = 6.7 Hz, 3H, H7); 13C NMR (126 MHz, CDCl3) δC 167.7 C2, 
148.4 Ar, 135.1 Ar, 132.5 Ar, 131.5 Ar, 130.3 Ar, 125.0 Ar, 80.9 C3, 77.3 C4, 53.0 C1, 30.7 C6, 
18.0 C7, 18.4 C7; m/z (ASAP-TOF) [M+H]+ calcd for 348.0753 [C13H18NO8S]+ found 348.0752. 
Determination of ee was found by HPLC using an AD-H Chiralpak column 25:75 hexane/IPA, 
254 nm, 0.8 mL/min, 25 °C. 
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(2S,3S)-methyl 2-azido-3-hydroxy-4-methylpentanoate 26439 
Synthesis of 264 from 283 via the epoxide 
 
Bromo-hydrin 283 (0.0285 g, 0.13 mmol) was dissolved in PEG-400 (0.23 mL). Triethylamine 
(0.025 mL, 0.18 mmol, 1.4 equiv) was added and the solution and stirred for 1 hour. Sodium 
azide (0.034 g, 0.52 mmol, 4 equiv) was added and the suspension stirred for 36 h. Water (20 
mL) was added and the solution extracted with ethyl acetate (20 mL x 2). The solution was 
dried with sodium sulphate, filtered and evaporated to a colourless oil. The crude material 
was purified by column chromatography using petroleum ether (40-60 °C)/ethyl acetate (9:1) 
as the eluent to produce azide 264 as a clear residue (2.1 mg, 9%). 
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Synthesis of 264 from the nosylated precursor 305 
 
Nosylated diol 305 (0.5933 g, 1.63 mmol) was dissolved in DMF (18 mL). Sodium azide (0.304 
g, 4.68 mmol, 2.9 equiv) was added and the mixture stirred at room temperature overnight. 
The solution was evaporated to dryness and water (50 mL) was added along with ethyl acetate 
(50 mL). The organic layer was removed, and the aqueous solution re-extracted with ethyl 
acetate (50 mL). The organic layers were combined and washed with brine (50 mL). The 
organic layer was dried (magnesium sulphate), filtered, and evaporated under reduced 
pressure. The resulting pale-yellow oil 264 (0.3051 g, 95%) could be used without further 
purification, however a small portion was purified for characterization purposes by column 
chromatography using petroleum ether (40-60 °C)/ethyl acetate (9:1) as the eluent.  
max(neat)/cm-1: 3435 O-H (b), 3020, 2966 C-H (s), 2113, 1741 C=O (s); [α]D 26 = −66 (c 1, CHCl3); 
(Lit39 [α]D 23 = -47.6 (c 1.1, CHCl3));  1H NMR (400 MHz, CDCl3) δH 3.93 (d, J = 6.5 Hz, 1H, H3), 
3.84 (s, 3H, H1), 3.68 (dd, J = 6.5, 5.5 Hz, 1H, H4), 2.00 – 1.87 (m, 1H, H6), 1.61 (bs, 1H, H5), 
1.00 (d, J = 6.8 Hz, 3H, H7), 0.97 (d, J = 6.8 Hz, 3H, H7); 13C NMR (126 MHz, CDCl3) δC 170.2 C1, 
76.6 C4, 64.0 C3, 52.9 C1, 30.30 C6, 19.4 C7, 16.6 C7. 
 
(2S,3S)-methyl 2-amino-3-hydroxy-4-methylpentanoate 265 
 
The azido alcohol 264 (0.2160 g, 1.15 mmol) was dissolved in MeOH (1.2 mL) and the solution 
gassed with nitrogen. Pd/C (0.042 g, 10% by weight) was added, and the suspension placed 
under a static atmosphere of hydrogen. The suspension was stirred overnight, filtered 
through celite, and washed with methanol. The resulting solution was evaporated under 
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reduced pressure, and purified by column chromatography using 99% Ethyl acetate 1% TEA 
to 10% MeOH/DCM as the eluent to produce amine 265 as a clear oil. (0.0737 g, 41%). max 
(neat)/cm-1: 3366 O-H (b), 2959 C-H (s), 2874, 1735 C=O (s); [α]D 25 = +31.6 (c 0.6, CHCl3); (Lit39 
[α]D 23 = +8.6 (c 0.7, CHCl3))  1H NMR (400 MHz, CDCl3) δH 3.75 (s, 3H, H1), 3.63 (d, J = 4.9 Hz, 
1H, H5), 3.47 – 3.41 (m, 1H, H3), 2.19 (s, 4H, H6 and 4), 1.78 (p, J = 6.8 Hz, 1H, H7), 0.96 (t, J = 
7.3 Hz, 6H, H8); 13C NMR (101 MHz, CDCl3) δC 174.9 C2, 78.6 C5, 56.8 C1, 52.2 C3, 30.7 C7, 
19.6 C8, 18.0 C8. HRMS (NSI-FTMS) m/z [M + H]+ calcd for [C7H16NO3]+ 162.1125, found 
162.1122. 
 
(2S,3S)-3-hydroxy-1-methoxy-4-methyl-1-oxopentan-2-aminium chloride 306 
 
The amino acid ester 265 (0.0555 g, 0.344 mmol) was dissolved in MeOH (2.4 mL) a solution 
of methanolic HCl was added (3 M, 2.4 mL) and the solution stirred for 3 h. The solution was 
evaporated to a waxy yellow residue providing the hydrochloride salt 306 (0.068 g, quant.). 
max (neat)/cm-1: 3391 O-H (b), 2965 C-H (s), 1745 C=O (s), 1618; [α]D 25 = +28.1 (c 0.48, CHCl3); 
1H NMR (500 MHz, CDCl3) δH 8.35 (s, 3H, H4), 4.88 (s, 1H, H5), 4.39 (s, 1H, H3), 3.84 (s, 4H, H1 
and 6), 1.90 (s, 1H, H7), 1.12 – 0.79 (m, 6H, H8); 13C NMR (126 MHz, CDCl3) δC 168.5 C2, 76.2 
C5, 56.4 C3, 53.6 C1, 31.1 C7, 20.1 C8, 19.1 C8. HRMS (NSI-FTMS) m/z [M - Cl]+ calcd for 
[C7H16NO3]+ 162.1125, found 162.1121. 
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3.3 X-ray crystallography data 
 
 
 
 
 
 
 
 
 
 
Compound number 179 
Space group P 21/n (14) 
Cell lengths a 15.59060(16) b 5.83233(5) c 19.3142(2) 
Cell angles  90.0000  112.9800(13)  90.0000 
Cell volume 1616.86 
Z, Z’ Z: 4 Z': 0 
R-factor % 4.11 
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Compound number 197 
Space group P 1 (2) 
Cell lengths a 10.3698(15) b 11.4667(12) c 12.0264(11) 
Cell angles  65.754(8)  80.975(12)  85.855(12) 
Cell volume 1287.69 
Z, Z’ Z: 0 Z': 0 
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Compound number 212a 
Space group P 21 21 21 (19) 
Cell lengths a 6.24701(5) b 17.78990(14) c 20.26860(16) 
Cell angles a 90.0000 b 90.0000 g 90.0000 
Cell volume 2252.52 
Z, Z’ Z: 0 Z': 0 
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Compound number 216a 
Space group P 21 (4) 
Cell lengths a 8.41466(6) b 22.42870(13) c 11.38440(9) 
Cell angles  90.0000  107.7070(8)  90.0000 
Cell volume 2046.79 
Z, Z’ Z: 0 Z': 0 
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Compound number 217 
Space group P 21 (4) 
Cell lengths a 10.3313(2) b 10.2519(2) c 26.4465(6) 
Cell angles  90.0000  98.891(2)  90.0000 
Cell volume 2767.44 
Z, Z’ Z: 0 Z': 0 
Compound number (±)-217 
Space group P 21/n (14) 
Cell lengths a 14.29830(9) b 10.41200(6) c 18.66340(11) 
Cell angles a 90.0000 b 105.0690(6) g 90.0000 
Cell volume 2682.95 
Z, Z’ Z: 0 Z': 0 
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Compound number 288 
Space group P 21 (4) 
Cell lengths a 8.19162(12) b 5.13934(7) c 15.5952(2) 
Cell angles  90.0000  92.5974(13)  90.0000 
Cell volume 655.876 
Z, Z’ Z: 0 Z': 0 
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Compound number 156 
Space group P 21/n (14) 
Cell lengths a 5.61665(15) b 22.0705(7) c 8.3267(3) 
Cell angles  90.0000  98.395(3)  90.0000 
Cell volume 1021.14 
Z, Z’ Z: 0 Z': 0 
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